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The World Health Organization reports that cervical cancer is the second most 
common malignancy that affects women worldwide1. Cervical cancer is defined by 
the National Cancer Institute as a malignancy that is formed in the tissue of the 
cervix, which is typically, asymptomatic and slow growing in nature. In 2011 alone, 
682 Australian women were diagnosed with cervical cancer, with the majority of the 
women aged between 30 and 59 years2. In 2012, there were 143 deaths from 
cervical cancer among women aged 20–69 years, the target population of the 
Australian National Cervical Screening Program (NCSP), equating to 1.9 deaths per 
100,000 women (age-standardised)2. There were 226 deaths or 1.8 deaths per 
100,000 women (age-standardised) among women of all ages2. 
Cervical cancer is highly preventable through cytologic screening programs that 
facilitate the detection and treatment of precancerous lesions2, 3. Consequently in 
1991, the Australian Health Ministers’ Advisory Council implemented Australia’s 
cervical screening program, now known as the NCSP. The NCSP operates as a 
joint program of the Australian Government and state and territory governments, 
targeting women aged 20–69. Since the NCSP was introduced in Australia, Pap 
smear testing has been associated with a sustained 50% reduction in cervical 
cancer incidence (7 new cases per 100,000 women of all ages compared to the 
previous figure of 18 new cases per year prior to the introduction of the NCSP) and 
mortality (4.0 to 1.8 deaths per 100,000 for women of all ages)2.  
When cervical cancer does occur, it most commonly presents amongst women who 
have never been screened or who have not been screened within the previous 5 
years2, 3, 5, 6 suggesting that women’s successful adherence to population-based 
cervical screening recommendations will assist in further reducing the morbidity and 
mortality linked to cervical cancer2, 3, 5, 6.   
Early detection greatly improves the chances of successful treatment and prevents 
early cervical changes from becoming malignant, however appropriate management 
of women with biopsy confirmed cervical pre-cancer is also a critical component of 
cervical cancer prevention programs3, 7. In Australia, the National Health and 
Medical Research Council (NHMRC) developed recommendations for practitioners 
to manage women with abnormal cervical screening test results and cervical cancer 
precursor lesions published in the  “Screening to present cervical cancer: Guidelines 
for the management of asymptomatic women with screen-detected abnormalities” 
and referred to as The Guidelines3.  
 15 
 
The most recent revised recommendations were implemented in July 2005 and 
replaced the initial 1994 guidelines3. These revised guidelines addressed the state 
of cervical cancer in Australia and were based on clarification of the biology and 
behaviour of cervical squamous disease and improved understanding of the 
diagnosis of endocervical glandular disease. The 2005 Guidelines included the 
treatment of glandular abnormalities that were emerging as an additional 
management problem due to improved recognition of precancerous changes in 
screening smears (e.g. the overall number of endocervical abnormalities increased 
from 914 in 2006 to 1,172 in 2013, with 67.2% biopsy samples confirmed as 
adenocarcinoma in situ (ACIS)2) and conservative treatment options for young 
women and the effectiveness of follow-up for women treated for high-grade 
squamous intraepithelial lesions (HSIL) 3.  
As the 10th anniversary since the introduction of the guidelines approaches, it is 
timely to undertake a review of the efficacy of its management recommendations 
based on an analysis of screening and treatment data for squamous and glandular 
lesions held by the Cervical Screening Registry of WA. Among the myriad outcome 
scenarios that will be addressed in this investigation are i) the clinical significance of 
low-grade glandular abnormalities, ii) the effectiveness of conservative treatment 
modalities in young women diagnosed with CIN2 or AIS, and iii) practitioners’ 
compliance with follow-up recommendations for all women treated for CIN2/3. 
Drawing on more recent available evidence will support a revision of Australian 
management guidelines (due to be completed by 2017). 
The work in this thesis largely draws on unique linked data system (Cervical 
Screening Registry of Western Australia (WA), Hospital Morbidity Database System, 
WA Cancer Registry and WA Death Registrations) available in WA; this research is 
well placed to inform the above-mentioned process by adding to the evidence pool 
for the revision of The Guidelines. 
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Thesis objectives 
The Guidelines for the management of Australian women with abnormal cervical test 
results will be revised by 2017. Consequently, the purpose of this research was to 
conduct epidemiologic population-based studies on the following critical topics that 
require evidence-based management recommendations to be developed.  
As this thesis is by publication, each chapter title page presents an overview of 
research output achieved and relevant publication(s) is presented at the end of each 
section. No publication is presented more than once within the manuscript. 
Additional output that resulted from this thesis, including delivery of presentations 
(i.e. UWA Rising Star’s Event and “What is the Gold Standard”) is presented in the 
appendices and translational material is located in the additional material section. 
Objective 1 
Investigate the risk factors and incidence of atypical endocervical cells of 
undetermined significance for Western Australian women in Pap smear test results 
and the associated health outcomes. 
Objective 2 
Analyse linked population-based administrative data to evaluate women with 
histologically confirmed adenocarcinoma in situ managed with conservative 
treatment in Western Australia. 
Objective 3 
Utilise linked population-based administrative data to investigate the spontaneous 
clearance rate among young women (aged <25 years) with histologically confirmed 
cervical intraepithelial lesion (grade 2). 
Objective 4 
Determine practitioners’ knowledge, awareness, and compliance with the Test of 
Cure management pathway. 
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Thesis overview  
This thesis presents a summary of the work undertaken to address the thesis 
objectives. It is divided into five chapters and is supported by six published 
publications in peer-reviewed journals (the candidate was first author on all 
publications). A further manuscript was accepted 21 November 2015 by Acta 
Obstetricia et Gynecologica Scandinavica (manuscript ID: AOGS-15-0599.R1). 
Chapter 1: Literature review:  Classification, treatment and follow-up o 
cervical epithelial lesions and data integration. 
Presents a literature review and addresses Objective 1 by describing the 
development and treatment of cervical cancer precursor lesions. A description of the 
“big data revolution”, administrative data and the role of the Western Australian Data 
Linkage System are also presented. Objective 1 resulted in one publication.  
Chapter 2: Investigation of the clinical significance of cytologically 
detected endocervical (glandular) abnormalities. 
Addressed Objective 2 by exploring women’s health outcomes after being 
diagnosed with a low-grade glandular lesion and resulted in one publication.    
Chapter 3: Investigation of the effectiveness of conservative treatment for 
high-grade endocervical (glandular) abnormalities. 
Explores the efficacy of conservative treatment for women diagnosed with 
adenocarcinoma in situ and addressed Objective 3 (resulting in 1 publication). 
Chapter three also outlines the Western Australian Data Linkage System and how 
administrative data are used to support this research.  
Chapter 4:  Spontaneous regression of CIN2: Investigation of incidence in 
women aged 18 to 24 years. 
Addressed Objective 4 by investigating the spontaneous regression of CIN2 in 
young women and their associated health outcomes. Chapter four resulted in one 
publication that was accepted 21 November 2015 by Acta Obstetricia et 
Gynecologica Scandinavica (manuscript ID: AOGS-15-0599.R1). 
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Chapter 5:  Investigation into the follow-up of women treated for high-
grade intraepithelial lesions  
Addressed Objective 5 by exploring GP awareness/knowledge and compliance with 
the Test of Cure management pathway. Chapter 5 resulted in two publications.  
Chapter 6: Discussion 
Presents the final discussion and explores the overall strengths and limitations of 
the work reported in this thesis. Additionally, areas for future research to be 
undertaken are discussed within Chapter 6. 
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1.1 Introduction 
This chapter formed the basis for a literature review, which was published by the 
Australian Family Physician. Additionally, content from this section was used to 
develop the content of WA Cervical Cancer Prevention Program’s website for health 
care providers (Additional Material 1), a Cervical Cancer Prevention Toolkit for 
Australian Midwives and Nurses (Additional Material 2) and the Western Australian 
Pap Smear Provider Synopsis (Additional Material 3).   
In many developing countries, cervical cancer remains the most common cancer 
among women and is recognised as a leading cause of death1. Fortunately, cervical 
cancer is a highly preventable disease if precancerous lesions are detected and 
treated in a timely manner1-5, 7-9. With our increased knowledge of the pathogenesis 
of cervical cancer and advancements in techniques of clinical diagnosis, new and 
interesting options for the prevention of cervical cancer have emerged1. Different 
methods for the prevention of cervical cancer are now available, namely cervical 
cytology screening (i.e. conventional cytology (Pap smear) or liquid-based cytology), 
human papillomavirus (HPV) screening, and vaccination against HPV1.  
In 1991, the Australian Government implemented the National Cervical Screening 
Program (NCSP), which is an organised population-based program that utilises the 
Pap smear as a screening tool to detect abnormal cervical changes and implement 
the necessary interventions for prevention of progression to cancer2, 4. In 2013 
alone, after age-standardisation (the 2001 Australian Standard Population), for 
every 1,000 Australian women (aged 20 to 69 years) screened, 8.5 had biopsy-
confirmed high-grade cervical abnormality (high-grade squamous intraepithelial 
lesion (HSIL) or adenocarcinoma in situ (ACIS))2. The detection of these high-grade 
abnormalities provides an opportunity for curative treatment avoiding potential 
progression to invasive cancer2.  
In 2007, Australia became the first country to adopt a National HPV Vaccination 
Program (NHVP)10, delivered through a school-based approach, providing HPV 
vaccination to girls and boys aged between 12 and 13 years. Preliminary analyses 
on the effectiveness of the NHVP (within five years of the program’s implementation) 
indicate a substantial reduction in low- and high-grade cervical abnormalities in 
women who received the HPV vaccine dose through the school-based program10. 
The Australian recommendations for the management of patients with abnormal 
cervical test results (cervical cytology and/or biopsy) are outlined by the National 
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Health and Medical Research Council (NHMRC) in Screening to prevent cervical 
cancer: Guidelines for the management of asymptomatic women with screen 
detected abnormalities7. Compliance with clinical practice and management 
guidelines by health care providers has been shown to reduce the morbidity and 
mortality attributable to cervical cancer1-4, 9. In 2014, the Australian Department of 
Health determined that the 2005 NHMRC Guidelines needed to undergo review and 
be updated to support the implementation of a revised cervical screening pathway 
scheduled to be adopted in Australia by 20172. 
1.2 Anatomy of the cervix 
The uterine cervix is the lower part of the uterus.  The cervix consists of three main 
parts (Figure 1)11: 
• The ectocervix (portio vaginalis) is the part of the cervix that projects into the 
vagina and is visualised using a speculum in a gynaecologic examination. 
This region, like the vagina is covered with stratified squamous epithelium.   
• The endocervix comprises highly branched glands and is lined by secretory 
columnar epithelium and forms the endocervical canal, which is continuous 
with the endometrial canal.  The endocervix is not seen in a speculum 
examination, and commences in the region of the external os.  
• The abrupt boundary of the ectocervix and endocervix occurs where the 
lining cells change from squamous to glandular type and is called the 
squamo-columnar junction (SCJ).  The location of the SCJ will vary 
according to age, hormonal status and parity12.  
Although all cervical cancers share the same site code (C53 under the International 
Classification of Diseases 10), there are a number of histological subtypes within the 
cervical cancer category. The most prevalent types (91.2% of all cervical cancer 
cases in Australia) of cervical cancer can be split into two main categories I) 
squamous cell carcinoma (which arises from the squamous cells that cover the 
outer surface of the cervix); and II) adenocarcinoma (which arises from the glandular 
(columnar) cells in the endocervical canal). In 2011, 457 new cases of squamous 
cell carcinomas were confirmed and 165 women were diagnosed with 
adenocarcinoma2. 
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Figure 1. Anatomy of the cervix presenting the ectocervix, endocervix,     
external os, and the transformation zone12 
 
1.3 Pathogenesis and natural history of cervical cancer and precursor 
lesions 
Improved understanding of the biology of cervical carcinoma has revealed that the 
main causative factor is persistent infection with oncogenic high-risk human 
papillomavirus (HR HPV), specifically types 16 and 1814, 17, 18, 20-23. There are 16 HR 
HPV types that have been linked to anogenital carcinoma in humans, of which 12 
(16,18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) have been definitively classified as 
oncogenic24, 25. Epidemiological evidence has highlighted other contributing risk 
factors that may influence the development of cervical cancer and its precursors, 
including tobacco smoking, long-term oral contraceptive pill use, human 
immunodeficiency virus infection, high parity, Herpes simplex virus infection, 
Chlamydia trachomatis infection as well as immune system suppression13-19. 
The International Agency for Research on Cancer coordinated a multicentre case-
control study which concluded that persistent HR HPV infection is a critical for the 
development of cervical cancer (squamous cell carcinoma and adenocarcinoma)8, 19. 
That study showed HR HPV DNA was present in 99.7% of 1,000 cervical cancer 
histological specimens collected from 22 countries worldwide19, 26. Furthermore, 
several cohort studies have since confirmed that persistent oncogenic HPV infection 
and high risk of developing cervical cancer were strongly related23, 27, 28. 
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Typically anogenital HPV infection occurs through sexual contact17, 24, 29. The risk 
factors for HR HPV infection are related to the individual’s sexual behaviour i.e. age 
at sexual debut and lifetime number of sexual partners 9-15. The incidence of HPV 
infection varies in different regions of the world; however, it is found to peak in 20–
30% of young women aged 20–24 years with a clear decline (3–10%) among 
women aged over 30 years19, 27, 28. It is estimated that more than 90% of young 
women (aged less than 30 years) infected with HPV will naturally clear the virus 
within 12–18 months of first acquisition29. Only a small proportion of women who are 
chronic carriers of HR HPVs are at increased risk of progression and development 
of neoplastic lesions of the anogenital tract23.  
1.4 Classification of cervical abnormalities 
In 2001, the National Advisory Committee to the National Cervical Screening 
Program (NCSP)7 requested that the management guidelines publication entitled 
Screening to Prevent Cervical Cancer: Guidelines for the Management of Women 
with Screen Detected Abnormalities be revised. This request was made to ensure 
that The Guidelines accurately reflected the contemporary understanding of the 
relationship between HPV, cervical cancer and its precursors7. Consequently, the 
NCSP established an Australian working party of experts to consider the adoption of 
the International classification for the diagnosis and management of cervical disease 
known as the Bethesda System7. The working party developed a unique terminology 
system suited for Australian code of practice known as the Australian Modified 
Bethesda System 2004 (AMBS)7. That was subsequently adopted. The AMBS is 
used to classify cervical cellular changes (squamous and glandular) in Pap smears 
and to outline standard follow-up recommendations7.  
Classification of the more prevalent squamous intraepithelial lesions (Table 1) is 
based on the features of morphologic changes in cells in Pap smears and biopsy 
specimens that reflected abnormal cellular proliferation and maturation, together 
with nuclear atypia. In low-grade intraepithelial squamous lesions (LSILs), the 
observed cellular changes occupy the upper third of the epithelium and may include 
the cytopathic effect (koilocytosis) of HPV. In the case of HSILs, the abnormal 
changes occur in the lower two thirds or entire thickness of the epithelium and 
HSILs demonstrate the presence of HR HPV as well as chromosomal instability30. 
The AMBS also recognises four categories for classifying glandular abnormalities 
(Table 2)7. ACIS is much less commonly diagnosed than squamous preinvasive 
lesions32. In Australia, the overall number of biopsy-confirmed endocervical 
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(glandular) abnormalities increased from 868 in 2005 to 1,172 in 20132. In 2013, 
67.2% of all glandular abnormalities were high-grade including endocervical 
dysplasia and ACIS2. No terminology for glandular lesions with lower degrees of 
nuclear atypia has been recognised owing to the rarity of biopsy samples31-33.  
1.5 Treatment of cervical epithelial abnormalities in Australia 
The National Health Medical Research Council (NHMRC) Guidelines for The 
Management of Asymptomatic Women with Screen Detected Abnormalities were 
implemented in 2005 as a guide for the treatment and follow-up of patients with 
squamous and glandular abnormalities (Table 1 and Table 2) to reduce cervical 
cancer incidence and mortality rates in Australia. To ensure clinical consensus these 
management guidelines were developed through national consultation with the 
relevant professional bodies, clinicians and consumers7.  
In Australia, best practice considers histological biopsy confirmation of cervical 
disease necessary prior to delivering treatment7. The adherence to management 
guidelines and appropriate clinical follow-up of women with high-grade cervical 
lesions has been a critical component of the success of the Australian National 
Cervical Screening Program (NCSP)2, 4, 7.  
1.5.1 Low-grade cervical epithelial abnormalities 
1.5.1.1 Squamous cells (see Table 1 (A and B)) 
In Australia, in cases where a low-grade squamous cervical abnormality is detected 
by cervical cytology, conservative management is recommended typically as repeat 
Pap smear within 12 months7. An exception to this recommendation is made for 
women aged over 30 years who have not had a negative screening history for the 
prior three-year period7. These women are directed straight to colposcopy for 
immediate investigation. Australian management guidelines also recommend that 
women aged over 30 years be offered immediate colposcopy and/or undergo a 
further Pap smear within six months of initial low-grade abnormality to ensure timely 
detection of potential occult HSIL7.  
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Table 1. The Australian Modified Bethesda System (AMBS 2004) for 
squamous abnormalities7 
 
 AMBS 2004 Features Cervical Cytology 
Image34 
A Possible low-grade 
squamous intraepithelial 
lesion  
 
Nonspecific minor 
squamous cell 
changes. Changes that 
suggest but fall short of 
HPV/CIN 1  
 
 
B Low-grade squamous 
intraepithelial lesion  
 
HPV effect, CIN 1  
 
 
C Possible high-grade 
squamous lesion  
 
Changes that suggest, 
but fall short of, CIN 2, 
CIN 3, or SCC  
 
 
D High-grade squamous 
intraepithelial lesion  
 
CIN 2, CIN 3  
 
 
E Squamous cell 
carcinoma  
 
Squamous cell 
carcinoma  
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Table 2. The Australian Modified Bethesda System (AMBS 2004) for glandular 
abnormalities7 
 
 
 AMBS 2004 Features Cervical Cytology Image34 
F Atypical endocervical cells 
of undetermined 
significance 
Nonspecific minor cell 
changes in endocervical 
cells  
 
 
G Atypical glandular cells of 
undetermined significance  
Nonspecific minor cell 
changes in glandular 
cells  
 
 
H Possible high-grade 
glandular lesion  
 
Changes that suggest, 
but fall short of, AIS or 
adenocarcinoma  
 
 
I Endocervical 
adenocarcinoma in situ 
Adenocarcinoma in situ  
 
 
J Adenocarcinoma Adenocarcinoma 
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In Australia, positive results for low-grade squamous abnormalities are commonly 
reported (4.5%) cytology. This can partly be a consequence of the young age at 
which cervical screening commences (18 to 20 years of age) as well the two-yearly 
rescreening interval that detects transient abnormalities7, 35. Given the prevalence of 
possible LSILs and LSILs, the optimal management of these women with these test 
results positive cervical test results is clear, although internationally countries are 
now recommending patients adhere to follow-up procedures such a cytological 
surveillance, HPV testing and/or colposcopy3, 7, 36.   
1.5.1.2 Glandular cells (Table 2 (F)) 
The current management practices for possible LSIL and LSIL is supported by 
current evidence, however, the management of women with a low-grade glandular 
lesion remains unclear due to the rarity of this lesion (Publication I). Cytology test 
results that report a possible low-grade or low-grade glandular lesion were very rare 
and accounted for only 0.04% of Australian cytology test results in 20122. Several 
studies have demonstrated that AEC may be associated with premalignant or 
malignant cervical lesions but most have been limited by short follow-up periods 
and/or relatively small numbers of cases39-42. Furthermore, the risk of significant 
pathology has not always been correlated with age, prior smear history, presence of 
endocervical cells in preceding cytology samples and/or the socio-economic status 
of the patient.  Consequently, in Australia, women with a suspected low-grade 
glandular lesion should be directly referred to colposcopic assessment to determine 
if a more severe lesion is present7.  The clinical significance of this lesion and 
associated health outcomes for affected women have been reported in Publication I 
and further assists practitioners in the management of these patients. 
1.5.2 High-grade squamous intraepithelial lesions  
Women with high-grade abnormality on cytology test results are recommended to 
undergo colposcopic examination to assess the transformation zone for the severity 
of the lesion and to improve the accuracy of a targeted biopsy7. Cervical lesions that 
are biopsy confirmed as CIN 2 or CIN 3 (Table 1 (D)) are treated using the same 
approach, as the distinction between the two grades is often ambiguous7, 46. Given 
that CIN 2/3 have a high risk of disease progression, prompt treatment, within two 
months of diagnosis, is recommended in Australia7. CIN2/3 may be treated by 
ablative (radical diathermy, cryotherapy, or laser ablation) or excisional (loop 
electrosurgical excision procedure (LEEP), laser conisation, or cold knife cone 
[CKC] biopsy) treatment modalities47.  
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It is important to be aware that not all women with histologically confirmed CIN2/3 
need to undergo excisional treatment. Women who are pregnant should only 
undergo an excisional procedure if invasive disease is suspected and women that 
desire fertility should be counselled about the benefits and risks associated with 
treatment procedures versus observation7. Additionally, the management of young 
women (aged < 25 years) with CIN2 remains controversial and requires further 
investigation (Publication III). For this reason, clinical acumen and experience is 
imperative in managing women diagnosed with high-grade CIN, as inappropriate 
management could unnecessarily increase the risk of cervical cancer; however, 
overtreatment also has consequences and could lead to complications for the 
patient7.   
1.5.3 High-grade glandular lesions 
ACIS (Table 2 (I)) occurs at a rate of 0.3 to 1.25 per 100,000 woman with Australian 
and international data show that its incidence is increasing2. Evaluation of women 
suspected with ACIS should include colposcopy, endocervical sampling, and 
targeted biopsy when appropriate7. Colposcopic detection of ACIS may be 
unreliable in some cases, as the anatomical placement of this abnormality may 
extend deep into the endocervical canal43. If ACIS is histologically confirmed, 
hysterectomy remains the preferred treatment option, but for women wishing to 
preserve fertility, conservative treatment (i.e. CKC biopsy or LEEP) may also be 
considered (publication II)7. 
1.5.4 Follow-up of women treated for high-grade epithelial cervical 
abnormalities 
1.5.4.1 High-grade squamous lesions (CIN2/3) 
Women treated for CIN2/3 are at increased risk of further high-grade disease and 
cervical cancer44. Disease recurrence may be attributable to inadequately treated 
disease or the further development of CIN. Recurrence rates tend to be high in the 
initial 6-12 months after treatment, remaining constant thereafter44-46. There is no 
evidence reporting that the risk of recurrence substantially declines at any definite 
point in time44-46.  
A major change in the management of HSIL abnormalities implemented in the 2005 
NHMRC Guidelines is the “Test of Cure” (ToC). The ToC is a pathway by which 
women return to the recommended two-yearly screening interval following treatment 
for an HSIL7. The ToC treatment pathway for a woman treated for HSIL requires a 
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colposcopy and cervical cytology 4-6 months after treatment. Twelve months after 
the treatment, cervical cytology and HR HPV DNA testing should be conducted; 
these would need to be conducted every 12 months until the patient shows negative 
results for both tests on two consecutive occasions7. Currently, there is no evidence 
on how successful the adoption of this management pathway has been in Australia, 
and international research is in a preliminary phase (publication IV and V)47-49.   
1.5.4.2 Adenocarcinoma in situ (ACIS) 
In Australia, optimal follow-up is yet to be defined for women treated for ACIS (who 
did not undergo a hysterectomy)7. However, the 2005 NHMRC Guidelines 
recommend, “follow-up cytology must include cytological sampling of the 
endocervical canal”. In view of the uncertainties in treating women with ACIS 
conservatively, “follow-up after treatment is best undertaken using both colposcopy 
and cytology”7.  
1.6 The “Big Data Revolution” 
“Big data” is a relatively new concept that is utilised to describe data so large and 
complex that it exceeds the computing capacity of most conventional systems that 
perform data analyses50,51. Huge amounts of data are generated from health-care 
sources such as electronic health records, health insurance claims and even smart 
phone applications that monitor patient health. “Big data” is the subject of intense 
interest as industry stakeholders and researchers recognise the huge potential in 
extracting data variables from existing systems. National governments are 
increasing their support to the ‘big data revolution’ by funding initiatives designed to 
develop and capitalise on ‘big data’ 51,52. 
Health researchers have long realised the value in large administrative databases. 
These databases contain a wealth of information that can now be accessed in a 
timely and cost-efficient manner due to advancements in computing power and 
further development of analytical methodologies53,54. These advancements have 
further facilitated data linkage or integration processes that offer greater utility over 
using individual databases for health research. Most importantly, these 
developments have led to valuable unbiased scientific contributions and have 
ensured identifiable advances in population health initatives54. 
 30 
 
1.7 Administrative data characteristics and data linkage 
1.7.1 Administrative data characteristics 
Administrative databases that are used in health research are pre-existing datasets 
whose primary purpose is the storage of information routinely collected from the 
point of service.  These databases typically cover large populations within a defined 
jurisdiction and can span years (if not decades) of service. The variables typically 
collected within these databases are dependent on the dataset, however, they will 
generally include: 
• A unique patient identifier number 
• Patient’s demographic information (e.g. first name, surname, residential 
address, date of birth etc.) 
• Clinical data (e.g. diagnostic code, procedural codes etc.) 
Clinical registries are different to administrative databases, they are designed to 
routinely collect detailed clinical information to follow-up patients, ensure quality 
assurance standards are adhered to and can be readily accessed to support the 
development of evidence-based guidelines. In Australia, cervical screening registers 
(CSRs) fulfil many important roles. including2:  
• Provision of a ‘safety net’ for women who have not had follow-up of an 
abnormal result. 
• Provision of women’s cervical screening histories to cervical cytology 
providers to allow a more detailed evaluation of present findings.  
• Provision of data on the epidemiology and natural history of precancerous 
lesions. 
These registers are powerful tools for researchers due to the level of detailed clinical 
information they contain that current administrative databases simply cannot match. 
In WA, the CSR is an integral component of the WA Cervical Cancer Prevention 
Program (WACCPP). The WACCPP manages and operates the Register – a 
centralised database of Pap smear and follow-up tests, including cervical biopsy and 
HPV results. Data pertaining to cytology, histology, and HPV test results have been 
coded as per WACCPP codification sheets (Appendix 3, Appendix 4) and by lesion 
severity.   
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The CSR of WA has been operational since 1994 and participation to the Register is 
voluntary. Confidentiality of the data held is governed by legislation: Health (Cervical 
Screening Register) Regulations 1991 (WA). Service providers are encouraged to 
inform women about the Register and if the woman does not object, the pathology 
laboratory will routinely forward the cervical screening test results (together with 
basic demographic information) to the Register. Currently (December 2014), the 
Register holds records of approximately 780,000 women screened in WA. Less than 
0.5% of the women have requested that their information be removed from the 
Register since its inception in 1994.  
1.7.2 Data linkage 
Data linkage (or data integration) is defined as the “bringing together from two or 
more different data sources that relate to the same individual, family and/or place”56. 
This concept was first suggested in 1946, Dr Halbert Dunn who proposed the 
development of a  “Book of Life”57. Within this book an individuals significant events 
would be recorded (i.e. birth, education, marriage, divorce, health history and 
death). This information would be collated for a population to assist in generating 
knowledge to further support health and welfare organisation’s. Dr Dunn defined this 
collection process as ‘record linkage’. 
1.7.3 Data linkage techniques 
The linkage of two or more datasets requires identifiers that are common to all 
datasets57,58. Such identifiers may be unique (e.g. patient’s Medicare number), or 
partial (e.g. first name, surname, date of birth, gender etc.) and are matched using 
any of three general techniques. 
1. Unique matching (deterministic matching) - data are linked according to 
unique identifiers (e.g. Medicare number). This would be the most 
expeditious way to link data; however, there are only a few datasets that 
share a common identifier limiting the potential data that can be linked. In 
addition, the potential for recording errors this method may only identify 80-
85% of true matches57. 
2. Fuzzy matching – data are linked according to partial identifiers (usually 
multiple). This technique allows for margin by error by linking records that 
are almost the same. The computer will either present a choice of matches 
to the user or will rely on a scoring system to confirm a match. This usually 
identifies 85-90% of true matches57. 
3. Probabilistic matching – the decision regarding the match is made by 
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decision rules that are built into a software package. These are based on the 
probability that two records are from different people given they have the 
same identifiers. The probabilities are then aggregated to form a score and a 
link is confirmed if a predefined threshold is reached. This typically identifies 
95-99% of true matches with a 1-2% false positive rate56-58. 
 
1.8 Benefits and limitations of administrative data for health research 
Since research arising from administrative data is observational by nature there has 
been some scepticism regarding its value59-60. This is compounded by the heavy 
emphasis on randomized controlled trials (RCT) as the ‘gold standard’ for evaluating 
treatment, which ignores the limitations inherent in RCT methodology59. RCTs do 
not reflect real-life community practice, leaving clinicians to use their judgement in 
extrapolating findings from trials that relate to highly selected patients that is seldom 
encountered. Observational studies using large databases complement RCTs by 
going some way towards addressing their limitations59. Their large size provides 
whole-population capture; thereby avoiding non-representative samples and 
selection bias, which may occur in randomized trials. They measure the true 
effectiveness of an intervention that is based on actual ‘real world’ practice unlike 
the highly controlled RCTs environment. They are also better powered to study rare 
events and small effect size due to very large sample sizes, and the typically long 
time span covered by many databases enables long-term events to be examined. 
Recall bias and bias related to non-participation and loss to follow-up is minimised 
since all eligible people are included and, because these databases are primarily 
created for administrative purposes, individual patient consent is usually not 
required or warranted54,63.  
The advantages and social benefits of research arising from large administrative 
data and data linkage systems over traditional research methods are significant and 
include: 
• Decreased cost of research; utilising existing data is relatively inexpensive 
and is an effective alternative to primary data collection39,61. 
• Increased efficiency of research: access to existing clinical information vastly 
reduces time compared to studies requiring primary data collection62. 
• Conservation of patient privacy: the privacy of individual patients is 
conserved since it is usually not required for personal identifiers to be 
provided to researchers63. Using de-identified administrative databases also 
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conserves the privacy of all patients, regardless of whether they would have 
given consent. A consent-based approach conserves the privacy only of 
those who do not participate, usually at a cost of making the research 
unachievable64. 
• Adding value to existing information assets: integrating datasets generates a 
greater return on investment in the original routine administrative data set 
and will facilitate quality improvement of data through the linkage process66. 
Limitations of studies using administrative data surround the use of data whose 
primary purpose is not for research67. The researcher should be cognisant of how 
the data was collected and coded. The first hurdle relies on the patient with a 
particular condition seeking care – if it is not serious enough to warrant seeking 
healthcare it will not be recorded and cannot be studied. There also needs to be a 
code attached to the condition or procedure of interest (usually International 
Classification of Diseases codes (ICD) e.g. ICD-10) and any additional uncoded 
clinical data cannot be studied. 
Data quality and completeness will tend to vary across databases and variables 
being studied. Some errors are less likely to occur e.g. coding for primary surgical 
procedures; while others have been shown to be prevalent e.g. omitted coding for 
secondary diagnosis66,67. Databases may also change over time with changes in 
codes and the addition or deletion of variables. The way data is generated or 
collected may also vary between datasets and with time66,67. 
It is essential that researcher have a strong understanding and appreciation of how 
their data was generated and how it may have evolved over time. A close working 
relationship between researcher and data custodian is essential to avoid errors in 
analysis and interpretation. Validation studies with chart review can help quantify the 
size of these issues with any given data collection. 
Finally, analysis of these databases should take into account the risk of confounding 
due to comorbidity, socio-demographic factors and effect modification68. Multivariate 
modelling techniques can be used to adjust for these effects so long as they are 
present within the data. 
If these limitations are addressed in the study design, data analysis and 
interpretation, then any study finding can provide valuable additional information to 
existing evidence.  
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1.9 Data linkage in the Australian setting 
The Population Health Research Network (PHRN) was established as a national 
network in 2009 to provide data linkage infrastructure across Australia as part of the 
National Collaborative Research Infrastructure Strategy. It is jointly funded by the 
Australian Commonwealth Government, State and Territory governments, 
universities and research institutes. The PHRN is project lead by the University of 
Western Australia and comprises a network of data linkage units that services each 
State and Territory in Australia and two national data linkage units for cross-
jurisdictional linkages69.  
A unique feature of the PHRN is the development of the Secure Unified Research 
Exchange (SURE) by the Sax Institute. This purpose built remote-access data 
research laboratory allows researchers to work on approved data extracts through a 
virtual computer while data remains stored in a highly secured environment. SURE 
minimises the risk of privacy and confidentiality breaches since data are not stored 
on local computers/networks, improves accessibility of data to researchers and 
facilitates collaborations between researchers across multiple institutes70. 
The facilities and infrastructure developed by the PHRN make it unique worldwide 
since very few countries (notably the UK, Canada and some Scandinavian countries 
such as Sweden and Denmark) have the capability to perform population-based 
data linkage. 
1.10 The WA Data Linkage System (WADLS) 
1.10.1 Western Australian population 
Western Australia covers a land area of 2.5 million square kilometres with a 
population of 2.5 million people71. Its capital city, Perth, is one of the most isolated 
cities in the world. The vast majority of the population (>70%) is located in the 
state’s south-western corner and the remainder scattered sparsely across the state. 
The population is bordered by the Indian Ocean to the west and a vast expanse of 
desert to the east72. The relative geographical isolation minimises the degree to 
which women travel out-of-state to use health care services and creates a ‘captive’ 
population that is ideal for population-based research. 
In 2010, Clark et al. confirmed that WA is ideal for population-based research and 
population-based research is representative of Australia73. Despite WAs isolation 
and only comprising of one-tenth of the national population, it is among three 
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jurisdictions that are closest to the eight-jurisdictional average, in six out of the eight 
socioeconomic and demographic indicators (i.e. proportion of privately insured and 
per capita health expenditure)73. Therefore the findings within this thesis are 
applicable to the wider Australian context. 
1.10.2 The WADLS technology 
The Data Linkage Branch within the WA Department of Health administers the 
WADLS74. The Data Linkage Branch uses computerised probabilistic matching 
based on best practice to create a dynamic master linkage key between more than 
40 population-based administrative and research health data collection in WA74. The 
linkages mean that the total historical population (approximately 3.7 million people 
over more than 30 years) can be researched for all major diseases, disease risk 
factors and health service utilisation and outcomes74.  
The system is built on a foundation of nine core elements: birth, death and marriage 
registrations, hospital separations, midwives’ and cancer notifications, mental health 
service encounters, emergency presentations and electoral roll registrations (Figure 
3). A key aspect of the system design is the separation of linkage-related processes 
from those operating on sensitive clinical and service data. Thus, the WADLS is not 
a database repository but instead consists of pointers or indices to source data 
elements known as the Master Linkage Key75. The original data is maintained under 
the jurisdiction of the individual data custodian and only upon a formal data request 
is the data retrieved from the relevant custodian76. 
The WADLS is both retrospective and prospective, as it is updated routinely with the 
additional capability to create links within and between new external and internal 
data resources. Linkages are identified using probabilistic matching techniques76, 
which are based on unit medical record number (unique only to public hospitals), full 
name and address, phonetic compression algorithms and demographic information 
such as date of birth, gender and postcode. Linkage to health related evens for 
individual subjects are ordered chronologically to form a ‘chain of events’. These 
links are readily broken and re-joined to insert new links or delete incorrect ones 
allowing huge flexibility for expansion. Manual clerical checking is performed to 
search for possible matches in ‘grey zones’ between definite matches and non-
matches75.  
Linkage accuracy has been well validated with the average proportion of invalid links 
(false positives) and missed links (false negatives) estimated as 0.11%77. An audit 
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conducted in 2001 and 2002, involving detailed clerical scrutiny of linked chains  (in 
some cases up to 2,000 links), resulted in an estimate of <0.3% of chains with one 
or more incorrect links78. 
Figure 2 The Western Australian Data Linkage System 
 
1.10.3 WADLS data access and privacy 
In response to rising concerns for patient privacy there has been an increase in the 
legislative and regulatory requirements for access to linked health data for medical 
and health research. This has resulted in a broader system of protocols being 
developed progressively within the WADLS to address the concerns of consumers 
and data custodians with respect to privacy and data release75. 
Access to WADLS is granted only to researchers who have the appropriate Human 
Research Ethics Committee approvals to conduct their research and who have been 
granted permission by relevant data custodians. This ensures the data variables 
requested is appropriate for the proposed research. Strict protocols that have been 
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designed to protect confidentiality and security of the data must be followed and 
researchers are strongly encouraged to only use unidentifiable data74. 
Rather than increasing the risk of privacy within the community, it has been shown 
that the WADLS has significantly reduced the exposure of private and confidential 
personal health information in WA. This has occurred as access to personal details 
in linked data is confined to a small-specialised linkage group that adhere to 
rigorous, strict privacy and confidentiality requirements. As linked data sources have 
come online the requirement for named data in studies has declined dramatically 
from 90% in 1991 to 36% in 200363. 
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The role of general 
practitioners in the continued 
success of the National Cervical 
Screening Program
HPV vaccines that protect against oncogenic HPV 
types 16 and 18, which are responsible for 70% of 
cervical cancers, have been available in Australia 
since 2007.9 Preliminary investigations analysing 
the effect of the HPV vaccine are promising, 
although longitudinal population studies are 
needed to further investigate and validate the 
effectiveness of the vaccine.9 HPV vaccination 
does not replace cervical screening because 30% 
of cervical cancer incidences are caused by other 
oncogenic HPV types that are not protected by the 
vaccine.10 In Australia, all women are advised to 
continue having regular Pap smears whether or not 
they have been HPV vaccinated.11 The National 
Cervical Screening Program (NCSP) has adopted an 
organised approach to cervical screening, which 
has halved cervical cancer mortality12 (Figure 1).
Despite Australia’s two-pronged approach to 
preventing cervical cancer, 771 women were 
diagnosed in 2009 and in 2010, 232 women died 
from this largely preventable disease.12 These 
incidence and mortality outcomes highlight the 
importance of women having routine (2-yearly) Pap 
smears, which can prevent up to 90% of the most 
common type of cervical cancer.13
Women’s participation 
In the general practice setting, about 1.7 per 
100 encounters will be for a Pap smear.14 
Consequently, general practitioners (GPs) play 
an important part in providing information and 
services for women. GPs are well placed to 
encourage women to participate in cervical 
screening, including those with known 
cervical cancer risk factors, such as a history 
of multiple sexual partners, young age at first 
sexual intercourse, current tobacco use and 
immunosuppression (eg. HIV-positive).15–18 
Human papillomavirus (HPV) infection 
is an extraordinarily common viral 
infection (11.4% of women in the general 
population are estimated to be infected 
at any given time1) and acquisition 
can occur rapidly after sexual debut.2–4 
Persistent infection by oncogenic HPV 
types is well recognised as a prerequisite 
for development of cervical cancer.5,6 
Consequently, many countries have 
implemented HPV vaccination and 
an organised approach to cervical 
screening.7 Worldwide, 40 countries 
have HPV vaccination as part of their 
national immunisation schedule8 and 
15 have a systematic cervical screening 
program.7
Aime Munro
Heidi Pavicic
Yee Leung
Victoria Westoby
Nerida Steel
James Semmens
Peter O’Leary
Background 
As the gateway to healthcare for Australian women, general practitioners (GPs) are 
critical to the success of the National Cervical Screening Program (NCSP). Despite 
an enviable record – halving the incidence and mortality of cervical cancer – in 
2010–2011 more than 2.7 million women did not comply with the recommended 
2-yearly screening interval. 
Objective 
General practice strategies are presented to assist GPs in encouraging all women, 
in particular, high-risk and vulnerable women, to participate in cervical screening. 
Discussion 
GPs play a crucial part in addressing the demographic, psychosocial and healthcare 
barriers that prevent women’s participation in cervical screening. Encouraging 
uptake of the human papillomavirus vaccine and educating all patients on the 
importance of continued participation in cervical screening is essential for further 
decreasing the prevalence of this disease through early detection and treatment of 
cervical abnormalities. 
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The continued success of the NCSP relies on 
sustaining a high rate of participation of eligible 
women (ie. those aged 20–69 years and with an 
intact cervix who have commenced sexual activity). 
In 2010–2011, 57.2% of eligible women participated 
in the NCSP at the recommended (2-yearly) interval, 
a significant decline from 63.4% in 1998–199912 
(Figure 2). The Practice Incentives Program (PIP) 
for cervical screening offers financial incentives to 
encourage GPs to perform Pap smears on under-
screened women aged 20–69 years. 
Potential barriers 
Unfortunately, the benefits of participation in 
cervical screening are not fully realised or shared 
equally by all women.19 The reasons for women not 
participating in cervical screening and the impact of 
not participating are complex and multifaceted and, 
therefore, difficult to quantify.20–23 Previous studies 
report that a lower uptake of cervical screening by 
vulnerable populations (ie. women from an ethnic 
background or low socioeconomic status) may be 
associated with cultural beliefs, language barriers, 
lack of information regarding cervical screening 
benefits and prohibition by male partners.22,24–29 
Women often prefer a female practitioner to 
perform their Pap smear. This is particularly relevant 
for Aboriginal and Torres Strait Islander and 
culturally and linguistically diverse women.31 
Different barriers exist at different stages of 
life. Studies have reported that menopausal and/
or post-menopausal women may not realise that 
participation in cervical screening is required 
after the reproductive years.26,27 Younger women 
(<25 years) have reported different barriers to 
participating in cervical screening including:
• being too busy to book an appointment27
• finding it difficult to book in for screening 
through the GP appointment systems28 
• believing they are covered by the HPV vaccine 
and no longer need to have regular (2-yearly) 
Pap smears.29
A GP’s approach to performing a Pap smear is 
critical in assisting women to overcome potential 
feelings of emotional unpleasantness, vulnerability, 
anxiety and fear.24,25 
In 2011, the Western Australia Cervical Cancer 
Prevention Program (WACCPP) conducted a pilot 
study investigating women’s attitudes, knowledge 
and understanding of cervical cancer prevention.25 
Participants included women aged 18–69 years 
(53% of participants were aged 31–54 years), living 
in the WA metropolitan area, with varying levels 
of education (Year 10 or lower, 23%; university 
qualification, 34%) and employment situations 
(full-time, 35% and home duties, 22%), who 
had ever been sexually active and had not had a 
hysterectomy. Thirty women were interviewed to 
investigate factors that contribute to reluctance or 
motivation to participate in cervical screening. Of 
particular relevance to GPs, the study found that 
participants request GPs to validate their emotions 
and to recognise that their feelings are not merely 
perception but are reality. If such acknowledgement 
occurs, it will support GPs in assisting their patients 
to make an empowered decision to have a Pap 
smear, rather than the patient simply following 
directions.25 
Breaking down the barriers
Communication
Talking through concerns and addressing why the 
patient may feel uncomfortable and/or be avoiding 
cervical screening will promote the patient’s 
commitment to overcoming perceived barriers 
and improve their adoption of preventive health 
behaviours. The WACCPP pilot study reported that 
66% (n = 368) of participants knew ‘not much/
nothing’ about cervical cancer.25 Allowing adequate 
time with patients to provide them with information 
about the benefits and limitations of the Pap smear 
will break down the barriers to patients accessing a 
screening service.30 
Before performing the Pap smear, the 
consultation should include advice on the 
implications of positive and negative test findings, 
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possible, providing access to female Pap smear 
providers (eg. employing a female nurse/midwife 
who can perform cervical screening services). In this 
way, general practices can contribute to a reduction 
in social inequalities and improve access to cervical 
screening services.30,41 
Promoting access to cervical screening can also 
be achieved by providing information about where 
patients can find practitioners whom they consider 
acceptable to perform the screening. It is important 
to have an awareness of:
• the Medicare Local
• local women’s health centres 
• Aboriginal medical services 
• healthcare services for women with disabilities
• healthcare services for migrant and refugee 
women.
A patient who attends a different practitioner for 
Pap smears instead of her usual GP should be 
encouraged to have a copy of her cervical screening 
test result forwarded to her usual GP. This will 
assist in:
• supporting the patient with follow-up care if an 
abnormality is detected 
• reminding the patient to re-screen at the 
appropriate interval.
Alternatively, with the patient’s permission, the 
appropriate state or territory Cervical Cytology 
Registry can be contacted (13 15 56) to request the 
patient’s most recent cervical test result. 
Conclusion
GPs play a critical part in educating women on the 
benefits of the HPV vaccine and participating in 
routine cervical screening. Providing comprehensive 
education to women provides the GP with an 
opportunity to espouse a life course approach 
to cervical cancer prevention. Implementation 
of key strategies in general practice, such as 
provision of accessible services, recall systems and 
opportunistic screening, will ensure GPs continue to 
contribute to the success of the NCSP. 
Key points
• Check eligibility for the PIP – Cervical 
Screening. Information can be found at www.
medicareaustralia.gov.au/provider/incentives/
pip/index.jsp
• Provide information (including posters, fact 
sheets, DVD’s, brochures etc.) to support 
patients. These can be found on the National 
and a plan for communication of the test result.31 
In particular, a process whereby normal Pap smear 
results are provided over the phone has been shown 
to be helpful.30,32–34
Recall and reminder systems have mutual 
benefits for patients and GPs35–37 by providing 
individual support to patients, promoting adherence 
to screening recommendations and improving 
continuity of care. Computerised patient record 
management software packages are available for 
use in practices and may assist GPs in having timely 
recall and reminder practice systems. Practices 
could use this software to identify patients who 
are due for screening, as well as those who are 
under-screening, and invite those patients to have 
a Pap smear. Australian cervical cytology registries 
complement general practice reminder services 
by providing a ‘safety net’ through contacting 
healthcare providers and the patient should they be 
overdue for their next cervical screening test. 
Opportunistic screening
It is imperative that GPs opportunistically encourage 
women’s participation in cervical screening. This is 
particularly important for women who are under-
screened (have not had a Pap smear in the past 4 
years) and can be achieved by identifying patients 
due for screening and encouraging eligible patients 
to have a Pap smear. Other strategies include 
educating patients about the screening pathway, 
when it is appropriate to commence and finish 
cervical screening, and offering a Pap smear during 
the consultation. Because of time constraints, these 
strategies may not always be feasible in the general 
practice setting. However, informing patients that 
they are due for their Pap smear and offering to 
make another appointment will serve to highlight 
the importance of cervical screening and encourage 
participation.
Delivery of screening 
services
Service delivery is critical, as communication alone 
will not result in sustained behaviour change. 
One of the most important strategies to ensure 
women’s participation in cervical screening is 
providing accessible and acceptable screening 
services.33,35–40 This can be achieved by offering 
patients a variety of clinic times (including 
facilitating booking appointments through email), 
offering bulk-billing for Pap smears and, where 
Cervical Screening Program website at www.
cancerscreening.gov.au 
• Be aware that the NCSP is conducting 
a Renewal, a review of the science and 
technologies related to cervical cancer 
prevention. The Renewal will ensure that all 
Australian women have access to a cervical 
screening program that is based on the best 
available evidence and promotes best clinical 
practice. Information can be found at www.
msac.gov.au/internet/msac/publishing.nsf/
Content/1276 
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Investigation of the clinical significance of cytologically 
detected endocervical (glandular) abnormalities  
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2.1 Background 
A variety of diseases affect the uterine cervix, of which glandular abnormalities 
comprise less than one-quarter79. As glandular abnormalities are uncommon, the 
acquisition of knowledge and clinical significance of these lesions has occurred 
slowly as compared to that of squamous lesions2, 4, 79. In 2004, the AMBS 
classification for cervical glandular abnormalities was revised because of our 
increasing understanding of the diagnostic importance of the range of endocervical 
changes observed in cytological specimens7.  
The revised low-grade glandular categories took into consideration indeterminate 
glandular cell changes without the features of ACIS. The revised low-grade 
glandular categories are 7: 
• “Atypical glandular cells of undetermined significance is to be reported when 
the medical scientist/pathologist is unsure whether the affected cells are 
endocervical (site unknown)”. 
• “Atypical endocervical cells (AEC) of undetermined significance is to be 
reported when the medical scientist/pathologist is confident that the affected 
cells are endocervical (site known)”. 
Currently, women diagnosed with AEC are referred to colposcopy with subsequent 
management dependent on the colposcopic and biopsy findings7. To date, no study 
has investigated the clinical outcomes for women with cytological findings of AEC 
and the risk of development of or of concurrent high-grade cervical disease, 
squamous or glandular. Consequently, Chapter 3 investigates women’s health 
outcomes after a diagnosis of low-grade glandular lesions and addresses Objective 
1. This thesis provides valuable insights into the clinical significance of AEC 
including associated health outcomes. Importantly, Publication 1 confirms that an 
AEC cytology test results definitively warrant further investigation. 
2.2 Aim  
Chapter 3 (Objective I) investigated the incidence of histologically confirmed high-
grade cervical dysplasia (CIN2, CIN3 or ACIS), cervical carcinoma and endometrial 
carcinoma in women that presented with AEC on cervical cytology. 
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2.3 Methods 
A population-based retrospective study examining the clinical outcomes of women 
with AEC detected on a screening cervical smear. Cytology and histology results 
were extracted from the Cervical Screening Registry (CSR) of Western Australia 
(WA). Time-to event analysis was used to predict the odds of having or developing 
in situ and/or invasive neoplasia. 
2.4 Results 
AEC was reported in index smears from 0.093% (584/622754) women during the 
study period. No follow-up data was available for 35 AEC cases. Sixty-six of the 
remaining 549 women (11.8%) had, or developed, high-grade cervical dysplasia 
within five years of their index AEC diagnosis. Endometrial cancer was diagnosed in 
21 women and cervical cancer in four women during the follow-up period. 
2.5 Conclusion 
Cytologic demonstration of AEC requires careful gynaecologic evaluation, 
particularly in younger women who may be found to have either high-grade cervical 
lesions (CIN2, CIN3 or ACIS), while in older women, the possibility of endometrial 
neoplasia needs to be considered (Publication 1). 
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Original Article
Risk of high-grade cervical dysplasia and gynaecological malignancies
following the cytologic diagnosis of atypical endocervical cells of
undetermined significance: A retrospective study of a state-wide
screening population in Western Australia
Aime MUNRO,1 Vincent WILLIAMS,2 James SEMMENS,3 Yee LEUNG,4 Colin J.R.
STEWART,4 Jim CODDE,3 Katrina SPILSBURY,3 Nerida STEEL,1 Paul COHEN4 and
Peter O’LEARY5
1Women’s Health Clinical Care Unit, WA Cervical Cancer Prevention Program, 2School of Biomedical Sciences, Curtin University,
3Centre for Population Health Research, Curtin University, 4School of Women’s and Infants’ Health, University of Western Australia,
and 5Faculty of Health Sciences, Curtin University, Perth, Western Australia, Australia
Background: In 2006, Australia adopted a revised cervical cytology terminology system, known as the Australian
Modified Bethesda System (AMBS). One substantial change in the AMBS was the introduction of the diagnostic category
of atypical endocervical cells (AEC) of undetermined significance.
Aim: The aim of this study was to investigate the incidence of histologically confirmed high-grade cervical dysplasia
(cervical intra-epithelial neoplasia (CIN) grades 2 and 3 and adenocarcinoma in situ (ACIS)), cervical carcinoma and
endometrial carcinoma in women presenting with AEC on cervical cytology.
Methods: A seven-year retrospective study examining clinical outcomes of women with AEC on a screening cervical
smear. Cytology and histology results were extracted from the Western Australia Cervical Screening Registry, and time-to-
event analysis was used to predict the odds of having or developing in situ and invasive neoplasia.
Results: AEC was reported in index smears from 0.093% (584/622754) women during the study period. No follow-up
was available in 35 AEC cases. Sixty-five of the remaining 549 women (11.8%) had, or developed, high-grade cervical
dysplasia within five years of their index AEC diagnosis. Endometrial cancer was diagnosed in 21 women and cervical
cancer in four women during the follow-up period.
Conclusion: Cytologic demonstration of AEC requires careful gynaecologic evaluation, particularly in younger women
who may be found to have either high-grade squamous (CIN) or glandular (ACIS) lesions, while in older women, the
possibility of endometrial neoplasia needs to be considered.
Key words: atypical endocervical cells, atypical glandular cells, cervical cancer, cervical cytology, cervical screening,
endometrial cancer, Papanicolaou smear.
Introduction
The incidence of and mortality from cervical cancer
(specifically squamous carcinoma) has been reduced in
many countries as a result of cytology screening using the
Papanicolaou (Pap) smear,1–5 but significant challenges
remain. In particular, there has not been a substantial
reduction in the number of invasive glandular neoplasms
(adenocarcinomas), which now represent up to 20% of all
cervical malignancies.1,6 Compared to squamous lesions,
endocervical (glandular) abnormalities are more likely to
be under-diagnosed cytologically and the role of the Pap
smear in identifying asymptomatic women with high-grade
pre-invasive glandular neoplasia (adenocarcinoma in situ,
ACIS) is less clearly defined.6 This may be partly
attributable to sampling error, given the anatomical
distribution of the endocervical epithelium, and may also
reflect the diagnostic difficulties encountered by
cytopathologists when interpreting the relatively rare
glandular lesions.1,6–8
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Atypical endocervical cells (AEC) of undetermined
significance is an uncommon cervical cytology finding,
being reported in less than 1% of Pap smear tests.1
Atypical endocervical cells are reported when the medical
scientist/pathologist is confident that the affected cells are
endocervical. These smears demonstrate changes in
glandular cells that are considered beyond those typical of
a reactive process but insufficient for a confirmed
diagnosis of endocervical neoplasia (ACIS or
adenocarcinoma).9 Several studies have demonstrated that
AEC may be associated with premalignant or malignant
cervical lesions but most have been limited by short
follow-up periods and/or relatively small numbers of
cases.7,10–12 Furthermore, the risk of significant pathology
has not always been correlated with age, prior smear
history, presence of endocervical cells in preceding
cytology samples or the socio-economic status of the
patient. In the present study, we have investigated the
potential relationship between these factors and the risk of
high-grade cervical dysplasia and gynaecological
malignancies in women with a cytological diagnosis of
AEC in Western Australia (WA) over a seven-year period.
Materials and Methods
Study design
This is a retrospective cohort study of women with an
index Pap smear demonstrating AEC during the period 1
January 2006 to 31 December 2012 in WA. Study data
were obtained in June 2013 following approval from the
Curtin University Human Research Ethics Committee
(ethics research project number: HR 86/2012).
Source of data
As part of the National Cervical Screening Program
(NCSP), the Western Australian Cervical Cancer
Prevention Program (WACCPP) encourages eligible
women (women aged 20–69 years that have not had
hysterectomy and have commenced sexual activity) to
undergo a screening Pap smear every two years. The
WACCPP maintains the Cervical Screening Register
(CSR) of WA which compiles the results of Pap smears
and related diagnostic tests from all laboratories in WA;
reporting of these data is a legislative requirement. The
CSR is an opt-out system and <0.1% of women request
that their results be excluded. A de-identified data set was
extracted from the CSR of cervical screening histories for
all women residing in WA who presented with AEC
during the study period.
Women were allocated measures of socio-economic
status using the Socio-Economic for Indexes for Areas
(SEIFA) for Australia obtained through the Australian
Bureau of Statistics.13 Additionally, women’s postcodes
were assigned to one of four Accessibility/Remoteness
Index of Australia levels based on their SEIFA values.14
Due to small numbers, remote and very remote postcodes
were collapsed into one category for the purposes of this
study.
Classification of cytology and histology results
Cervical cytology results were classified in accordance with
the Australian Modified Bethesda System (AMBS) 2004
which is directly comparable to the Bethesda System 2001
(Table 1).9 Histologically, the high-grade cervical lesions
included cervical intra-epithelial neoplasia (CIN) grades 2
and 3, ACIS and cervical carcinoma (all types). For
primary endometrial abnormalities, only cases with a
diagnosis of endometrial carcinoma (all types) were
recorded. Endometrial hyperplasia data were not available
within this study cohort. All histology results were
classified according to the highest grade abnormality
identified.
Inclusion and exclusion criteria
Only women aged 18–75 years with index cervical
cytology showing AEC (with a normal, low-grade or
possible low-grade squamous component) were included
in this study. Exclusion criteria included: (i) any prior
screening history of a high-grade abnormality; (ii) previous
histological confirmation of low- or high-grade CIN or
invasive cervical cancer; (iii) hysterectomy; and (iv) no
available follow-up data.
Management pathway following AEC
Women were managed in accordance with the 2006
NHMRC Guidelines which recommend that women with
AEC be referred directly for colposcopy.9 Women with
normal colposcopy usually would be managed
conservatively with repeat cytology and colposcopy at six
months whereas women with abnormal colposcopic
findings generally underwent diagnostic biopsy.9
Australian cervical cytology registries do not routinely
collect colposcopy data; however, the CSR of WA does
record the practitioner’s status (ie a specialist code for
gynaecologist, gynaecologist/oncologist), and therefore, this
study was able to determine whether women had further
investigation under the care of a specialist.
Correlative analyses
Time-to-event analyses were performed to investigate the
risk factors associated with a subsequent high-grade
cervical lesion after the cytological diagnosis of AEC. This
was not performed with the cervical or endometrial
cancers in view of the small number of cases. The follow-
up interval was defined as the time from the index AEC
test until the diagnosis of a high-grade lesion histologically
or the study censor date (the last cervical smear result).
Covariates included in the time-to-event analysis were
age, socio-economic status, an index of accessibility to
services, Pap smear screening history and calendar period.
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The interval between the index AEC smear and the
preceding cervical cytology was calculated, and the
screening history was categorised as outlined in Table 2. It
was also noted whether the preceding cytology sample
included endocervical cells.
Statistics
Kaplan–Meier graphs were constructed to investigate the
survivorship function (time until biopsy-confirmed high-
grade cervical lesion or malignancy), and log-rank tests
were used to assess equality of the survivorship function.
Parsimonious proportional hazards models were
constructed to investigate the relative rate (hazard rate) of
having, or subsequently, developing a high-grade cervical
lesion postindex AEC after simultaneously adjusting for
multiple factors. Models were constructed using
purposeful selection of covariates. Violation of the
proportional-hazard assumptions was assessed, and
biologically plausible interaction terms between variables
were tested. The 95% confidence intervals (CI) for the
hazard rate ratios were also calculated. STATA/IC 13.0
(STATA Corporation, College Station, TX, USA) was
used for statistical analysis.
Results
During the study period, 3,237,906 cervical smears were
performed on 622,754 women. Of these, 584 women
(0.1%) with no previous history of histologically confirmed
low- and/or high-grade cervical lesions had AEC. Thirty-
five women were excluded from further analysis as follow-
up data were unavailable. For the remaining 549 women,
the mean age at index AEC smear was 41.4 years (range
18–75 years) and the median follow-up was 1.9 years
(range <1–6.8 years). Baseline characteristics of the cohort
are presented in Table 2.
Table 1 The Bethesda System (2001) and Australian Modified Bethesda System (AMBS) (2004) classification of cervical cytology
abnormalities9
The Bethesda System AMBS 2004 Incorporates
Squamous abnormalities
Atypical squamous cells,
undetermined significance (ASC-US)
Possible low-grade squamous
intra-epithelial lesion
Nonspecific minor squamous cell changes.
Changes that suggest, but fall short of,
HPV/cervical intra-epithelial neoplasia (CIN) 1
Low-grade squamous
intra-epithelial lesion
Low-grade squamous
intra-epithelial lesion (LSIL)
HPV effect, CIN 1
Atypical squamous cells,
possible high-grade lesion (ASC-H)
Possible high-grade squamous
intra-epithelial lesion
Changes that suggest, but fall short of, CIN 2,
CIN 3 or squamous cell carcinoma
High-grade squamous
intra-epithelial lesion (HSIL)
High-grade squamous
intra-epithelial lesion (HSIL)
CIN 2, CIN 3
Squamous cell carcinoma Squamous cell carcinoma Squamous cell carcinoma
Glandular abnormalities
Atypical endocervical cells of
undetermined significance
Atypical endocervical cells of
undetermined significance
Nonspecific minor cell changes in endocervical cells
Atypical glandular cells of
undetermined significance
Atypical glandular cells of
undetermined significance
Nonspecific minor cell changes in glandular cells
Atypical endocervical cells,
possibly neoplastic
Possible high-grade glandular lesion Changes that suggest, but fall short of,
AIS or adenocarcinoma
Endocervical
adenocarcinoma in situ
Endocervical adenocarcinoma in situ Adenocarcinoma in situ
Adenocarcinoma Adenocarcinoma Adenocarcinoma
Table 2 Summary of demographic details
Characteristics n = 549 Percentage
Age at index smear (years)
≤24 52 9.5
25–34 111 20.2
35–44 162 29.5
45–54 153 27.9
≥55 71 12.9
Previous screening interval prior to index AEC (years)
Never screened 77 14.0
≤1 and required follow-up 43 7.8
<1 year early rescreen 39 7.1
>1 year although required follow-up 16 2.9
≥1- 4 years 321 58.5
>4 years 53 9.7
Endocervical component present in Pap smear prior to AEC?
Yes 379 69.0
No 93 16.9
No Pap smear 77 14.1
Number of women than underwent specialist evaluation
Yes 456 83.1
No (repeat Pap smear) 93 16.9
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Of this patient cohort, 198 women were managed
conservatively with repeat cytology; 105 (53%) of these
women were under the care of a specialist who performed
the cytology test. No high-grade lesions were identified on
follow-up of this cohort. The remaining 351 women
underwent biopsy within 24 months of the AEC smear.
The histological findings for the subset of women who
underwent biopsy (n = 351) are summarised in Table 3.
Ninety-one (25.9%) demonstrating high-grade
abnormalities, including 28 (8.0%) CIN 2/3, 38 (10.8%)
ACIS, 4 (1.1%) cervical carcinoma and 21 (6.0%)
endometrial carcinoma.
Of the women diagnosed with endometrial cancer, the
majority (66.7%) of cases occurring for women aged
≥55 years (Table 4). The median follow-up time from
index AEC to endometrial diagnosis was 0.2 years (range
<1 month to 6 years). All women with endometrial cancer
had a hysterectomy performed.
Younger women were more likely than older women to
have high-grade cervical lesions, particularly within the
first three to four years postindex AEC smear (Table 4).
The probability of remaining high-grade lesion free five
years postindex AEC was 66% (95% CI 0.5–0.7) for
patients aged 25–34 years (P-value = 0.003) compared to
97% (95% CI 0.9–1.0) for patients aged 45–54 years
(P-value = 0.001). Age at AEC result remained strongly
associated with the risk of developing a high-grade lesion
even after adjusting for other covariates (Table 4).
Women aged 25–34 years were at higher risk of
developing high-grade lesions (HR 2.3) compared with
women aged 35–44 years.
Compared to women with previous normal cervical
screening, women with a previous low-grade abnormality
and those with no prior screening history were also at
increased risk of developing a high-grade lesion (Table 4).
There was no correlation between socio-economic status,
accessibility to services, the presence or absence of
endocervical cells in the preceding cervical smear and the
risk of developing a high-grade cervical lesion.
Discussion
To our knowledge, this is the first Australian study to
investigate the clinicopathological correlations of AEC on
cervical cytology since the AMBS introduced this
diagnostic category in 2006.9 Advantages of this study
include the large size (584 cases) and population-based
nature of the patient cohort together with a relatively long
follow-up period of up to 6.8 years. Furthermore, by
performing extensive data matching review, the CSR of
WA was able to accurately determine clinical outcomes,
including subsequent cervical cytology and histopathology
findings in the great majority (94%) of cases.
The present study confirmed the low incidence (1%) of
AEC in routine Pap smears. However, similar to earlier
Table 3 Histological abnormality (highest grade lesion) according
to age
Age group (years)
≤24 25–34 35–44 45–54 ≥55 Total
Histology outcomes
Unsatisfactory 0 0 0 0 2 2
Negative 8 30 75 72 24 209
Low grade* 9 7 17 10 6 49
High-grade intra-epithelial lesions
CIN 2 0 3 6 1 0 10
CIN 3 3 9 5 1 0 18
ACIS 6 20 10 1 1 38
Cervical malignancy
Adenocarcinoma 0 2 0 1 0 3
Adenosquamous
carcinoma
0 1 0 0 0 1
Endometrial malignancy
Endometrial
carcinoma
0 0 1 6 14 21
Total 26 72 114 92 47 351
*Low grade includes Atypia – atypical immature squamous
neoplasia, HPV effect, Mild dysplasia (CIN I).
Table 4 Hazard ratios of confirmed cervical high-grade lesion postindex atypical endocervical cells (AEC) smear according to age,
screening history and date of index smear
Hazard rate ratio 95% CI P-value
Age (years)
≤24 1.2 0.5–2.7 0.649
25–34 2.3 1.3–4.0 0.003
35–44 (reference group) 1.0
45–54 0.1 0.1–0.5 0.001
≥55 0.1 0.1–1.1 0.059
Importance of screening interval prior to index AEC (years)
Never screened 2.5 1.4–4.6 0.003
≤1 and required follow-up* 2.7 1.2–6.2 0.015
≤1 year early rescreen 0.8 0.2–3.4 0.748
≥1 year although required follow-up* 3.1 1.1–9.0 0.033
≥1–4 years no follow-up was required (reference group) 1.0
≥4 years 1.7 0.7–4.0 0.199
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investigations, we found that a significant minority of
patients (12%) had, or subsequently developed, high-grade
cervical dysplasia (CIN 2/3 or ACIS), and cervical and
endometrial carcinomas were identified in a further 0.7
and 3.8% cases, respectively. In addition, 8.9% of
patients had a biopsy-confirmed low-grade squamous
abnormalities, including HPV changes or CIN 1 that
would require closer cytological surveillance. Thus, the
presence of AEC requires careful gynaecological
evaluation.
While the cytological diagnosis of AEC implies an
abnormality in endocervical cells, like earlier reports we
found that a significant proportion of in situ cervical
neoplastic lesions proved on histology to be of squamous
(CIN) rather than endocervical (ACIS) type. This
illustrates the cytological difficulty in distinguishing
squamous and glandular lesions in some instances,
particularly when cellular material is limited or poorly
preserved, or when CIN involves endocervical crypts.15,16
Similarly, most adenocarcinomas identified in this series
were of endometrial rather than endocervical origin. It is
well recognised that the distinction of endocervical and
endometrial carcinoma can be problematic even on
biopsy material, sometimes necessitating additional
immunohistological studies for resolution.17
We found that the risk of high-grade cervical dysplasia
was greater in younger women (aged 25–34 years), and in
those with no cervical screening history or a previously
detected low-grade cytological abnormality. In contrast,
there was no correlation with socio-economic status or
with access to services. Such factors could be taken into
account in stratifying patient management, including the
type or time interval for follow-up. There was also no
correlation between the detection of high-grade dysplasia
and the presence of endocervical cells in the cervical
smear preceding the index AEC smear. This may be
partly explained by the significant proportion of lesions
ultimately classified as being of nonendocervical type, as
discussed above.
In the present study, 4.8% of patients with AEC had
invasive malignancies and the majority were endometrial
cancers in women aged >45 years. Indeed, 30% of patients
aged ≥55 years with AEC proved to have endometrial
carcinoma. To our knowledge, there is no other Australian
or international study that is directly comparable to the
data presented in this study. Study comparisons are
challenging due to previous Australian studies being
conducted prior to implementation of the AMBS (2004)
and in the majority of cases having grouped together AEC
with other glandular abnormalities (ie endometrial and
ovarian abnormalities).18,19 Whilst Mitchell (2004)20
reported on minor nonspecific changes of glandular cells,
the results presented here are still noncomparable due to
the classification changes.
Regardless, the present study demonstrates the
requirement to exclude significant endometrial pathology
in older women presenting with AEC. It is also worth
noting that our study did not include patients who would
be considered at increased risk of endometrial malignancy
such as those with histologically documented endometrial
hyperplasia.
Recently Australia’s Medical Services Advisory Council
recommended that the NCSP should move towards five
yearly screening using primary HPV testing with partial
HPV genotyping and reflex liquid-based cytology triage.21
This is potentially beneficial in that HPV testing should
identify most cervical neoplasms (in situ or invasive) and
could help to differentiate cervical from noncervical
lesions. However, it should be noted that not all cervical
adenocarcinomas (or their precursors) are HPV-related,22
and women with a cytological diagnosis of AEC will still
require thorough investigation.
In summary, the present study supports the current
recommendation that women with AEC on a cervical
smear be referred for colposcopic examination. In
general, further management will be dictated by the
findings at colposcopy and/or biopsy, but more intense
follow-up may be appropriate in younger women and in
those with no previous cervical screening or with
previous low-grade cytological abnormalities. Conversely,
in older patients (particularly those aged ≥55 years),
endometrial sampling is indicated in view of the risk of
endometrial carcinoma.
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3.1 Background 
The treatment options for women with histologically confirmed ACIS remain 
controversial globally and there is a lack of reliable data to support the 
development of evidence-based management. In Australia, conservative 
treatment of ACIS by CKC biopsy is the “gold standard”7. CKC is currently 
preferred, as it appears to achieve more success with negative margins within the 
cone specimen. However, this procedure comes with the risk of complications, 
specifically for women desiring fertility preservation. CKC complications may 
include antagonistic obstetric outcomes such as second trimester miscarriage or 
pre-term delivery30, 79. Unfortunately, the majority of ACIS studies to date have 
been institutional reviews with a small number of cases and short follow-up 
intervals80-82. Furthermore, studies investigating the efficacy of other ACIS 
treatment modalities are limited83-86.   
Further epidemiological studies that report health outcomes of women treated 
conservatively (i.e. not with hysterectomy) for ACIS are required. The results of 
this work contributed to one of the first publications to explore this question. This 
is particularly important given that evidence-based management for glandular 
abnormalities of the cervix guidelines are lacking and the incidence of ACIS and 
invasive adenocarcinoma continues to increase, especially amongst young 
women. Therefore, the efficacy of adopting a conservative treatment approach for 
women with biopsy-confirmed ACIS were compared within Chapter 3 (Objective 
2). Publication IV provides clinicians with clinical management recommendations 
for patients wishing to preserve their fertility. 
3.2 Aim 
The outcomes of patients with ACIS treated with CKC biopsy or LEEP for the 
treatment of ACIS were compared in Chapter 3 (Objective 2). 
3.3 Methods 
This is a retrospective, population-based cohort study of Western Australian 
patients with ACIS diagnosed between 2001 and 2012. Health outcomes 
included the patient’s pathological margin status and the incidence of persistent 
or recurrent endocervical neoplasia (ACIS and adenocarcinoma) during follow-up 
(<12 months) and surveillance (≥12 months) periods. 
 47 
 
3.4 Results 
The study group comprised 338 patients including 107 (32%) treated initially by 
LEEP and 231 (68%) treated by CKC biopsy. Overall, 27 (8.0%) patients had 
ACIS persistence/recurrence while 9 (2.7%) were diagnosed with 
adenocarcinoma during the follow-up and surveillance periods. No patient died of 
cervical cancer within the study period.  
There were no significant differences in the incidence of persistent and/or 
recurrent endocervical neoplasia according to the type of excisional procedure.  
3.5 Conclusion 
LEEP and CKC biopsy appear equally effective in the treatment of ACIS for 
women wishing to preserve fertility (Publication 2). Patients undergoing 
conservative management for ACIS should be closely monitored, particularly if 
biopsy margins are positive in initial excision specimens. Patients and their 
clinicians should be aware of the potential risks of residual and recurrent disease. 
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H I G H L I G H T S
• Women treated for ACIS by cold knife cone biopsy or LEEP were monitored for disease persistence.
• There was no difference in ACIS disease persistence between CKC and LEEP after 3.6 years of follow-up.
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Objective. To compare the outcomes of patients with cervical adenocarcinoma in situ (ACIS) treated with
cold knife cone (CKC) biopsy or loop electrosurgical excision procedure (LEEP) for the treatment of cervical
adenocarcinoma in situ (ACIS).
Study design. This is a retrospective, population-based cohort study of Western Australian patients with
ACIS diagnosed between 2001 and 2012. Outcomes included pathological margin status and the incidence of
persistent or recurrent endocervical neoplasia (ACIS and adenocarcinoma) during follow-up (b12 months)
and surveillance (≥12 months) periods.
Results. The study group comprised 338 patients including 107 (32%) treated initially by LEEP and 231 (68%)
treated by CKC biopsy. The mean age was 33.2 years (range 18 to 76 years) and median follow-up interval was
3.6 years (range b1 year to 11.8 years). Overall, 27 (8.0%) patients had ACIS persistence/recurrencewhile 9 (2.7%)
were diagnosed with adenocarcinoma during the follow-up and surveillance periods. No patient died of cervical
cancer within the study period. There were no significant differences in the incidence of persistent and/or
recurrent endocervical neoplasia according to the type of excisional procedure. Patients with positive biopsy
margins were 3.4 times more likely to have disease persistence or recurrence.
Conclusion(s). LEEP and CKC biopsy appear equally effective in the treatment of ACIS for women wishing
to preserve fertility. Patients undergoing conservative management for ACIS should be closely monitored,
particularly if biopsy margins are positive in initial excision specimens. Patients and their clinicians should be
aware of the potential risks of residual and recurrent disease.
© 2015 Elsevier Inc. All rights reserved.
1. Introduction
The incidence of cervical cancer in developed countries has
decreased significantly in the past few decades largely due to the
adoption of public health screening programmes, but this mainly
reflects a decrease in squamous cell carcinoma [1–3]. By contrast,
the incidence of cervical adenocarcinoma has increased in both rela-
tive and absolute terms, and now represents 20–25% of all cervical
cancer cases [1–3]. The recognised precursor to cervical adenocarcino-
ma is adenocarcinoma in situ (ACIS), and this frequently coexists with
high-grade squamous intraepithelial neoplasia (CIN) and/or squa-
mous cell carcinoma [4–6]. Cervical cytology is generally less sensitive
in the detection of cervical glandular abnormalities compared to CIN,
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and it is reported that ACIS may also evade detection at colposcopy
[7–10].
Conservative management of women with ACIS is controversial
since these lesions can persist/recur and may co-exist with, or progress
to, cervical adenocarcinoma [5,6,11]. Consequently hysterectomy is
regarded as the definitive treatment [12,13]. However, ACIS commonly
affects young women who may wish to preserve fertility and therefore
local excisional procedures such as cold knife cone (CKC) biopsy or
loop electrosurgical excision procedure (LEEP) have been utilized as
alternatives to hysterectomy [6,7,11–14].
In Australia, CKC is regarded as the ‘gold standard’ treatment for ACIS
[12]. There is a perception that there is a greater likelihood of incom-
plete excision with LEEP because the depth of excised tissue and the
overall dimensions of the specimen tend to be smaller in comparison
to CKC. It is also argued that the tissue margins in a LEEP biopsy may
show significant thermal artefact, which can interfere with the patho-
logical assessment of biopsy margins [15,16]. Some studies have
shown a greater risk of a positive endocervical margin with LEEP but
these have included cases in which ACIS was not suspected prior to
the excisional procedure [17–19]. Conventional management has also
been challenged by recent data which suggest that the risk of positive
margins and disease recurrence are equivalent following LEEP or CKC
biopsy [6,11]. Such findings could potentially alter treatment guidelines
since accepted advantages of LEEP include the avoidance of general
anaesthesia, provision of treatment in an outpatient setting, lower
morbidity, and reduced rates of obstetric complications, all of which
have significant cost benefits [6,11,19–23].
Nevertheless, the efficacy of conservative treatment of ACIS remains
uncertain since most studies to date have been limited by small sample
size and short follow-up [6,7,17–19]. In the present study we have
determined the rates of residual and recurrent endocervical neoplasia
in a large, population-based cohort of women in Western Australia
(WA) who had conservative management of ACIS. Outcomes were
correlated with patient age and socioeconomic background, type of
excisional procedure, margin status, and the presence of concurrent
high grade CIN.
2. Methods
2.1. Data sources and linkage procedure
The Cervical Screening Register (CSR) of WA is required by legisla-
tion to compile all cervical test results (human papillomavirus (HPV)
detection, cytology and histology) for women who reside in WA. The
CSR is an ‘opt out’ register and less than 0.05% ofwomen request remov-
al of their demographic information and results. The WA Data Linkage
System (WADLS) provided a de-identified extraction of linked cancer
registrations and death records for all women with ACIS identified by
the CSR of WA from 2001 to 2012. The WADLS is an internationally
renowned, population-based, validated and ongoing data linkage sys-
tem that creates links among a number of state health administrative
data sets [24–26].
Follow-up data were available up to May 2013. Death records were
used to verify the number of cervical cancer related deaths and to censor
womenwhodied during follow-up. Study datawere obtained following
approval from the Curtin University Human Research Ethics Committee
(ethics research project number: HR 86/2012) and the Western
Australian Department of Health Human Research Ethics Committee
(ethics research project number: 2012/49).
2.2. Participants
The CSR was used to identify women aged 18 years or older
who were reported to have ACIS on either routine cervical cytology
screening or on cervical punch biopsy. Only women who had histologi-
cal confirmation of ACIS following CKC or LEEP biopsy were included in
the study. Patients were excluded if they had prior histological docu-
mentation of CIN or cervical cancer. Cervical cytology was classified
according to the Australian Modified Bethesda System 2004 [12].
Patient age at the time of treatment was classified as ≤30 years or
N30 years. Postcode of residence was used to assign a socioeconomic
level using the Australian Bureau of Statistics 2006 Socio Economic
Indexes for Areas (SEIFA) [27]. Patients underwent CKC or LEEP proce-
dures according to the surgeon's standard practice.
2.3. Histopathology findings
The following biopsy findings were determined from review of the
histopathology reports: the type of biopsy (CKC or LEEP), depth of the
specimen (measured macroscopic extent along the cervical canal),
presence of concurrent CIN and resection margin status. The latter was
considered ‘positive’ if any margin (ectocervical, endocervical or deep/
circumferential) was involved by ACIS, ‘negative’ if all margins were
histologically clear, and ‘indeterminate’ if margins could not be assessed
or were not documented.
2.4. Follow-up
Management following the initial CKC biopsy or LEEP was deter-
mined. Subsequentmanagement potentially included cytological review,
repeat CKC biopsy or LEEP, or hysterectomy. The follow-up period was
defined as the date of the initial ACIS treatment to the date of the last
follow-up procedure (e.g., cervical cytology, biopsy or hysterectomy).
2.5. Principal outcomes
The principal outcomes investigated were i) persistence of ACIS
or diagnosis of adenocarcinoma during the follow-up period (defined
as disease detection b12 months after the initial diagnosis), and ii) re-
currence of ACIS or diagnosis of adenocarcinomawithin the surveillance
period (defined as disease detection ≥12 months after the initial
diagnosis). Cancer mortality was a secondary outcome measure.
2.6. Statistics
STATA/IC 13.0 (STATA Corporation, College Station, USA) was used
for data manipulation and statistical analysis. Fisher's exact test was
used to evaluate similarities between the CKC and LEEP groups. Time-
to-event (survival) analysis was performed using Cox models to inves-
tigate patient and clinical factors associated with disease persistence
and/or recurrence. Variables included in the modelling process were
age at diagnosis, SEIFA indices, type of treatment (CKC or LEEP), margin
status, and depth of excised tissue. Statistical significance was deter-
mined as a p-value b 0.05 and the 95% confidence intervals (CI) for haz-
ard rate ratios were calculated. Plausible interaction terms were tested
using likelihood ratio tests. Violation of the Coxmodel proportional haz-
ard assumption was tested using Schoenfeld residuals. Due to small
numbers, time to event analysis was not performed for cervical cancers.
3. Results
3.1. Study cohort
There were 338 patients with ACIS eligible for the study following
exclusion of 8 patients who had a hysterectomy as initial treatment
and 16 patients for whom follow-up data were not available. An
overview of the study cohort is presented in Fig. 1. The mean age was
33.2 years (range 18 to 76 years) and the median follow-up interval
was 3.6 years (range b 1 year to 11.8 years). Two hundred and thirty
one patients (68.3%) had a CKC while the remainder (n = 107, 31.7%)
had a LEEP procedure. The clinicopathological findings are summarised
in Table 1.
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3.2. Margin status
The biopsy margins were indeterminate in 17 cases (Fig. 1). In the
remaining 321 specimens, positive margins were documented in 93
(29%) cases including 34 LEEP biopsies (31.8%) and 59 CKC specimens
(25.5%) (p = 0.432, Fig. 1 and Table 1).
3.3. Number of surgical specimens excised
LEEP was associated with a greater likelihood of more than one
surgical specimen being excised during the procedure compared to
CKC (see Table 1).
3.4. Follow-up period (b12 months post treatment)
In the 12 months following the initial CKC or LEEP biopsies, 105
(31%) patients underwent further histological evaluation due to an
abnormal Pap smear and/or abnormality at colposcopy. Of these, 70
had negative findings, 5 had CIN 1, 24 had persistent disease (ACIS)
and eight patients were diagnosed with endocervical adenocarcinoma.
Of the 24 cases with persistent ACIS, 10 (41.7%) had negative patho-
logical margins in the original treatment specimen. The remaining
233 patients underwent cytological surveillance which was either neg-
ative or showed only low-grade abnormalities within the immediate
post treatment 12 month period.
3.5. Surveillance period (≥12 months post treatment)
After excluding the 86 patients who had disease persistence, adeno-
carcinoma, or who underwent hysterectomy in the follow-up period,
252 women entered the surveillance period. Of these, 57 (22.6%)
women underwent further treatment (CKC biopsy or LEEP) and histo-
logical evaluation. Forty-four had negative findings, 7 had CIN 1, 2 had
CIN 2/3, 3 had recurrent ACIS, and 1 patient had adenocarcinoma. The
remaining 195 (77.4%) women had cytological surveillance showing
either negative findings or low-grade abnormalities. No patient died of
cervical cancer during the study period. Overall, 27 (8.0%) patients
had ACIS persistence/recurrence and a further 9 (2.7%) patientswere di-
agnosed with adenocarcinoma during the follow-up and surveillance
periods.
Fig 1. Overview of patient cohort and their associated health outcomes following initial treatment of ACIS.
Table 1
Clinicopathological summary according to initial treatment (n = 338).
CKC biopsy LEEP p-Value
n = 231 % n = 107 %
Age (years)
≤30 92 39.8 47 43.9 0.476
N30 139 60.2 60 56.1
Socio-economic index
Least disadvantaged 76 32.9 29 27.1 0.159
Less disadvantaged 48 20.8 17 15.9
Middle 36 15.6 30 28.1
More disadvantaged 49 21.2 21 19.6
Most disadvantaged 22 9.5 10 9.3
Initial diagnosis
Cervical cytology 156 67.5 77 72.0 0.413
Punch biopsy 75 32.5 30 28.0
Number of specimens
1 209 90.5 72 67.3 0.000
N1 22 9.5 35 32.7
Specimen depth (mm)
Mean (range) 16.1 (2–40) 10.7 (2–27) 0.000
Specimen depth group (mm)
≤10 58 25.1 63 58.9 0.000
N10–15 58 25.1 27 25.2
N15– ≤ 40 115 49.8 17 15.9
Concurrent CIN
Absent 92 39.8 50 46.7 0.232
Present 139 60.2 57 53.3
Margin status
Negative 161 69.7 67 62.6 0.432
Positive 59 25.5 34 31.8
Indeterminate 11 4.8 6 5.6
CKC — cold knife cone, LEEP — loop electrosurgical excision procedure.
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3.6. Significance of positive margins
The initial treatment specimen in 93 patients showed positive path-
ological margins. Of these patients, 54 (58%) underwent a subsequent
excisional procedure and the findings are presented in Table 2. The
remaining 39 (42%) patients had surveillance only; none of these
patients had recurrent ACIS or developed cervical adenocarcinoma.
3.7. Factors associated with disease persistence and recurrence
The results of the Cox regression analysis for disease persistence and
recurrence are summarised in Table 3. Positive margin status was
associated with a 3.4 (95% CI 1.5–7.8) times increased rate of ACIS
persistence and/or recurrence. After adjusting for margin status there
was no statistically significant association between patient age, socio-
economic status, coexistence of CIN 2/3, specimen depth or treatment
type (CKC biopsy or LEEP) and ACIS persistence and/or recurrence.
4. Comment
This large population-based study found no difference in ACIS dis-
ease persistence/recurrence between CKC and LEEP and no significant
difference in the rate of positive margins between the two treatment
modalities.
To date there have been only a small number of studies which have
compared the efficacy of CKC biopsy to LEEP for the treatment of ACIS.
Many are single institution reviews and are limited due to age restric-
tion (excluding either older or younger women) and/or small sample
size [5,6,11,17–19,28]. Women wishing to preserve their fertility may
opt for conservative treatment following the diagnosis of ACIS, but to
date there are conflictingdata regarding rates of recurrence and residual
disease in these patients [29–32].
To our knowledge this is the largest study of women with biopsy
confirmed ACIS to have analysed outcomes according to patient age,
socio-economic status, coexistence of CIN 2/3 andmargin status follow-
ing treatmentwith either LEEP or CKC biopsy.We also investigated ACIS
persistence and recurrence by specimen depth because a possible
explanation for our results is that LEEP may have been used to treat
smaller ACIS lesions. However, there were no significant differences be-
tween LEEP and CKC in the proportion of persistent or recurrent ACIS
when stratifying outcomes according to specimen depth (Table 3).
It is interesting to speculate whether deep excisions (N15 mm) are
required to adequately treat ACIS given that the depth of excision was
significantly greater in the CKC group compared to the LEEP group but
there were no differences in outcomes. However, our study was not
designed to assess this as the differences in depth of excision between
the two groups may have reflected clinical decisions, which we were
unable to verify. For example, clinicians may have opted to use LEEP
for smaller ACIS lesions and CKC for larger lesions so we cannot
conclude that deeper excisions are ‘over-treatment’ of ACIS. A carefully
selected procedure will likely be the appropriate procedure for a partic-
ular patient.
LEEP was associated with a greater likelihood of more than one
surgical specimen being excised compared to CKC but many of these
are likely to have included intentional two-stage procedures (LEEP
followed by ‘top hat’ endocervical sampling) as well as technically
difficult procedures which resulted in multiple, fragmented or incom-
plete specimens. Many of the latter would, however, likely result in
indeterminate margins histologically. It is noteworthy that there was
no significant difference in margin status between CKC and LEEP. A sin-
gle intact specimen is, of course, ideal for comprehensive histological
assessment.
The management of women diagnosed with ACIS following LEEP or
CKC biopsy is often dependent on the patient's age and fertility require-
ments and the status of the excision margins. Hysterectomy is recom-
mended for women who have completed child bearing [6,11–13,33]
because cytological follow-up is less reliable and rates of recurrence
may be high [5,12,17,19,32]. It is also noteworthy that 10/24 patients
in this series who had ACIS on a second excisional procedure had nega-
tive initial biopsymargins. Thismay reflect themultifocal distribution of
ACIS in some cases and emphasizes the requirement for follow-up even
after apparently complete local excision.
The main limitation of this study is its retrospective design so it is
conceivable that selection bias or exposure to confounding variables
may have influenced outcomes between the two treatment groups.
Although this is the largest population-based study ever reported, it
was only sufficiently powered to detect a relatively large difference in
Table 2
Histology findings in patients with positive margins who underwent a second excisional
procedure (n = 54).
Second procedure Initial procedure
CKC biopsy
n = 35
LEEP
n = 19
CKC biopsy
Negative 3 4
Low-grade changes 1 0
ACIS 6 2
Adenocarcinoma 1 2
LEEP
Negative 1 0
Low-grade changes 0 0
ACIS 1 1
Adenocarcinoma 0 0
Hysterectomy
Negative 14 8
Low-grade changes 0 0
ACIS 4 1
Adenocarcinoma 4 1
CKC — cold knife cone, LEEP — loop electrosurgical excision procedure.
Table 3
Hazard ratios of persistent or recurrent endocervical neoplasia according to age, socio-
economic index, concurrent CIN and margin status.
Variable Hazard rate ratio 95% confidence interval p-Value
Age (years)
≤30 0.7 0.3–1.8 0.477
N30 (base) 1.0
Socio-economic index
Least disadvantaged (base) 1.0
Less disadvantaged 1.6 0.4–5.9 0.469
Middle 1.7 0.5–6.1 0.433
More disadvantaged 3.0 0.9–9.6 0.068
Most disadvantaged 0.6 0.1–5.8 0.689
Initial treatment
LEEP 0.8 0.3–2.0 0.578
CKC biopsy (base) 1.0
Number of specimens
1 (base) 1.0
N1 0.9 0.3–2.5 0.847
Concurrent CIN
Absent (base) 1.0
Present 0.9 0.4–2.2 0.870
Margin status
Negative (base) 1.0
Positive 3.4 1.4–7.8 0.004
Indeterminate 1.2 0.1–9.5 0.885
Specimen depth (mm)
≤10 1.6 0.6–4.0 0.337
N10–15 0.4 0.1–1.5 0.183
N15– ≤ 40 (base) 1.0
CKC — cold knife cone, LEEP — loop electrosurgical excision procedure.
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the treatment effects due to the small number of recurrent ACIS cases.
Themedian follow-up interval was only 3.6 years and it is our intention
to continue to follow this patient cohort. Strengths of the study are its
large population-based cohort and data linkage.
Potential sequelae of CKC and LEEP include adverse obstetric
outcomes such as second trimester miscarriage and pre-term delivery
[14,20,22,23,34]. Epidemiological data suggest that these risks correlate
with depth of excision and are more frequent following CKC [22,23].
This study demonstrates thatwomenwhoweremanaged conservative-
ly following the diagnosis of ACIS had equivalent rates of positive
margins and oncologic outcomes whether they were treated by LEEP
or CKC. Given that CKC may be associated with an increased risk of
adverse obstetric outcomes compared to LEEP, and that rates of ACIS
persistence/recurrence are comparable for both treatment modalities,
LEEP may be the preferred treatment option in patients in whom
fertility preservation is important. The only significant determinant of
disease persistence or recurrence was the presence of a positive histo-
pathologicalmargin,which is in accordancewithfindings fromprevious
studies [6,9,35–39].
In conclusion, LEEP may be an appropriate treatment option for
women with ACIS who wish to preserve fertility since this does not
appear to compromise oncologic outcomes when compared to CKC.
However, further prospective studies are needed to confirm these
findings.
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4.1 Background 
The acquisition of knowledge has occurred much more rapidly for the 
epidemiological and biological features of HSIL than for glandular lesions (AEC 
and/or ACIS). Consequently, in 2001, evidence-based management guidelines 
were implemented in Australia for women aged < 25 years with histologically 
confirmed HSILs7.    
It is well accepted that the persistent infection of the cervix with high-risk or 
oncogenic HPV (HR HPV) is a prerequisite for the development of CIN and 
cervical cancer88. A histological diagnosis of CIN1 is linked with benign viral 
replication that regresses in most cases89. Previous studies involving adult 
women report CIN1 regression rates of 70–80%, whereas spontaneous 
regression has been reported up to 90% in adolescent and young women82-92. 
Because of the high regression rate, it is recommended in Australia and the USA 
that clinicians conservatively manage adolescents with CIN1 with observation 
rather than administering treatment3, 7.  
However, the biological behaviour and treatment of CIN2 remains controversial 
for many clinicians. Few studies have investigated CIN2 regression rates for 
young women (<25 years) while preliminary analyses report that up to 65% of 
CIN2 cases naturally regress for this population of women27, 64, 65. Although it has 
been widely accepted that conservative management for adolescents with CIN2 
is reasonable, there is limited data examining the issue in women aged 20 to 25 
years. Given the potential for adverse health complications after treatment, a 
large proportion of practitioners offers women in this age group conservative 
management for CIN227, 93, 94. The 2005 NHMRC Guidelines currently do not have 
specific management recommendations for young women aged <25 years with 
biopsy confirmed CIN2. Given the diversity of management practices and the lack 
of evidence on patient outcomes on a global scale, there is an urgent need to 
determine if surveillance could be an appropriate option for this young cohort of 
women.  
Therefore, Chapter 4 (Objective 3) provides important findings that could be used 
to help clinicians avoid excisional or ablative treatment (LEEP/CKC biopsy) for 
selected patients who have received appropriate counselling and who are able to 
comply with the more intensive and prolonged follow-up required in a 
conservative management approach (Publication 3). 
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4.2 Aim 
This study aimed to investigate health outcomes in conservatively managed 
young women with CIN2. 
4.3 Methods 
A retrospective study of women aged 18 to 24 years diagnosed with CIN2 on 
cervical biopsy between 01 January 2001 to 31 December 2012. Women who 
remained untreated at ≥4 months were allocated to a "conservative 
management" group.  
Cervical cytology and/or biopsy test results were used to report lesion regression 
(defined as the absence of dysplasia or an epithelial lesion of lower grade than 
CIN2) and disease persistence (defined as CIN2, CIN3 or adenocarcinoma in 
situ). 
4.4 Results 
There were 924 (38.2%) women with CIN2 who were 'conservatively' managed. 
There were 152 (16.4%) women who had a lesion more severe than CIN2 
detected within 24 months of initial diagnosis, of which 144 were CIN3 and 8 
were ACIS.  
Overall, there was no statistically significant association identified between rates 
of regression and the patient's age, Socio-Economic Indexes for Areas or 
Accessibility/Remoteness Index of Australia indices. The two-year CIN2 
regression rate was estimated to be 59.5% (95% CI 0.5 - 0.6) in this cohort of 
young women. 
4.5 Conclusion 
In conservatively managed young women with CIN2 there was a high rate of 
spontaneous disease regression. Thus, excisional or ablative treatments may be 
avoided in selected patients who received appropriate counselling and who are 
able to comply with the more intensive and prolonged follow-up required in 
conservative management of CIN2. 
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Abstract
Introduction. CIN2 has a high rate of spontaneous regression in young
women and may be managed conservatively in appropriately selected patients.
This study aimed to investigate health outcomes in women aged 18–24 years
with biopsy-confirmed CIN2. Material and methods. A retrospective cohort
study of Western Australian women aged 18–24 years diagnosed with CIN2
on cervical biopsy from 1 January 2001 to 31 December 2010. Women who
had not received treatment at ≥4 months following CIN2 diagnosis were clas-
sified as managed ‘conservatively’. Subsequent cervical cytology and/or biopsy
test results were used to report lesion regression (absence of dysplasia or an
epithelial lesion of lower grade than CIN2) and disease persistence (CIN2,
CIN3 or ACIS). Results. Follow-up data were available for 2417 women of
whom 924 (38.2%) were ‘conservatively’ managed. In all, 152 (16.4%) con-
servatively managed women had a lesion more severe than CIN2 detected
within 24 months of initial diagnosis, of which 144 were CIN3 and eight
were ACIS. There was no statistically significant association between rates of
regression and patient age, Socio-economic Indexes for Areas or Accessibility/
Remoteness Index of Australia indices. The 2-year regression rate for CIN2
was estimated to be 59.5% (95%CI 0.5–0.6) in this cohort of women. Con-
clusion. In conservatively managed young women with CIN2 there was a high
rate of spontaneous disease regression. Thus, excisional or ablative treatments
may be avoided in selected patients who receive appropriate counseling and
who are able to comply with more intensive and prolonged follow-up
requirements.
Abbreviations: ACIS, adenocarcinoma-in-situ; CIN, cervical intraepithelial
neoplasia (grade 2/3); HSIL, high-grade squamous intraepithelial lesion; LEEP,
loop electrosurgical excisional procedure; LSIL, low-grade squamous
intraepithelial lesion; WA, Western Australia.
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Introduction
High-grade cervical intraepithelial neoplasia (CIN) is a
precursor to cervical squamous cell carcinoma (1–3). The
peak incidence of high-grade CIN is in women under the
age of 25 years but cervical squamous cell carcinoma is
rare in this age group (4–7). There are data to show that
a significant proportion of cases of CIN2 in adolescent
and young women (under the age of 21 years) will spon-
taneously regress (7–9) and because the risk of progres-
sion to malignancy appears to be low in this age group,
excisional or ablative treatment may not be indicated.
Young women diagnosed with CIN2 who are likely to
comply with follow up may be offered conservative man-
agement including observation with colposcopy and cyto-
logical evaluation every 4–6 months to permit
spontaneous regression of CIN2 and to avoid potentially
unnecessary and costly treatment (7–12). Excisional treat-
ments such as the loop electrosurgical excisional proce-
dure (LEEP) are associated with physical, psychological
(13–15) and obstetric morbidity (16–18) and may have a
negative impact on sexual function (14,19,20).
Guidelines suggest that conservative management for
adolescents with CIN2 may be considered in appropri-
ately selected cases, but few studies have addressed this
issue in women aged 20–25 years (7,10). Given the poten-
tial for treatment-related complications, many practition-
ers have offered women in this age group who are
diagnosed with CIN2 the option of conservative manage-
ment. The aim of our study was to investigate the rate of
spontaneous regression of CIN2 in Western Australian
women aged 18–24 years to determine whether conserva-
tive management for appropriately selected patients in
this age group may be a reasonable alternative to imme-
diate treatment.
Material and methods
This study was a retrospective cohort study. Women aged
18–24 years were followed-up from the time of their first
CIN2 diagnosis (cervical biopsy test result) until their last
cytology/histology record. Ethical approval for this study
was granted by the Human Research Ethics Committees
of Curtin University (ethics research project number: HR
86/2012) and the Western Australian Department of
Health Human Research Ethics Committee (ethics
research project number: 2012/49).
The Western Australian Data Linkage System provided
a de-identified extraction of linked data for the period 1
January 2001 to 31 December 2010 from the Cervical
Screening Register of Western Australia (WA) and the
Hospital Morbidity Data System (HMDS). The Western
Australian Data Linkage System is an internationally
renowned, population-based, validated and ongoing data
linkage system that creates links among a number of state
health administrative datasets (21–23).
The National Cervical Screening Program encourages
eligible women (women that have not had a hysterectomy
and have commenced sexual activity) aged 18–69 years to
have a cervical smear every 2 years. As part of the
National Cervical Screening Program, the WA Cervical
Cancer Prevention Program maintains and operates the
Cervical Screening Registry of WA. The Cervical Screen-
ing Registry of WA is a voluntary “opt-off” confidential
register which compiles all cervical test results [cervical
smear, cervical biopsy and Human Papillomavirus (HPV)
tests] that cytopathology laboratories are legislatively
required to report. A de-identified dataset was extracted
from the CSR of WA that contained cervical screening
histories for all women under the age of 25 years who
resided within WA at the time of their CIN2 diagnosis.
Cervical Screening Registry follow-up data were available
until May 2013.
Women were allocated measures of socioeconomic sta-
tus using the Socio-economic Indexes for Areas for Aus-
tralia obtained through the Australian Bureau of Statistics
(24). Additionally, women’s postcodes were assigned to
one of four Accessibility/Remoteness Index of Australia
categories (25). Due to small numbers, remote and very
remote postcodes were collapsed into one category for
the purposes of this study.
The Hospital Morbidity Data System records discharge
summaries from all Western Australian hospitals (private
and public and day surgery clinics). For women who did
not have a biopsy treatment record, the International
Classification of Disease code N87.1 for moderate cervical
dysplasia and associated procedural codes were used to
identify women who had ablative and excisional tech-
niques performed. Procedural codes included excision
(cone biopsy by cold knife or laser) and ablation (radical
diathermy of cervix, large loop excision transformation
zone, laser ablation of cervix and other ablative proce-
dures of the cervix).
Cervical cytology test results were classified according
to the Australian Modified Bethesda System 2004. This
classification system is comparable internationally and
Key message
Conservatively managed young women with CIN2
had a 59.5% spontaneous regression rate. Conserva-
tive management is an option for selected patients
who receive appropriate counseling and who are able
to comply with follow up.
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reflects the increased understanding of HPV biology and
the development of cervical cancer. In the present study
we refer to findings from cervical cytology as high-grade
squamous intraepithelial lesion (HSIL) or low-grade squa-
mous intraepithelial lesion (LSIL). Histological findings
are referred to as CIN2 and CIN3.
Only women aged 18–24 years with a histological con-
firmation of CIN2 were included in this study. Women
were excluded if they (1) had a past history of a histolog-
ically confirmed high-grade intraepithelial lesion that was
more severe than a CIN2, or (2) 12 months of follow-up
data (cervical cytology or histology) were unavailable.
The Australian Guidelines recommend that women
with a cervical smear test result of HSIL should be
referred to a gynecologist for colposcopic assessment and
targeted biopsy4. Ideally women with cervical cytology
showing HSIL or possible HSIL should be assessed within
2 months of diagnosis. Assessment includes colposcopy
+/ cervical biopsy. As such, women were allocated into
a group dependent on when CIN2 treatment (excisional
or ablative) was performed. To allow for women’s atten-
dance for gynecological assessment and treatment, time-
frames were slightly extended to the following:
(1). If the woman was treated for CIN2 within 4 months
she was allocated to the “immediate treatment”
group (4).
(2). If treatment for CIN2 was performed after more
than 4 months women were allocated to the “conser-
vative management” group (4,7).
Outcome measures were disease regression (i.e. nega-
tive or low-grade lesions including an LSIL on cytology
and/or mild dysplasia (CIN1) or atypia on a subsequent
biopsy), disease persistence including HSIL (CIN2, CIN3
or adenocarcinoma-in-situ) and disease progression (cer-
vical cancer). Disease regression, persistence or progres-
sion were determined from histology test results where
possible.
In the absence of histology, cytological findings were
used and a hierarchical system was adopted to report the
most severe diagnosis for the patient. In the event that a
patient had evidence of regression but at a later follow-up
visit cytology or histology confirmed persistence or dis-
ease progression, the latter diagnosis was reported.
Statistical analysis
Equality of demographic and clinical characteristics of
women on different treatment pathways was tested using
the chi-squared test. Time-to-event analyses were per-
formed to investigate factors associated with the rate of
regression for women who remained untreated (n = 924)
for CIN2 by 24 months. The follow-up interval was
recorded as the time from the CIN2 diagnosis to disease
regression (the event) defined as negative cytology and/or
biopsy, LSIL or a low-grade glandular abnormality. Par-
ticipant follow up was censored at treatment of CIN2 dis-
ease, progression or at the time of the last available
cervical cytology and/or biopsy result. If women under-
went treatment but had a negative treatment specimen on
histopathology they were recorded as having had disease
regression. Covariates included in the time-to-event anal-
ysis were age, socio-economic status and an index of
accessibility to services.
Statistical significance was determined as a p-value
<0.05. STATA Version13.0 (Stata Corporation, College
Station, TX, USA) was used for data manipulation and
statistical analysis.
Results
During the 10-year study period, 2692 women were aged
18–24 years at the time of their initial CIN2 diagnosis. Of
these, 275 women were excluded from the study because
12 months of follow-up data (cytology or histology test
results) were unavailable (n = 275). For the remaining
2417 women, demographic information and comparative
statistics are reported in Table 1. Conservative manage-
ment was more likely, the younger the age of the woman
and in those living in urban areas. Management approach
did not vary by socio-economic status. A total of 38% of
women had an HSIL (CIN2/3) detected on their referral
cytology test result within 24 months prior to their CIN2
diagnosis.
There were 1493 (61.8%) women who underwent treat-
ment within 4 months of diagnosis (immediate treatment
group). The mean time from initial diagnosis to treat-
ment was 1.5 months in this group. Of the 1493 women
immediately treated, 58 (3.9%) women underwent laser
ablation of the cervix and no histological specimen was
available. Of these women, 56 had negative follow-up
cytology and/or histology findings and two women were
confirmed to have disease persistence. The remaining
1435 women were treated by either LEEP or cold knife
cone biopsy. The majority of women immediately treated
had CIN2 (62.5%) in their surgical specimen findings
(Table 2) and a smaller proportion of women either had
either negative histopathology or a low-grade cervical
abnormality (17.3%).
There were 924 (38.2%) women managed ‘conserva-
tively’. During the 24-month follow-up period, 25 women
subsequently underwent laser ablation and their follow-
up cytology test results were negative (n = 17), LSIL
(n = 5), possible and persistent HSIL (n ≤ 5). In all, 437
women who were initially managed conservatively subse-
quently underwent treatment within the 24-month fol-
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low-up period with either LEEP (n = 402) or cervical
cold knife cone biopsy (n = 35). Their histopathology
findings are reported in Table 2. Most were CIN2
(22.9%), although a proportion of women (15.6%) had
CIN3 confirmed in their treatment specimen. Of the 152
(16.4%) women who had a lesion more severe than CIN2
detected within 24 months of their initial CIN2 diagnosis,
144 were CIN3 and eight were ACIS.
There were 462 women with a histological diagnosis of
CIN2 (on cervical punch biopsy) who did not undergo
treatment during the follow-up period. The majority
(n = 404) of these women had repeat cervical cytology
within 6 months of initial diagnosis. A small proportion
(3.7%) subsequently had cervical cytology reported as
CIN3 during the study follow-up period but are yet to
have histological confirmation (outside the study period).
In 445 women, follow-up cervical cytology and histology
indicated disease regression. The median follow-up time
for women without a treatment record was 1.8 years.
Multivariate time to event analysis was performed for
those women (n = 924) conservatively managed to obtain
the disease regression hazard rate ratio. Women were
censored after treatment and/or when disease progression
was confirmed. There was no statistically significant asso-
ciation identified between the rate of regression and
patient age (potentially due to age intervals being very
narrow, hazard ratio (HR) 1.2, 95% CI 1.0–1.5), Socio-
economic Indexes for Areas for Australia (HR 1.1, 95%
CI 1.0–1.2) or Accessibility/Remoteness Index of Australia
indices (HR 1.0, 95% CI 0.8–1.1).
A Kaplan–Meier graph (Figure 1) was constructed
(censoring women at the time of treatment and/or if dis-
ease progression was identified) which highlights that the
majority of women within the “conservative manage-
ment” group regressed within 12 months following their
initial CIN2 diagnosis. The 2-year CIN2 regression rate
was estimated to be 59.5% (95% CI 0.5–0.6) in this
cohort of young women.
Discussion
The aim of our study was to investigate disease outcomes
of conservatively managed women aged 18–24 years
with biopsy-confirmed CIN2. Outcome variables mea-
sured included rates of CIN2 regression, persistence or
progression to higher grade dysplasia or invasive cervical
Table 1. Women’s baseline demographic information by management category
Immediate
treatment
group (n = 1493)
Percentage
(%)
Conservative
treatment
group (n = 924)
Percentage
(%)
Chi-squared
p-value
Women’s age (years)
18–19 208 13.9 176 19.1 0.003
20–21 464 31.1 281 30.4
22–24 821 55.0 467 50.5
Women’s referral cytology test result (within 24 months of biopsy confirmed CIN2 diagnosis)
Negative 7 0.5 4 0.4 0.000
Low-grade squamous intraepithelial lesion (CIN 1) 19 1.2 61 6.6
Possible high-grade squamous intraepithelial lesion (HSIL) 6 0.4 20 2.2
HSIL (CIN2/3) 567 38.0 439 47.5
No referral cytology test result present 894 59.9 400 43.3
Accessibility/Remoteness Index of Australia
Major city 995 66.6 690 74.7 0.002
Inner regional 235 15.7 109 11.8
Outer regional 128 8.6 60 6.5
Remote/very remote 117 7.9 58 6.3
Unknown
(Post Office Box)
18 1.2 7 0.7
Socio-economic Indexes for Areas for Australia
Least disadvantaged 467 31.3 323 35.0 0.315
Less disadvantage 243 16.3 155 16.8
Middle 334 22.4 181 19.6
More disadvantaged 266 17.8 165 17.8
Most disadvantaged 165 11.0 93 10.1
Unknown
(Post Office Box)
18 1.2 7 0.7
CIN, cervical intraepithelial neoplasia; HSIL, high-grade squamous intraepithelial lesion.
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cancer or other associated gynecological disease. Linked
administrative health datasets were used to ascertain these
outcomes in a large cohort of Western Australian women
with biopsy-confirmed CIN2. From Kaplan–Meier analy-
sis it was estimated that 59.5% of conservatively managed
women with CIN2 regressed by 24 months post diagno-
sis. There were no cases of invasive cervical cancer among
the conservatively managed cohort. Furthermore, 331
(13.7%) patients who received immediate or conservative
treatment were found to have either normal or low-grade
histology in the excisional specimen.
The management of young women (<25 years) with
screen-detected cervical abnormalities is contentious as
there is no clear evidence to suggest that screening
patients under this age prevents cervical cancer (26–28).
Thus, previous management strategies are no longer
universally accepted for young women with biopsy-con-
firmed CIN2 (7,9,11). As such, specialist obstetrician/gy-
necologists are encouraged to consider offering
conservative management to appropriately selected
patients, in order to minimize potential treatment-
related physical, psychological and obstetric morbidity
(7).
There is evidence demonstrating CIN2 regression in up
to 65% of adolescents and young women (<21 years)
over an 18-month period and hence conservative man-
agement in this population may be warranted (8,9,12).
However, only a small number of studies have investi-
gated the rate of CIN2 regression in women up to
25 years of age, most of which are limited due to their
small sample size (7). To our knowledge this is the largest
population-based study to have analysed outcomes by
patient age and socio-economic status in women aged
18–24 years with biopsy-confirmed CIN2. This study
Table 2. Treatment performed and final histologic condition at time of treatment by management category (within 12 months of CIN2
diagnosis)
Immediate
treatment
group
(n = 1493)
Percentage
(%)
Conservative
treatment
group
(n = 924)
Percentage
(%)
Treatment performed
Laser destruction 58 3.9 25 2.7
Cold knife cone biopsy 138 9.2 35 3.8
LEEP 1,297 86.9 402 43.5
No treatment record present (within
24 months of CIN2 diagnosis)*
0 0 462 50.0
Treatment outcome
Negative 82 5.5 24 2.6
Low-grade intraepithelial abnormality 176 11.8 49 5.3
CIN2 933 62.5 212 22.9
CIN3 231 15.5 144 15.6
Adenocarcinoma-in-situ 11 0.7 8 0.9
Squamous cell carcinoma <5** – 0 0.0
Adenocarcinoma <5** _ 0 0.0
No treatment outcome available 58 3.9 487 52.7
CIN, cervical intraepithelial neoplasia; LEEP, loop electrosurgical excisional procedure.
*No histologic condition was reported because cervical cytology test results were used to determine the outcome in the conservative treatment
group, or the treatment was ablation and no histologic condition was available.
**Due to small case numbers, <5 has been reported to ensure women’s confidentiality.
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Figure 1. Kaplan Meir Curve showing the proportion of women who
underwent conservative treatment (n = 924) who remained with
CIN2 within 24 months of initial diagnosis. Women were censored at
time of treatment or when disease progression was identified as they
could not contribute further time at risk of regression.
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contributes to and reinforces the health outcomes high-
lighted in previous research (7).
In any study of natural history outcomes in untreated
CIN2, an important consideration is misclassification of
histopathological diagnosis. The reporting of cervical
specimens (cytology and biopsy specimens) possesses a
degree of subjectivity and CIN2 may be over-diagnosed
in some cases. In Australia, laboratories that report cervi-
cal abnormalities are required to comply with mandatory
annual Performance Measures (29) and are subject to
independent verification of data submitted by the labora-
tory to the Royal College of Pathologists Australasia
Cytopathology Quality Assurance Program. These mea-
sures have enhanced external quality assurance procedures
in Australia (29).
Limitations of our study include its retrospective design
and the error inherent in all databases. For example, exci-
sional procedures may have been performed on an outpa-
tient basis and not captured in hospital records. However,
the mandatory reporting of the histological findings of
cervical specimens to the Registry ensures data complete-
ness is obtained. The quality assurance processes employed
ensure the level of error within the register is acceptable. A
further limitation of our study is the lack of information
regarding colposcopy findings, and therefore no informa-
tion on other factors, which may have influenced whether
women were treated immediately or not. This could intro-
duce bias in the results. The reasons women had treatment
performed were not clearly identified and consequently
treatment intervals varied. Additionally, disease regression
could not always be confirmed histologically.
Furthermore, our inclusion criteria to this study
required biopsy confirmation of a CIN2 lesion. As such,
the lesion may not have “truly” spontaneously cleared, as
the biopsy may have accelerated the clearance of the dis-
ease (i.e. specifically if it was a very small lesion). It is
important to note that CIN2 is the least reproducible of
all cervical diagnoses, and it is possible that the “regres-
sion” of CIN2 is dependent on the individual pathologist
reporting the lesion (30–33). The potential inclusion of
“equivocal” CIN2 lesions could also be expected to
increase the overall regression rate and, consequently,
regression may have been over-reported (30,31). These
limitations emphasize the need for further prospective
studies that report treatment determinants and also repro-
ducible biomarkers (i.e. p16 staining of CIN2 specimens).
In recommending conservative management following
the diagnosis of CIN2, patient safety is paramount. In our
study among those patients who were treated conserva-
tively, none progressed to invasive cervical cancer,
although eight cases of adenocarcinoma-in-situ (ACIS)
were identified (0.9%). Among those women who received
immediate treatment, there were cases of ACIS (n = 11),
squamous cell carcinoma (n ≤ 5) and adenocarcinoma
(n ≤ 5) that had not been identified initially. These cases
highlight the need for cautious implementation of a con-
servative management protocol in young women diag-
nosed with CIN2, and the need for careful selection of
patients, regular follow-up evaluation, maintenance of
clinical standards and appropriate follow-up systems.
Potential sequelae of conization and LEEP include not
only the physical and psychological but also adverse
obstetric outcomes such as second trimester miscarriage
and early pre-term delivery (34–37). Epidemiological data
suggest that these risks correlate with depth of excision
and are more frequent following conization (34,37).
Based on the 59.5% regression rate reported in this study,
conservative treatment of CIN2 may be an appropriate
option, in the form of regular surveillance, for patients
less than 25 years of age. These women should remain
under specialist care, which routinely provides col-
poscopy, cytological testing and quality assurance
throughout the patient’s clinical management for at least
24 months prior to invasive treatment.
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Chapter 5:  
 
Investigation of follow-up of women treated for 
high-grade squamous intraepithelial lesions 
 
 
 
Research output 
Published manuscripts 
1. Munro A, Codde J, Semmens J, Leung Y, Spilsbury K, Williams V, Steel N, Cohen P, 
Pavicic H, Westoby V, O’Leary P. Utilisation of co-testing (human papillomavirus 
DNA testing and cervical cytology) after treatment of CIN: A survey of GP’s 
awareness and knowledge. AFP 2015; 44(1): 64-8.   
2. Munro A, Codde J, Semmens J, Leung Y, Spilsbury K, Williams V, Steel N, Cohen P, 
Pavicic H, Westoby V, O’Leary P. The Human Papillomavirus Test of Cure: A 
lesson on compliance with the NHMRC Guidelines on Screening to Prevent 
Cervical Cancer. A N Z J Obstet Gyn 2015; 55(2): 185-90. 
Conference presentations 
1. Munro A, Codde J, Semmens J, Spilsbury K, Williams V, Steel N, Cohen P, Pavicic 
H, Westoby V, O’Leary P. Utilisation of cotesting (human papillomavirus DNA 
and cervical cytology) after treatment of CIN: A survey of GPs awareness and 
knowledge. 2014 World Cancer Congress. Melbourne, Australia, December 2014 
(poster). 
Translational output 
1. The ToC survey and linked data analysis findings have been shared with the National 
Cervical Screening Program managers to facilitate the provision of further education 
and training to GPs for the management of these high-risk women. Additionally, these 
findings were also shared at a Western Australian Pap Smear Provider Professional 
Development session held in May 2014, which was attended by metropolitan and 
rural health care providers. 
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5.1 Background 
Although the follow-up of women with biopsy confirmed ACIS is not widely 
reported, a new management pathway was outlined for women treated for HSILs 
in 20057. Prior to 2005, the Australian guidelines for follow-up after treatment for 
HSILs recommended ongoing annual cytological testing. An alternative strategy 
is to use DNA testing for HPV (in conjunction with conventional cytology) as a 
ToC7. This screening policy change significantly alters the screening pathway for 
women treated for HSILs as it brings women back to routine screening earlier, 
thereby reducing the amount of post-treatment surveillance required.  
The ToC was introduced into the 2005 NHMRC Guidelines as the link between 
HR HPV infection and the development of cervical cancer is well recognised, with 
almost 99.7% of cervical cancers associated with a type of HR HPV8. It is also 
known that women who have been treated for an HSIL and test negative for HR 
HPV infection are at a low risk of developing cervical cancer in the short to 
medium term. 
Although this management pathway is clearly beneficial to women that have been 
treated for an HSIL and despite its national implementation in Australia since 
2005, there has been little national evaluation of practitioner’s 
awareness/knowledge of and their compliance with the ToC management 
pathway48, 94, 95. The NCSP found that WA was well equipped to utilise 
jurisdictional CSR data and the WADLS link to other administrative datasets (see 
Chapter 2) to determine whether women with biopsy confirmed CIN2/3 were 
treated. By accessing linked data, WA has been able to provide an overall ToC 
compliance rate to the NCSP that could in turn use this evidence to support the 
future development of educational policies to promote this critical follow-up 
protocol among GPs who are at the fore in terms of the ToC for eligible women.  
5.2 Aim 
To conduct a population-based study investigating practitioners’ knowledge of 
and compliance with ToC. 
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5.3 Methods 
5.3.1 Investigation into GPs knowledge and awareness of ToC through 
dissemination of a questionnaire 
After consultation with key stakeholders, an anonymous, self-completion 
questionnaire was developed and disseminated to GPs who had provided 
cervical cytology. Effectively engaging GPs to participate in research initiatives is 
challenging because of their high workload and limited availability of time to 
complete surveys. To facilitate the participation of GPs in this initiative, a survey 
(see Appendix 6) requiring a maximum of five minutes for completion was 
designed. The survey was piloted with five GPs to determine whether the survey 
questions were clinically appropriate, clear, and sequenced logically. The 
feedback from this pilot was used to restructure the survey questions and ensure 
ease of collection. 
The WACCPP utilised the CSR of WA to identify all GPs that had provided 
cervical screening in the prior 12-month period (1 July 2012 to 30 June 2013). 
Once specific GPs were identified (approximately 2,500 GPs), a manual review of 
the GPs demographic information was performed to confirm their latest practice 
address. Using the pilot feedback received, a short survey (25 questions) was 
developed in a tick-box format and included a final comments section for those 
GPs who wished to provide further comments/information. The survey format was 
ideal for GPs to complete between seeing different patients. 
The CSR of WA disseminated the survey and invitation letter as GPs routinely 
receive follow-up letters from this service. To further encourage participation in 
this activity, a well-recognised women’s health specialist, Professor Yee Leung 
(Gynaecologist-Oncologist at King Edward Memorial Hospital), signed the 
invitation letter calling the GPs to complete the enclosed survey. 
5.3.2 Investigation into GPs compliance with the ToC 
Women treated for an HSIL between the five-year period 01 Jan 2006 to 31 Dec 
2010 were identified and followed up for at least a 27-month period. Proportions 
and relative odds were determined for women entering and completing the ToC 
management pathway within recommended time frames. 
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5.4 Results 
5.4.1 GP questionnaire results 
Responses were received from 745 GPs (30.9% response rate). A significant 
number (34.3%) of GPs were unaware of the use of co-testing (HPV DNA testing 
and cervical cytology) for the management of patients after HSIL treatment.  
5.4.2 GP compliance rate with ToC 
There were 5,194 women identified as ‘eligible’ to enter the ToC management 
pathway. Of these, 1,916 (37%) were managed with annual Pap smears and 
never had a HR HPV test performed.  
There were 1,296 (25%) women who entered the ToC management pathway 
within the recommended time frames.  
5.5 Conclusion 
Overall, a significant number of Australian women did not enter (~37%) and 
complete (~50%) the ToC management pathway (Publication 4).  
The challenge remains to advocate the ToC to practitioners to ensure women are 
returned to the population-screening interval in a timely manner. GPs require 
further support and education to ensure successful adoption of co-testing (HPV 
DNA testing and cervical cytology), specifically, for patients treated for an HSIL 
(Publication 5). 
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Conventional cervical cytology is the 
standard screening test for identifying 
women who are at increased risk of 
cervical cancer by detecting premalignant 
cervical lesions.1–3 Worldwide, countries 
that have adopted an organised 
approach to cervical screening have 
been successful in detecting and treating 
high-grade squamous intraepithelial 
lesions (HSIL) before possible progression 
to cervical cancer.1–3 HSIL refers to 
moderate-to-severe changes in the 
cells of the cervix known as cervical 
intraepithelial neoplasia (CIN) 2 or        
CIN 3.4 A study conducted recently 
reported the positive predictive value of 
biopsy confirmed precancerous cervical 
lesions to be as high as 71% for patients 
with an HSIL cervical cytology test 
result.5 Consequently, a patient with an 
HSIL result should be referred as soon as 
practicable for colposcopic assessment 
and targeted biopsy.4 
Acceptable treatment options for patients 
with an HSIL cytology test result that was 
confirmed with colposcopy and biopsy include 
ablative or excisional modalities.4 However, 
if colposcopy is unsatisfactory or if the HSIL 
persists, a diagnostic excision is recommended.4 
The majority of patients will clear human 
papillomavirus (HPV) infection within 24 months 
post-treatment; however, previous studies have 
shown that patients with a history of treated 
CIN 2 and/or CIN 3 are at increased risk of 
recurrent high-grade disease and cervical cancer.6 
Persistent disease (≥6 months post-treatment) 
is often associated with endocervical gland 
involvement7 and continuing HPV infection8,9 
(specifically high-risk HPV16). Our improved 
understanding that oncogenic HPV infection 
is instrumental in the development of cervical 
cancer has led to the development and utilisation 
of tests that can detect HPV DNA oncogenic 
types.5,6,10–12
HPV DNA testing may be implemented as 
an auxiliary tool, in combination with cervical 
cytology, to improve the management of patients 
at risk of further cervical disease.4,12–14 This 
screening protocol takes advantage of the 
high sensitivity of HPV DNA tests and also the 
specificity of cervical cytology.12 In 2005, best 
practice guidelines, known as the ‘Test of Cure’, 
were implemented in Australia. These guidelines 
recommend that patients should have a 
colposcopy and cervical cytology test 4–6 months 
after treatment for an HSIL.4 If these two tests 
(using the two modalities) are negative, then the 
patient is able to return to the care of the GP and 
should be managed as follows:
• Cervical cytology accompanied by high-risk 
HPV DNA testing should commence 12 months 
after treatment and continue annually until the 
patient has tested negative for both tests on 
two consecutive occasions.4
• When the above four tests (using two 
modalities) are negative, the patient is 
encouraged to return to a regular screening 
regimen as appropriate for the general female 
population.4 
Background 
Patients have an increased risk of 
persistent/recurrent cervical disease if 
they received treatment for a high-grade 
squamous intraepithelial lesion (HSIL). 
Consequently, understanding whether 
co-testing (human papillomavirus [HPV] 
DNA testing and cervical cytology) is fully 
utilised by general practitioners (GPs) is 
paramount. 
Methods 
After consultation with key stakeholders, 
an anonymous, self-completion 
questionnaire was developed and 
disseminated to GPs who had provided 
cervical cytology.
Results
Responses were received from 745 GPs 
(30.9% response rate). A significant 
number (34.3%) of GPs were unaware of 
the use of co-testing (HPV DNA testing 
and cervical cytology) for the management 
of patients after HSIL treatment. 
Additionally, the majority of GPs reported 
they did not ‘always’ receive a clear follow-
up plan for patients after treatment of an 
HSIL. 
Discussion 
GPs require further support and education 
to ensure successful adoption of co-testing 
(HPV DNA testing and cervical cytology), 
specifically, for patients treated for an HSIL. 
Keywords 
cervical intraepithelial neoplasia; human 
papillomavirus DNA tests; Papanicolaou 
test; general practice
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To date, no studies have addressed compliance 
with the Test of Cure. Recently, Dr Heley, a senior 
liaison physician with the Victorian Cytology 
Service raised a concern that health practitioners 
in Australia were failing to perform HPV tests 
on eligible women.15 Understanding whether 
this pathway has been fully utilised by GPs is 
important given the risk of persistent/recurrent 
cervical disease for patients treated for an 
HSIL.6,15 Consequently, the aims of this study were 
to investigate GPs’ awareness of and compliance 
with performing co-testing (high-risk HPV DNA 
and cervical cytology) on eligible patients (as 
per Australian guidelines) and the perception of 
support from specialist obstetrician/gynecologists 
(ob/gyns) in providing clear care plans that 
promote this management pathway for patients 
after treatment of an HSIL.
Methods
Participants
The Cervical Cytology Registry (CCR) of Western 
Australia identified all GPs who had provided a 
cervical cytology test in the period 1 July 2012 to 
30 June 2013. Data cleansing (contacting the GP 
practice and reviewing the Medicare Australia list 
of provider contact details) was undertaken for all 
individual GPs to ensure the Registry had up-to-
date demographic details.
Measures
The survey design included a combination of 
questions with categorical and Likert scale 
response options and, where applicable, 
space for participants to provide additional 
comments. Information was collected about the 
GP respondents (age, number of direct patient 
contact hours, number of years practicing as a GP) 
and questions were focused on current practices 
regarding management of patients who had been 
treated for an HSIL. 
Procedure
Following approval by the Curtin University Ethics 
Committee (Reference number HR 86/2012), 
the survey was mailed to GPs, together with 
a covering letter and reply paid envelope. To 
encourage GP participation in this study, and to 
ensure confidentiality, the survey respondents 
were de-identified. 
Table 1. Characteristics of survey respondents
Survey respondents
Characteristics n = 745 Percentage (%)
Sex
Female 431 57.9
Male 311 41.8
Not reported 3 0.4
Age (years)
<35 64 8.6
35–44 188 25.2
45–54 239 32.1
≥55 252 33.8
Not reported 2 0.3
Years practicing as a GP
<2 41 5.5
2–5 70 9.4
6–10 81 10.9
11–19 172 23.1
≥20 379 50.9
Not reported 2 0.3
Direct patient contact hours per week
<10 32 4.6
11–20 133 17.9
21–40 397 53.3
41–60 164 22.0
>60 14 1.9
Not reported 5 0.7
Index of relative social disadvantage
Most disadvantaged 48 6.4
More disadvantaged 94 12.6
Middle 94 12.6
Less disadvantaged 162 21.7
Least disadvantaged 265 35.2
Not reported 85 11.4
Accessibility/Remoteness Index of Australia
Major city 361 48.5
Inner regional 186 25.0
Outer regional 62 8.3
Remote/Very remote 51 6.9
Not reported 85 11.4
Utilisation of co-testing (human papillomavirus DNA testing and cervical cytology) after treatment of CIN: a survey of GPs’ awareness and knowledgeRESEARCH
66  REPRINTED FROM AUSTRALIAN FAMILY PHYSICIAN VOL. 44, NO. 1–2, JANUARY–FEBRUARY 2015
Statistical analysis
Anonymous postal survey responses were 
manually entered into a specific Survey Monkey 
collation spreadsheet and then exported into 
STATA/IC 13.0 (STATA Corporation, College 
Station, USA) for statistical analysis. GPs’ age 
(at the time of the survey) was classified into 
<35, 35–44, 45–54, ≥55 years age groups. 
Practice postcode was used to assign the practice 
location into quintiles of Index of Relative Social 
Disadvantage (ABS 2011) and into one of three 
Accessibility/Remoteness Index of Australia 
(ARIA) levels. Logistic regression analysis was 
used to investigate GP factors associated with 
the odds of having Test of Cure knowledge and 
involved purposeful selection of covariates at the 
5% significance level.
Results
According to the CCR of Western Australia, 
2545 GPs had performed a cervical cytology test 
in the 12-month period from 1 July 2012 to 30 
June 2013. Of these 2545 GPs, to whom surveys 
were posted, responses were received from 
745 (29.3%) GPs. After removing the 136 (5.4%) 
surveys that were returned as 'undeliverable' or 
‘blank’, this corresponded to an adjusted response 
rate of 30.9%. As GPs have different provider 
Table 2. Percentage of participants who answered selected items correctly
Question Percentage 
correct (%)
Q1
Factors considered most important when offering an HPV DNA test:
• If the patient has received treatment for an HSIL
• The patient enquires about the test
• Test of Cure management pathway
85.3
40.5
44.1
Q2
Immediate guideline recommendation for patients who have received 
treatment for a HSIL? (colposcopy and Pap smear at 4–6 months  
post-treatment)
64.2
Q3
If the colposcopy and first Pap smear are both negative what is the 
next step for your patients? (Pap smear and HPV DNA test at 12 
months post-treatment)
73.9
Q4
Once patients have had two consecutive annual tests (2 x Pap smears 
and 2 x HPV DNA tests) that are negative, what would be your 
recommendation for a patient? (return to routine (2-yearly) screening)
69.3
Correct answers are in parentheses where applicable
numbers for each practice, the number of GPs 
offering cervical screening services may have 
been overestimated. GP demographic details 
are summarised in Table 1. The majority (79.7%) 
of responding GPs reported being aware of the 
current National Health and Medical Research 
Council (NHMRC) guidelines and almost 60% 
(59.6%) reported that they always complied 
with the recommendations. Almost one-third 
(29.5%) of participating GPs reported that 
they ‘always’ received a clear follow-up plan 
from gynaecologists/colposcopists for patients 
following treatment of an HSIL. Overall, just over 
one-third (34.3%) of GPs were unable to identify 
all of the steps in the NHMRC’s Test of Cure 
management pathway (Table 2).
There were identifiable factors associated 
with GPs’ awareness of the Test of Cure 
management pathway (Table 3). Younger female 
GPs were more likely to be aware of the screening 
pathway when compared with male GPs aged 
over 55 years. Statistical differences in the 
awareness of the Test of Cure by the accessibility 
(metro, rural, remote) and socioeconomic status of 
the practice location were also analysed (Table 3).
Of the 34.3% of GPs who did not know the 
Test of Cure guidelines, the following comments 
were included with their surveys: 
‘I am unsure of HPV DNA testing’ 
‘I know nothing about this test’ 
‘I did not know this existed’
‘I am not confident with this test or its 
follow-up at all’
‘Unsure of guidelines on this; would this be 
offered by a specialist?’ 
‘I don’t offer it – I am uncertain where it fits in 
the management algorithm’.
Discussion
Our study specifically investigated the 
management of patients after treatment for  
CIN 2 and/or CIN 3, and identified that the 
majority of GPs did not ‘always’ receive a clear 
follow-up plan from the specialist ob/gyn to whom 
the patient had been referred. A proportion of 
GPs were unaware of these post-treatment best 
practice guidelines, which is inefficient. The use of 
co-testing (HPV DNA testing and cervical cytology) 
in general practice is a useful tool to identify 
patients with a history of HSIL, who are at the 
greatest risk of disease persistence/recurrence.12,16 
The major knowledge gaps identified in this 
study include knowing when it was appropriate 
to perform HPV DNA tests and how to manage 
patients if they had two consecutive annual 
negative test results (2 x Pap smears and 2 x HPV 
DNA tests). We found that female GPs were more 
likely to be aware of the Test of Cure management 
pathway than male GPs. This difference may be a 
reflection of women’s preference to see a female 
healthcare provider to discuss sensitive topics, and 
the GP’s personal motivation to know the Test of 
Cure management pathway. 
Our study’s results and qualitative feedback 
suggest that there is a clear need for further 
education and promotion of using high-risk 
HPV DNA tests as a management pathway for 
GPs. The GP’s armamentarium should include 
knowledge of how and when HPV DNA testing 
should be performed. GPs should have confidence 
in the use of this testing modality because, 
even if a cervical cytology test result is normal, 
the increased sensitivity of the HPV DNA test 
will detect high-risk HPV DNA types, indicating 
the presence of persistent cervical disease. 
Patients who successfully complete the Test 
of Cure should then be encouraged to return to 
routine cervical screening with a high degree of 
confidence.5,10,12,16,17  
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provision of the first preliminary insight into 
GPs’ receipt of patient follow-up plans and their 
awareness of utilising co-testing (HPV DNA 
testing and cervical cytology) for patients who 
have been treated for an HSIL.
Given the benefits and importance of the Test 
of Cure management pathway, there is a role 
for professional development activities, such as 
workshops, conferences and online educational 
models, to provide GPs with contemporary 
knowledge of clinical practices in the area of 
cervical cancer prevention. Further efforts should 
be aimed at specifically enhancing GPs’ skills in 
managing patients with cervical abnormalities 
detected through screening, and providing 
This is beneficial, as the patient will not be 
required to return for annual screening.15 Improved 
communication between the specialist ob/gyn 
and GP, through provision of clear follow-up 
instructions, will ensure GPs are equipped to 
provide patients with care that is effective and 
delivers a high level of surveillance.15
One of the limitations of this study was the 
low GP response rate (30.9%). However, it is well 
recognised that collecting information via surveys 
is difficult, specifically from physicians in the 
primary healthcare setting, and is challenging as 
time commitments may preclude GPs’ participation 
in survey initiatives.18–20 Nonetheless, the number 
of GP responses in our study has assisted in the 
Table 3. Factors associated with GPs' awareness of the Test of Cure 
screening pathway
Rate ratio 95% CI P-value
Gender
Female 2.3 1.6–3.2 0.000
Male (reference group) 1.0 – –
Age (years)
<35 1.4 0.7–2.5 0.315
35–44 (reference group) – – –
45–54 0.8 0.5–1.2 0.327
≥55 0.5 0.3–0.8 0.002
Aware of NHMRC guidelines (Test of Cure) 
Yes (reference group) – – –
No 0.5 0.3–0.8 0.003
Index of relative social disadvantage
Most disadvantaged 0.6 0.2–1.4 0.215
More disadvantaged 1.2 0.6–2.2 0.644
Middle 1.9 1.2–3.2 0.012
Less disadvantaged 0.9 0.5–1.4 0.520
Least disadvantaged 
(reference group)
– – –
Accessibility/Remoteness Index of Australia
Major city (reference group) – – –
Inner regional 1.2 0.7–1.5 0.491
Outer regional 0.7 0.3–1.4 0.291
Remote/Very remote 0.9 0.4–2.0 0.838
Logistic regression was performed, estimating the odds of GPS being aware of the  
Test of Cure screening pathway.
CI, confidence interval
information about high-risk HPV DNA testing. 
This information could assist GPs in transitioning 
these high-risk patients back to the recommended 
screening interval. There is also an opportunity 
for specialist obs/gyns who perform colposcopy 
and surgical procedures to assist GPs in the 
management of these patients by providing 
a clear follow-up plan for patients who have 
undergone treatment for an HSIL when they are 
discharged from specialist care. 
Finally, future research investigating 
longitudinal health outcomes associated with 
women who have undergone and completed 
the Test of Cure is required. Studies performing 
economic modelling to determine potential cost 
savings by the reduction in annual cytology tests 
and colposcopic examinations are required. 
Australia was the first country to introduce the 
Test of Cure pathway in 2006 and is well placed to 
provide such evidence.15
Implications for general 
practice:
• GPs should have confidence in HPV testing, 
as it is a sensitive test that can detect the 
presence of high-risk HPV oncogenic types.
• When HPV testing is utilised in the 
management of patients post HSIL treatment it 
is eligible for a Medicare rebate.
• Co-testing can assist GPs in transitioning 
high-risk patients back to the recommended 
screening interval with a high degree of 
confidence.
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The human papillomavirus Test of Cure: A lesson on compliance with
the NHMRC guidelines on screening to prevent cervical cancer
Aime MUNRO,1 Katrina SPILSBURY,2 Yee LEUNG,3 Peter O’LEARY,4 Vincent WILLIAMS,5
Jim CODDE,6 Nerida STEEL,1 Paul COHEN3 and James SEMMENS2
1WA Cervical Cancer Prevention Program, Women’s Health Clinical Care Unit, 2Centre for Population Health Research, Curtin
University, 3School of Women’s and Infants’ Health, University of Western Australia, 4Faculty of Health Sciences, Curtin University,
5School of Biomedical Sciences, Curtin University, Perth, Western Australia, Australia and 6Institute for Health Research, University of
Notre Dame Australia
Background: In Australia, high-risk human papillomavirus (HR HPV) testing is recommended for follow-up of women
treated for a high-grade squamous intra-epithelial lesion (HSIL). The sensitivity of HR HPV testing is critical to identify
women at risk of further high-grade cervical disease. In Australia, this management protocol is known as the ‘Test of
Cure’ (ToC).
Aim: To conduct a population-based study investigating practitioners’ compliance with ToC.
Materials and Methods: Women treated for an HSIL between the five-year period 01 Jan 2006 to 31 Dec 2010 were
identified and followed up for at least a 27-month period. Proportions and relative odds were determined for women
entering and completing the ToC management pathway within recommended time frames.
Results: There were 5,194 women identified as ‘eligible’ to enter the ToC management pathway. Of these, 1,916 (37%)
were managed with annual Pap smears and never had a HR HPV test performed. There were 1,296 (25%) women who
entered the ToC management pathway within recommended time frames, and a further 1,978 (38%) women entered
outside of the recommended time frames. Overall, 961 women completed the ToC and were classified as ‘cured’ and were
eligible to return to two-yearly Pap smears. Women’s demographic information was significantly associated with ToC
commencement, specifically, age and year of treatment, and Index of Relative Socioeconomic Disadvantage.
Conclusion: Overall, a significant number of Australian women did not enter (~37%) and complete (~50%) the ToC
management pathway. The challenge remains to advocate its use to practitioners to ensure women are returned to the
population screening interval in a timely manner.
Key words: cervical, high-grade squamous intra-epithelial lesion, management.
Introduction
Women treated for a high-grade squamous intra-epithelial
lesion (HSIL) remain at an increased risk of developing
further cervical dysplasia and/or cervical cancer, and
consequently, intensive follow-up protocols have been
required.1–4 Prior to 2005, the Australian management
guidelines for post-treatment cytological surveillance for
HSIL recommended annual cytological testing for life. In
2005, the National Health and Medical Research Council
(NHMRC) introduced revised management guidelines
recommending an alternative management pathway
(Table 1) using high-risk human papillomavirus testing
(HR HPV) in conjunction with cervical cytology as a
‘Test of Cure’ (ToC).1 This management pathway returns
eligible women back to routine screening (two yearly) and
reduces previously required post-treatment surveillance
frequency.1 Multiple follow-up studies have shown HR
HPV testing to be efficacious for detecting residual or
recurrent disease inpatients treated for HSIL.5–11
A ToC involves cervical cytology and HR HPV testing
at 12 and 24 months post-treatment. If both sets of the
cervical cytology and HR HPV tests are negative, then a
woman is considered to have completed her ToC, and
advised to return to the routine cervical screening
interval.1 However, should any of the cytology or HR
HPV tests remain abnormal during post-treatment
surveillance, the woman is encouraged to continue with
cotesting every 12 months until two consecutive negative
cytology and HR HPV tests 12 months apart occur1
(Table 2).
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The primary objective of this study was to confirm
whether women treated for an HSIL are entering the ToC
within the recommended time frames, the number of
women who have the second set of cotests performed and
the number of women who successfully completed the
ToC. The secondary objective was to explore patient-
related factors that influenced participation in the ToC
management pathway.
Materials and Methods
This was a retrospective cohort study that followed up
women from time of HSIL treatment (ie excision or
ablative therapies) until their last cervical test result,
hysterectomy or death record. The Cervical Screening
Register (CSR) of Western Australia (WA) was used to
identify the study cohort. The CSR is legislated to compile
all cervical test results (HPV, cervical cytology and
histology) for women who reside in WA. Cervical test
results were classified according to the Australian
Modified Bethesda System 2004.1
A deidentified extraction of Hospital Morbidity Data
System (HMDS) records and death registry records for
these women was obtained from the Western Australian
Data Linkage System for 01 Jan 2006 to 31 Dec 2010.
The HMDS records all discharge summaries from all
Western Australian acute hospitals (private and public)
and day surgery clinics. In the International Statistical
Classification of Diseases and Related Health Problems,
Tenth Revision, Australian Modification (ICD-10-AM),
codes were used to identify cervical dysplasia and relevant
procedural codes (ie hysterectomy).
Ethical approval was granted from the Human Research
Ethics Committees of the Western Australian Department
of Health (ethics research project number: 2012/49) and
Curtin University (ethics research project number: HR 86/
2012).
The CSR was used to identify women aged 18 years or
more with histological confirmation of an HSIL for the
period 01 Jan 2006 to 31 Dec 2010. The woman’s full
screening history was reviewed to confirm incident cases
of HSIL. All women were followed up until (May 2013)
Table 1 Australian Test of Cure management pathway for
women treated for an high-grade squamous intraepithelial
abnormality (HSIL)
Post-HSIL treatment Pap smear Colposcopy
HPV
testing
4–6 months √ √
1st set of tests at 12 months √ – √
2nd set of tests at 24 months √ – √
Continue cervical cytology and HPV testing every 12 months
until these tests are both negative on two consecutive occasions.
Table 2 Test of Cure potential annual cotesting (cytology and
HR HPV) outcomes
12 months 24 months 36 months Test of Cure outcome
C0 H0 Incomplete
C0 H0 C0 H1 C0 H0 Incomplete
C1 H0 C0 H0 C0 H0 Complete
C0 H0 C0 H0 Complete
C0 H0 C1 H1 C0 H0 Incomplete
C0 = normal cytology, C1 = abnormal cytology, H0 = HR HPV
negative, H1 = HR HPV positive.
Table 3 Women’s demographic information
Number of
women
(n = 5,194)
Percentage
(%)
Age (years)
≤24 1,385 26.7
25–34 2,396 46.1
>35 1,413 27.2
Treated lesion grade
CIN2 2,161 41.6
CIN3 3,033 58.4
Referral Pap smear†
(screened within two years
prior to treatment)
Unsatisfactory 22 0.4
Normal 135 2.6
Possible LGEA/LGEA 777 15.0
Possible HGEA 1,105 21.3
HGEA/Invasive 3,107 59.8
No referral Pap smear result‡ 48 0.9
Treatment performed
Excisional treatment
Cone biopsy or LOOP/LLETZ 4,995 96.2
Ablative treatment
Radical diathermy/laser
destruction/other destruction
of the cervix
199 3.8
Pap smear result post treatment
(within 3–7 months of
treatment performed)
Unsatisfactory 42 0.8
Normal 2,579 49.7
Possible LGEA/LGEA 356 6.9
Possible HGEA 33 0.6
HGEA 72 1.4
Pap smear occurred
outside 3–7 months
2,073 39.9
No post treatment Pap
smear result†
39 0.7
†Most severe Pap smear test result was reported for the defined
period. ‡Although women may have been identified as not having
a Pap smear result post treatment within 3–7 months, they may
have been followed up earlier or post seven months.
LGEA = low-grade epithelial abnormalities; HGEA = high-grade
epithelial abnormalities; LLETZ = large loop excision of
transformation zone; CIN = cervical intraepithelial neoplasia.
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to allow a post-treatment follow-up time of at least
27 months. All diagnoses of HSIL in this study refer to
pathologists’ histopathologic interpretations of surgical
pathology specimens, including cervical biopsies
endocervical curettage specimens, and/or therapeutic
excisional procedures.
Women were excluded if a hysterectomy was performed
as their initial treatment or if they had histological
confirmation of an adenocarcinoma in situ (AIS), or
cervical cancer.
Demographic information and previous cervical
screening history were obtained for all women. Age at
treatment was categorised into 10-year age groups.
Postcode of residence at time of treatment was used to
assign a socioeconomic level using Australian Bureau of
Statistics 2006 Indices of Education and Occupation
(IEO), Relative Socioeconomic Disadvantage (IRSD) and
Economic Resources (IER).12 Postcodes were also used to
allocate a 2006 Accessibility/Remoteness Index of
Australia (ARIA+) category.13
In the majority of cases, the HR HPV test and cervical
cytology occurred at the same time; however, in some
instances (eg the woman had an unsatisfactory Pap smear
or HR HPV test), they may not have occurred on the
same date. Therefore, cotests were identified if either of
the tests occurred within 60 days of each other.
The HR HPV result was recorded as either HR HPV
detected, not detected or unsatisfactory sample. Specific
HR HPV subtypes were not recorded in this study. A
concurrent positive cytology result was defined as a low-
grade squamous intra-epithelial lesion (LSIL) or higher
severity.
Adherence to Test of Cure guidelines
To investigate women’s compliance with ToC guidelines,
they were classified as (i) ToC nonstarters (never had a
HR HPV test performed); (ii) commenced ToC within
recommended guidelines; or (iii) commenced ToC outside
recommended guidelines. These categories were developed
to support the NHMRC’s Guidelines for the Management of
Asymptomatic Women with Screen Detected Abnormalities.
These Guidelines advise that women treated for an HSIL
require colposcopy and Pap smear at 4–6 months
following treatment. Cotesting (cervical cytology and HR
HPV) should then be performed at 12 months post-
treatment and annually thereafter until both tests are
negative on two executive occasions. For this analysis,
follow-up time frames were defined as 12 and 24 month
periods. A time extension of three months on either side of
the 12- and 24-month period was incorporated to allow
women adequate time to return for their screening tests.
This time extension also took into consideration laboratory
and cervical screening register processing and reporting
times.
A woman was determined to have completed the ToC
if she tested negative on her Pap smear and negative for
HR HPV on two consecutive occasions (Table 1). If a
woman had a cervical abnormality or tested positive for
HR HPV, the ToC time frame was reset to start from
the next first set of negative cotests (Table 2). Women
were classified as having undergone ToC cotests within
the recommended time frames or outside the time
frames. Women who did not undergo any ToC cotesting
were considered ToC nonstarters, while women who did
not return for the second or subsequent cotests within
the time frame were considered to be ToC non-
completers.
Post-ToC disease persistence and/or progression was
investigated and defined as a high-grade histology result
such as an HSIL (cervical intra-epithelial neoplasia grade
2 or 3) or AIS. Disease progression was classified as
cervical cancer. Histology results were classified to the
most severe histological abnormality found.
Logistic regression models were constructed to
investigate whether women’s social, demographic and
health-related factors were associated with starting the
ToC pathway within the recommended time frames. A
binary variable was created that divided women into those
who commenced ToC within recommended time frames
and those who did not. Women who did not start the
ToC process were not included. Variables included in the
modelling process were age and year of treatment,
accessibility index and socioeconomic status. Statistical
significance was determined as a P-value <0.05, and the
95% confidence intervals (CI) for odds rate ratios were
calculated. Plausible interaction terms were tested using
likelihood ratio tests. Goodness-of-fit tests were used to
assess model suitability. STATA/IC 13.0 (STATA
Corporation, College Station, TX, USA) was used for
data manipulation and statistical analysis.
Table 4 Logistic regression results investigating women’s relative
odds entering the Test of Cure management pathway within
recommended intervals
Odds ratio
95% confidence
interval P-value
Age (years)
≤24 (base)
25–34 1.1 0.9–1.3 0.601
>35 1.3 1.1–1.6 0.011
Year of treatment
2006 (base)
2007 0.8 0.6–1.1 0.109
2008 1.1 0.9–1.4 0.382
2009 1.4 1.1–1.7 0.007
2010 1.6 1.36–2.0 0.000
IRSD†
Most disadvantaged 0.7 0.5–0.9 0.017
More disadvantaged 0.9 0.7–1.1 0.298
Middle 0.9 0.7–1.1 0.305
More advantaged 0.9 0.8–1.1 0.423
Most advantaged
(base)
†Index of relative socioeconomic disadvantage.
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Results
For the study period, 5,453 women were confirmed to
have received treatment for HSIL; however, 259 women
did not have a record of any further follow-up data post-
treatment and were considered ‘lost to follow-up’. The
remaining 5,194 women were identified as ‘eligible’ to
undergo the ToC management pathway, and their first
two post-treatment screening histories were investigated
(Fig. 1). Of these, 61 women were confirmed to have had
a hysterectomy, and a further eight women had died
during follow-up period. The mean age at time of HSIL
treatment was 30.9 years (range 18–87 years). Most
women (96%) were treated with excisional procedures,
and the remainder (4%) were treated with ablative
procedures (Table 3).
Of the 5,194 women who were eligible to undergo the
ToC, 1,916 (37%) only had subsequent Pap smears and
no record of HR HPV tests performed post-treatment.
These women were considered ToC nonstarters. Of the
ToC nonstarters, 1,460 (76%) had normal cervical
cytology results post-HSIL treatment and continue to have
annual Pap smears. All women who were treated for an
HSIL remain eligible to enter the ToC management
pathway to support their return to the routine (two yearly)
population-based screening interval.
There were 1,296 (25%) women who had their first pair
of cotests performed between 9 and 15 months post-HSIL
treatment. At first annual follow-up, 336 women tested
positive for HR HPV and/or cervical abnormality and had
to restart the ToC process.
A further, 960 (74%) tested negative for both the
cervical cytology and HR HPV. Of the 960 women who
tested negative for their first set of cotests, there were 449
women who returned for cervical cytology but no second
HR HPV test was performed. There were 286 women
who returned for their second set of cotests within the
recommended time frames with 281 (22%) completing
ToC following a second set of negative results.
Although outside the recommended time frames, a
further 225 women returned for their second set of
cotests. Of the 1,296 women, there was no further follow-
up data available for 39 women post the first set of
cotests.
Of those eligible, 1,978 (38%) women commenced ToC
outside the recommended interval (eg >15 months post-
treatment). Of these, 1,415 women tested negative for a
cervical abnormality and/or HR HPV and 563 (28.5%)
tested positive for their initial cotest. However, there were
861 women who returned for cervical cytology HR HPV
test. Overall 98 (<10%) women had no further follow-up
data available post the first set of cotests.
Figure 1 This flow diagram indicates the number of women who tested negative for both sets of cotests and was eligible to return to
biannual cervical screening. The follow-up of women who tested positive is not shown.
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Of the 3,274 women who commenced the ToC
management pathway, 961 (29%) women successfully
completed the ToC and all were identified as ‘cured’.
There were a further 441 (13.5%) women who
commenced the ToC; however, they tested positive (on
either their initial or second set of cotests) and are yet to
test negative on two sets of consecutive tests (cervical
cytology and HR HPV). There were no subsequent
disease persistence or progression histology test results
recorded for the ToC completers in the remaining follow-
up time (the median follow-up time was 2.3 years, range
<1 year to 5 years) although longer follow-up is required.
Logistic regression models were constructed to identify
factors associated with whether a woman (n = 3,274)
entered the ToC pathway within recommended time
frames or not, regardless of their ToC test finding
(Table 4). Women aged >35 years were found to be more
likely to enter the ToC management pathway compared to
women aged <25 years (OR 1.3, 95% CI 1.1–1.6). Year
of treatment was also identified as a significant factor with
a positive trend indicating increased compliance. Women
treated in 2010 were 1.6 times more likely (95% CI
1.3–2.0) to enter the ToC at the recommended time frame
compared to women treated in 2006. Socioeconomic
status was also a significant factor with women classified
as ‘most disadvantaged’ 30% less likely to enter ToC at
the recommended interval compared to women classified
as ‘least disadvantaged’ (OR 0.7, 95% CI 0.5–0.9).
Accessibility and whether the original HSIL lesion was
classified as CIN2 or CIN3 were not associated with
commencing ToC within the recommended time frames.
Discussion
This is the first population-based Australian study to
investigate the utilisation of HR HPV as a cotest for
women post-treatment for HSIL through linked person
administrative data sets. The study found that over 50%
of women who commenced the ToC management
pathway did not have the second HR HPV test performed
and consequently did not achieve a ‘cured’ status. These
women continued to have annual Pap smears and
potentially unnecessary biopsy and/or colposcopy
investigations. The study also revealed that a large
proportion of women (~37%) did not have a HR HPV
tests performed post-treatment despite the NHMRCs
Guidelines introducing HR HPV testing as a cotest with
conventional cytology in 2006. This is a particularly
important finding for Australian policy makers, given
Australia is going to be implementing significant policy
changes to the current screening pathway.
The number of women entering the ToC management
pathway continues to increase yearly, and healthcare
providers should be commended and encouraged to
manage women in accordance with these best practise
guidelines. Practitioners may be unaware that HR HPV
testing is performed in a similar way to performing a Pap
smear, using a swab or bush which collects cells from the
cervix. Rather than smearing the sample collected onto a
microscope slide (conventional Pap smear), the head of
the spatula is broken off and placed into a small glass vial
containing preservative fluid, or rinsed directly into a
preservative fluid. The vial is then transported to the
laboratory for processing.
Consequently, it is possible the slow uptake of the ToC
management pathway amongst practitioners highlights the
importance of early community engagement and planned
educational programmes when changes to guidelines are
introduced.
Our study also confirmed that there were more women
completing the ToC outside the NHMRC recommended
time frames. Given the overall treatment success within
this cohort, Australian healthcare providers involved in the
follow-up care of women need to be aware of and adhere
to the ToC management pathway. This will ensure
women’s timely and safe return to routine screening
(currently two yearly).
The results here indicate that an overall low ToC
completion rate is similar to findings recently reported in a
New South Wales retrospective study.9 As reported by
Morrell and Qian, it is possible that general practitioners
and other women’s health clinicians believe that a single
HR HPV-negative test result, along with successive
negative cytology, is sufficient to indicate successful
treatment. However, Munro et al. surveyed general
practitioners found 30% of responding GPs had no or
limited knowledge of ToC. A clear need exists for
gynaecologist/colposcopists to provide referring GPs (and
their patients) with a clear discharge summary that outline
required time intervals for follow-up screening and the
rationale that supports this.14
This study has confirmed the importance of women’s
demographic information that supports a timely ToC
commencement. A rural address was not found to be a
barrier to compliance in a ToC management plan.
However, younger women (aged <35 years) and women
living in areas of lower socioeconomic status were found
to be at risk for not entering the ToC management
pathway. Healthcare providers who are involved in the
management of these women play a critical role in
explaining the importance of having two consecutive
cotests and the role of HR HPV testing. By explaining the
benefits of ToC, including confirmation of oncogenic HPV
clearance, decreased unnecessary referrals to colposcopists/
gynaecologists (less unnecessary psychological stress and
lower financial costs) may further encourage follow-up
attendance. Additionally, if the practitioner is uncertain of a
patient’s medical history, Australian State and Territory
cervical screening registries can usually provide
comprehensive cervical screening histories for patient’s to
guide subsequent testing.
This study has important strengths. Firstly, it used a
state-wide population cervical screening register with
virtually complete coverage since late 1994 and we have
increased confidence that all women with histological
confirmation of an HSIL were identified. Additionally,
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through linked hospital morbidity, cancer and death
records, women who were no longer eligible to complete
the ToC (eg women who had a hysterectomy or were
deceased) could be excluded. Limitations of the study
included those women who were lost to follow-up were
nonassessable, and we were unable to investigate whether
the impact of the woman’s socioeconomic status was
confounded by patient care being delivered by a specialist
verse GP after their original surgery. A further limitation
of this study is the well-acknowledged inherent error that
exists in all databases, which can never entirely be
eliminated. However, the CSR of WA routinely carries out
quality assurance (QA) processes to ensure high-quality
data capture and completeness is obtained. The QA
processes employed ensure the level of error within the
CSR of WA is acceptable.
In this study, we confirmed a high rate of treatment
success and that no disease persistence or cervical cancer
incidence occurred for any woman who completed the
ToC within the limited follow-up time. To strengthen these
findings, several more years of follow-up data are required.
Nonetheless, the absence of cervical disease persistence and
cervical cancer after completing ToC is a positive and
reassuring finding to healthcare providers involved in the
post-treatment management of these women.
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Chapter 6:  
 
Discussion
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Since the release of the NHMRC Guidelines in 2005, several studies have 
provided new and updated findings regarding the awareness and management of 
women with abnormal cervical cell histology. As a consequence it is timely for 
these guidelines to undergo a review3, 97, 98.  
This thesis and its publications aimed to provide up-to-date data that can support 
the revision of the NHMRC Guidelines and further contribute to sound clinical 
evidence. The updated NHMRC Guidelines will assist clinicians in providing 
education to their patients regarding age-related management strategies (i.e. 
surveillance versus immediate treatment) and importance of co-testing (HPV and 
cervical cytology) after treatment of high-grade cervical lesions, in turn reducing 
the number of follow-up visits, alleviating potential patient fears, and reducing 
unnecessary anxiety.  
As GPs are at the cold face in delivering cervical screening services to and 
following-up women with cervical abnormalities, two publications were developed 
to provide clinically relevant and evidence-based information to GPs. These 
articles were purposely submitted and subsequently published by the Australian 
Family Physician to further assist GPs in their delivery of the highest quality 
patient care based on best practice. Clinician adherence to revised Australian 
management and follow-up guideline recommendations, delivery of patient 
education, and appropriate referrals will be essential in the initial detection and 
successful treatment of early cervical changes. 
6.1 Strengths and limitations 
The strengths and limitations specific to the individual studies are discussed in 
detail in the discussion section of each publication, this section provides a more 
holistic overview.  
A major strength of this work was it was based on large administrative databases 
from a stable and isolated WA population73. This results in almost complete case 
ascertainment with minimal loss to follow-up over the study period and study 
findings are externally valid to the wider Australian context. This is of critical 
importance when investigating rare cervical pathologies (i.e. AEC and ACIS 
(Publication 1 and 2) and when women’s longitudinal health outcomes are 
investigated (Publication 1, 2, and 3). The large sample sizes also allowed 
investigation into multivariate models controlled for multiple risk factors and 
potential confounders simultaneously. 
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As this research was able to use population-based administrative datasets 
(Publications 1, 2, 3, 4), the limitations of this thesis are related to its 
retrospective observational design. These issues were discussed in further detail 
in Chapter One. As with all retrospective studies, the work reported in this thesis 
that utilised administrative data also has a number of constraints. Examples 
include the quality of the data (e.g. data reliability/completeness) and potential 
confounding variables not present in the datasets (e.g. women may have been 
symptomatic, on medication, e.g. contraception; lifestyle factors, e.g. multiple 
sexual partners, high parity etc.) and lack of other relevant clinical details.  
Attempts were made to address some of these potential short comings, for 
example within the ACIS Publication, a manual review of all women’s 
histopathology variables was conducted to collect critical treatment information 
(i.e. specimen depth, margin clearance (yes, no, or undetermined), specific 
margin involvement (i.e. endocervical, ectocervical, or both) in the lesion, and the 
presence of another lesion type present (i.e. CIN and ACIS) etc.).  
Similarly while the administrative data provided readily accessible information 
about GP compliance rates with the ToC, it could not provide details on GP 
knowledge and awareness of this management pathway. This data needed to be 
acquired through dissemination of a survey (Publication 4). The major limitation 
of the survey was selection and response bias, as the GPs may or may not have 
reported positive compliance rather than reporting non-compliance with the 
Guidelines. Additionally the response ratio also needs to be considered when 
interpreting the survey data. Although the survey response rate was 30% of all 
GPs in WA (including the rural and metropolitan areas), the survey results further 
supported the quantitative population-based findings and further reinforced the 
importance of GPs being provided with educational tools and promotion of the 
ToC management pathway (Publication 5).  
6.2 Key findings and their clinical significance 
The major topics presented in this thesis encompass three broad themes: the 
clinical significance of low-grade glandular lesions (Objective I), management of 
women with glandular lesions (Objective II) and treatment of young women with 
CIN2 (Objective III) and practitioner’s awareness/knowledge, and compliance 
with recommendations for the follow-up of women treated for CIN2/3 (Objective 
IV). The major findings from each research objective are discussed below. 
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6.2.1 Clinical significance of AEC  
The clinical importance of the test for AEC (Objective I) and revealed its 
implications for women (i.e. presence of a high-grade cervical abnormality or 
gynaecological malignancy) were investigated in Chapter 3. This was a novel 
study both nationally and internationally, so the results are unique when 
compared to those of previously published studies. 
Importantly, the study confirmed that a positive test result for AEC definitively 
warrants further investigation for both cervical and endometrial abnormalities. 
This is especially important for younger patients with a) no cervical screening 
history or b) low-grade cervical disease and for older women (40 years) to 
exclude endometrial pathology. In future, the Federal Health Department of 
Australia is expected to mandate five-yearly cervical screening using the HPV 
test as the primary cervical screening test; however, reflex liquid-based cytology 
testing will be performed for women with a positive result for the HR HPV test. 
Consequently, reflex cytology tests may still report the presence of AEC and thus 
the findings from this study are still highly applicable in the Australian setting. 
6.2.2  Effectiveness of conservative treatment for women histologically confirmed 
with ACIS 
Conservative treatment of ACIS remains controversial both within Australia and 
overseas3, 32, 33, 40, 41, 79 81-87.  For women who have completed their childbearing, 
total hysterectomy remains the treatment of choice for the following reasons: 
• Extension into the endocervical canal is frequent and determination of the 
desired depth of excision can be difficult.  
• ACIS can be multifocal and discontinuous in nature, so negative margins 
on an excision specimen do not provide 100% assurance that the lesion 
has been completely excised.  
• Invasive cervical cancer cannot be confirmed unless a diagnostic 
excisional procedure is performed.  
For younger women, especially as the incidence of ACIS in this age group 
continues to increase2, investigation into conservative treatment options and their 
associated health outcomes is necessary. As such, this thesis used linked health 
administrative data coupled with a comprehensive histopathology review of all 
women with biopsy-confirmed ACIS (Objective II) within WA to report their health 
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outcomes after conservative treatment. Positively, the study did not find a 
significant difference in health outcomes for women that were treated by LEEP 
and those treated with CKC biopsy. Therefore, this thesis is in agreement and 
supports the 2012 ASCCP Guidelines and recommends that the NHMRC 
Guidelines be amended to include the following: In cases of women with biopsy-
confirmed ACIS that desire future fertility, conservative treatment with 
LOOP/LLETZ is an acceptable treatment modality for carefully selected patients 
(i.e. patients that can comply with follow-up instructions). Additionally, follow-up 
recommendations for these patients should include the following: 
• Re-excision of the lesion is recommended if the margins of the specimen 
are positive (i.e. CIN and/or ACIS is involved)  
• Counselling of patients treated conservatively is imperative to ensure they 
attend long-term follow-up investigations. 
• Patients should be followed-up at six months and undergo co-testing 
(HPV and cervical cytology, specifically endocervical sampling) in 
conjunction with colposcopy. 
Updating the NHRMC Guidelines to include a specific management protocol will 
greatly assist clinicians in managing women with biopsy-confirmed ACIS that 
wish to preserve fertility and are able to adhere to rigorous follow-up throughout 
this time period. 
6.2.3 Importance of spontaneous regression of CIN2 for young women 
Clinicians were provided with further evidence in Chapter 4 (Objective III) to 
support the adoption of a conservative approach (i.e. surveillance) for young 
women with histologically confirmed CIN2 (approximately, 60% show 
spontaneous regression). To date, this is the largest population-based cohort of 
young women (n = 924) that analysed follow-up data for two years. Clinicians can 
be confident that those women who undergo comprehensive counselling and 
agree to adhere to follow-up protocols can be managed conservatively without 
risk of progression in a two-year period (i.e. CIN2 in young women behaves as a 
low-grade lesion).  
Importantly, the study’s findings and conclusions were consistent with current 
guidelines of the 2012 American Society for Colposcopy and Cervical Pathology 
(ASCCP), which support conservative management of young women. However, a 
larger study (cohort and prospective design) is still needed to validate this 
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approach. It is hoped that these study findings will support the revision of the 
NHMRC Guidelines to ensure all Australian clinicians involved in the 
management of young women with CIN2 are aware of the benefits/risks of 
treating versus surveillance management approaches.  
6.2.4 Practitioner’s awareness/knowledge of and compliance to ToC  
Women with CIN2/3 are treated by local excision or ablation to prevent 
progression to cervical cancer. Although conisation is proven to be an effective 
treatment for removing CIN, it does not necessarily lead to elimination of the HPV 
virus.  Clinician’s awareness of HR HPV testing as outlined by the NHMRC 
Guidelines is a key step in ensuring the best patient outcomes but this relies on 
practitioner compliance to the recommendations. GPs’ awareness/knowledge 
and subsequent compliance (Objective IV) in managing women in accordance 
with the ToC management pathway was found to be very low in Chapter 5. This 
finding confirmed a similar observation in a recent study performed in New South 
Wales52.  
Clearly there is a need to provide GPs with ongoing education in the delivery of 
these (and future revised guidelines). To this end, the findings from the survey 
and population-based analysis were shared with the NCSP Program managers’ 
who will look for opportunities to further promote this pathway among health care 
providers involved in the management of women. Since these findings were 
obtained, ToC has been promoted at a Western Australian Pap Smear Provider 
Professional Development day (for metropolitan and rural health care providers), 
promoted in the Medical Forum and Medical Observer. It is hoped that further 
education sessions will be delivered to GPs in future. 
6.3 Implication of research findings 
The research findings obtained in this thesis have been presented at local, 
national, and international meetings. At a local level, the findings have been 
shared with the WA Cervical Cancer Prevention Program (WACCPP) as well as 
at the professional development sessions that the WACCPP provides to health 
care providers that provide cervical screening services. Additionally, this research 
has been utilised to further enhance (provision of clinically up-to-date information 
of i.e. pathogenesis of cervical cancer and its precursors, classification of cervical 
abnormalities etc.) the WACCPP’s website content (Additional material 1) which 
is accessible by health care providers and consumers.  
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At the national level, research findings have been shared with the National 
Cervical Screening Program managers’ ensuring dissemination to other states 
and territories. This has facilitated effective completion of the research feedback 
loop (i.e. other States and Territories will work towards developing new research 
initiatives that builds on our existing evidence).  
Three studies (Publication I, IV and V) were published in Australian medical and 
obstetric/gynaecology journals to further support Australian practitioners in the 
management of women with cervical abnormalities. These were critical forums 
and will inform the revision of the 2005 NHMRC Guidelines (to be completed by 
2017) in support of the implementation of a revised cervical screening pathway. 
Internationally, some of these findings were presented at the International 
Gynecological Cancer Society Meeting and the 2014 World Cancer Congress as 
well as published in a high-ranking international gynaecology journal (Publication 
II). 
6.4 Future avenues for research 
In the Australian landscape, the value and importance of “big data” has long been 
acknowledged and there is a clear necessity to develop and capitalise on the 
availability of these data through innovative linkage/integration processes. The 
work in this thesis has started to explore some of the large body of linked 
population-level data that can support the Australian National Cervical Screening 
Program as it enters an era of great change. The Australian Government is 
working collaboratively with the states and territories to develop a National 
Cancer Screening Register that will support the delivery of the national cervical 
and bowel screening programs to be effective 1 May 2017. Establishment of this 
national register would enhance data integration/sharing (e.g. collection of 
cervical screening test results, HPV vaccination status, collection of colposcopy 
outcomes etc.) and has the potential to: 
• Provide “one woman, one record” – allowing health care providers to 
access a women’s complete screening history in one central system 
o Provide predictive analytics to more effectively identify early 
treatments in a patient’s history, to prevent future medical events 
and avoid future readmissions. 
o Incorporate family history and current health conditions for 
increased effective pre-emptive care. 
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o Decrease cross border issues e.g. assists in managing and 
following-up the eligible population more efficiently. 
• Eliminate costs of maintaining and storing duplicate health records. 
• Provide researchers with access to increased sample sizes (e.g. national 
population data) that could be used to investigate rare events (e.g. 
incidence and treatment of small cell carcinoma); including effectiveness 
of different treatment modalities, post surgical management strategies 
and longitudinal health outcomes associated with these diseases. 
However, it is important to acknowledge the success of the current Australian 
CSRs and consider the potential pitfalls of attempting to implement a national 
system, such as: 
• Loss of State specific initiatives (e.g. data cleansing for Aboriginal health 
services or provision of individualised data requests). 
• Potential for failure of the national register and the subsequent 
implications that could occur for women. 
• Loss of jurisdictional knowledge and expertise (e.g. manual data 
cleansing). 
• Potential loss of jurisdictional quality assurance processes that ensure 
data completeness and validity  (e.g. collaborative relationships with 
laboratories in the codification of cervical test results and timely 
transmission of data). 
It is of critical importance to be aware that should a national cancer register be 
developed, it must possess increased functionality and capability (when 
compared to existing jurisdictional cervical screening registers) to store patient’s 
demographic information and medical records, and would need to be 
prepared/developed systematically. This would ensure that data collected is of a 
high quality to support delivery of patient care (e.g. patient follow-up of abnormal 
test results) and possess the potential to translate into meaningful research 
initiatives (e.g. monitoring the safety of extended screening intervals). Future 
studies utilising ‘big data’ obtained from a national cancer-screening registry 
should focus on meaningful and objective criteria, such as clinical and social 
effectiveness, and interventions that can improve efficiency of service delivery. 
Key areas of further work stemming from this thesis included investigation into 
the management of young women (aged < 25 years). Specifically, could patients 
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with CIN3 lesions be left untreated and remain under surveillance to allow 
spontaneous regression? Studies that report the safety of observation for young 
women with histologic CIN3 are needed, as long-term outcomes after apparent 
regression without treatment remain currently unknown.  
Other studies that examine the long-term follow-up data to help inform post-
treatment outcomes and optimal long-term follow-up intervals for women with 
treated for CIN2/3 are required. This work could detail when women could  
“safely” return to a routine screening interval and inform the future NHRMC 
Guidelines. 
Finally, the effect of the HPV vaccination on large populations of women over 
long periods of follow-up is yet to be fully studied. Research is required to 
determine whether HPV vaccination alters the natural history and/or management 
of cytologic or histologic abnormalities?  
6.5 Achievements against thesis objectives 
The work of this thesis set out to investigate three broad areas of interest 
including diagnosis and clinical significance of low-grade glandular abnormalities, 
treatment and management of women with high-grade cervical abnormalities. 
The work was defined by 4 specific objectives:  
Objective 1: Investigate the risk factors and incidence of atypical endocervical 
cells of undetermined significance for Western Australian women in Pap smear 
test results and the associated health outcomes. 
Objective 2: Analyse linked population-based administrative data to evaluate 
women with histologically confirmed ACIS managed with conservative treatment 
in WA. 
Objective 3: Utilise linked population-based administrative data to investigate the 
spontaneous clearance rate among young women (aged <25 years) with 
histologically confirmed CIN2. 
Objective 4: Determine practitioners’ knowledge, awareness, and compliance 
with the Test of Cure management pathway. 
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In addition, it was hoped this work would help inform the revision of the NHMRC 
Guidelines for the management of women with rare cervical pathologies and to 
identify areas requiring further improvement, which is due for release in 2017.  
To this end, work that has underpinned each objective has resulted in at least 
one publication in a peer-reviewed journal, presentation at national and 
international conferences and further dissemination to appropriate state and 
national bodies. As such, it is believed that by these measures the outcomes of 
this thesis have been achieved. 
6.6 Vision for future research initiatives 
As this thesis draws towards completion, I look forward to starting a new chapter 
within my early research career. I believe that I was awarded a great privilege to 
have worked with experts in the field of clinical sciences, specialists that are 
interested and committed to improving women’s health and those who have been 
involved in utilising “big data” for many years.  
Through valuing these relationships and working collaboratively across multi-
disciplines, we were able to investigate research questions that resulted in 
translational clinical findings for the Australian female population. As science is a 
dynamic field and continues to evolve at a significant pace, I am excited to further 
contribute to emerging knowledge that may improve women’s health outcomes, 
specifically in the area of gynaecology oncology. 
This thesis has only commenced exploration into a potentially very large body of 
population-based work that needs to be conducted in support of women with 
gynecological disease. Consequently, I have commenced discussions with the 
WACCPP and other research institutions (i.e. King Edward Memorial Hospital, 
Saint John of God Hospital) to further identify gynecological research priorities 
that are yet to be investigated.  It is my hope that through utilising “big data” 
inconjunction with chart reviews, we will be able to positively contribute to an 
ever-growing evidence base that supports women with gynaecological conditions 
such as cervical, ovarian and/or endometrial cancer.  
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Appendix 4: Cervical Screening Registry of WA Histology Codification Sheet 
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Appendix 5: Survey sent to Western Australian 
General Practitioners
Demographic information
Partners in ensuring success of the National Cervical Screening Program
1. Please enter your practice postcode
2. What is your gender?
Female
Male
3. What is your age?
< 35 years
35-44 years
45-54 years
> 55 years
4. How many years have you been practising as a general practitioner?
< 2 years
2-5 years
6-10 years
11-19 years
20+ years
5. How many direct patient hours do you work per week?
 25%
Powered by
See how easy it is to create a survey.
< 10 hours
11-20 hours
21-40 hours
41-60 hours
> 61 hours
6. Is your general practice registered to claim the Practice Incentive Program for
cervical screening?
Yes
No
Unsure
7. Does your practice employ nurses or midwives who are able to perform Pap
smears?
Yes
No
Next
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Cervical Cancer Prevention Tool Kit  
for Australian Nurses and Midwives  
By Heidi Pavicic, Aime Munro, Nerida Steel and Natalie Williams
Cervical cancer is a worldwide 
health issue and one of the most 
preventable of all cancers (World 
Health Organization [WHO] 2013). 
Australia adopts an organised 
approach to cervical screening and 
encourages women’s participa-
tion in cervical screening to detect 
abnormal cell changes in the 
cervix, which if left undetected and 
untreated may progress to cervical 
cancer (National Cervical Screening 
Program [NCSP] 2011). In Australia, 
631 new cases of cervical cancer 
were diagnosed in 2009 and 152 
women died from the disease in 
2010 (Australian Institute of Health 
and Welfare [AIHW] 2013). All 
women who are sexually active are 
at risk of human papillomavirus 
(HPV) infection; it is estimated 
75% will involve an oncogenic HPV 
type (Peto et al 2004). Throughout 
Australia in 2011, eight out of every 
1,000 women screened had a his-
tologically confirmed high-grade 
cervical abnormality, providing an 
opportunity to treat women before 
possible progression to cancer 
(AIHW 2013).
Nurses and midwives are well 
placed to provide cervical screen-
ing services, as they can identify 
and support each woman’s right to 
have access to complete infor-
mation and actively encourage 
women to participate in all aspects 
of their health care (WA Cervical 
Cancer Prevention Program 2013; 
Queensland Cervical Screening 
Program 2012). Through col-
laboration with, and support of, 
Australian nurses and midwives 
we can increase women’s access 
to safe and culturally appropriate 
cervical screening services. To 
support the delivery of high quality 
services, nurses and midwives 
have the opportunity to undertake 
appropriate education and training 
and, if available, to credential as a 
Pap smear provider. The credential-
ling of nurses and midwives as Pap 
smear providers is demonstration 
of an ongoing commitment to de-
liver high quality provision of Pap 
smears throughout Australia (WA 
Cervical Cancer Prevention Pro-
gram 2013; Queensland Cervical 
Screening Program 2012).   Further 
information related to education 
and credentialling as a nurse/mid-
wife Pap smear provider may be 
obtained by contacting your local 
cervical cytology (‘Pap smear’) 
registry or local cervical cancer pre-
vention program. 
As a Pap smear provider you are 
responsible for supporting each 
individual woman throughout the 
screening pathway, from recruit-
ment through to diagnosis (WA 
Cervical Cancer Prevention Pro-
gram 2013; Queensland Cervical 
Screening Program 2012). A Pap 
smear may be a personally chal-
lenging procedure for a woman; 
therefore, it is important to ensure 
women participating in cervical 
screening are both psychologi-
cally and physically comfortable 
throughout the examination (WA 
Cervical Cancer Prevention Pro-
gram 2013; Queensland Cervical 
Screening Program 2012; Stewart 
and Thistlethwaite 2010). 
National competency 
standards for pap smear 
providers 
As a Pap smear provider you are 
required to adhere to and uphold 
the National Standards for Nurse 
Pap Smear Providers. These stan-
dards relate to the legal and ethical 
responsibilities for Pap smear 
providers, and include:
• Demonstrates accurate knowl-
edge for safe practice.
• Protects the rights of individuals.
• Recognises own ability and level 
of professional competence.
• Acts to enhance the dignity and 
integrity of women.
• Maintains a physical and 
psycho-social environment 
which promotes safety, security 
and optimal health care.
• Acts to maintain the right of 
women to make informed deci-
sions.
• Integrates comprehensive 
health assessment and interpre-
tive skills to achieve optimal 
care for women.
• Collaborates with the health 
care team to achieve desired 
outcomes.
How do you assess who 
needs a pap smear?
The NCSP recommends all women 
aged 18 to 69 years, who have ever 
been sexually active, whether vac-
cinated or not, participate in two-
yearly cervical screening (NCSP 
2011). This policy applies only to 
asymptomatic women. Symptom-
atic women require referral and 
further investigation. The policy 
states (NCSP 2011): 
• All women with an intact cervix 
who have ever been sexually ac-
tive (any genital-skin to genital-
skin contact) should commence 
having Pap smears between the 
ages of 18 and 20 years, or one 
to two years after sexual debut, 
whichever is later. 
• Women who have had a hys-
terectomy may cease having 
Pap smears, providing their 
hysterectomy included removal 
of the cervix and was performed 
for benign reasons. 
• Pap smears may cease at the 
age of 70 years for women 
who have had two normal Pap 
smears within the past five 
years. Women 70 years and 
over that have never had a Pap 
smear, or who request a Pap 
smear, should be screened.
• Women with a past history of 
high-grade cervical lesions, 
or who are being followed-up 
for previous abnormal smears 
should be clinically managed in 
accordance with the National 
Health and Medical Research 
Council (NHMRC) guidelines 
Screening to prevent cervi-
cal cancer: guidelines for the 
management of asymptomatic 
women with screen detected 
abnormalities (2005).
How do you assess women 
for their pap smear?
First, a thorough medical, gynaeco-
logical and obstetrical history 
needs to be obtained, particularly 
enquiring about any:
• postmenopausal bleeding 
(PMB) or spotting;
• postcoital bleeding (PCB) or 
spotting; 
• intermenstrual bleeding (IMB) or 
spotting; and
• abnormal vaginal discharge.
If any of these symptoms are 
present, a Pap smear should be 
taken and the woman should be 
immediately referred to a medical 
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practitioner. A thorough history will 
also assist in determining the need 
for opportunistic testing for sexu-
ally transmitted infections. 
key factors for a positive 
patient experience 
Pap smear providers should seek 
feedback from their patients as 
part of their quality assurance 
measures to ensure a positive Pap 
smear experience occurs for the 
woman. Positive outcomes for the 
woman may include (WA Cervical 
Cancer Prevention Program 2013; 
Queensland Cervical Screening 
Program 2012):
• Equipping the woman with infor-
mation to support her decision 
to have a Pap smear.
• Creating a safe and supportive 
environment where a woman 
can ask sensitive questions. 
• Establishing a plan to commu-
nicate the Pap smear results to 
the woman.
• Taking the time to alleviate anxi-
ety and ensure understanding 
of what the Pap smear results 
mean.
• The roles and benefits of 
cervical cytology registries are 
explained to the woman.
• The woman knows when her 
next Pap smear is due.
The human papillomavirus 
Human papillomavirus (HPV) is 
a common sexually transmitted 
infection with approximately four 
out of five women being infected 
at some point throughout their 
lifetime (Castellsague et al 2009; 
Castellsague 2008; Bosch and 
de Sanjose 2003).  Studies have 
identified approximately 99.7% 
of cervical cancers are positive for 
HPV DNA (Wallboomers et al 1999). 
Transference of HPV to the genital 
region primarily occurs through 
genital-skin to genital-skin contact 
(Rodriguez et al 2010). The majority 
of HPV infections are cleared by the 
woman’s body within one to two 
years (Rodriguez et al 2010), with 
approximately 50% of HPV infec-
tions spontaneously clearing within 
eight months of initial infection 
and 90% being cleared within two 
years (Moscicki et al 2006). There 
are more than 100 types of HPV, 
with 40 types affecting the genital 
region. Among the genital HPV 
infections, there are both low-risk 
(LR) HPV and high-risk (HR) HPV 
types. LR HPV is non-cancer caus-
ing and often presents as genital 
warts, with types 6 and 11 causing 
90% of these cases (Munoz et al 
2003).  HR HPV is recognised as a 
necessary, although not sufficient, 
cause of virtually all cervical cancer 
cases (Bosch et al 2002; Bosch 
et al 2006; Castle et al 2005). HR 
HPV types 16 and 18 alone are 
responsible for 70% of cervical 
cancer cases (Bosch et al 2008). 
The progression from HPV infection 
to cervical cancer may take up to 
five to 15 years (Castellsagué et al 
2009); however, the majority of HR 
HPV infections do not progress to 
cervical cancer as the body is often 
able to clear this infection (Castell-
sagué et al 2009; Burd 2003).
Tips for explaining Hpv 
infection to women
• Most sexually active women 
(four out of five) will have this 
virus at some point in their lives.
• Most women clear the virus on 
their own within two years.
• Over 100 types of this virus exist.
• 40 types of HPV can affect the 
genital region, of these there 
exist low-risk and high-risk HPV 
types.
• Low-risk HPV types are non-
cancer causing and often cause 
genital warts.
• High-risk HPV types may cause 
cancer, if the body does not 
clear the virus.
• High-risk HPV types 16 and 
18 cause over 70% of cervical 
cancer.
• Timeline from getting HPV to 
cervical cancer may take up to 
five to 15 years.
Cervical cancer prevention 
Primary prevention: HPV 
vaccines
HPV vaccination is a primary pre-
vention intervention and protects 
against HR HPV types 16 and 18 that 
cause 70% of all cases of cervical 
cancer (Brotherton 2008; Harper et 
al 2006; Villa et al 2005). HPV vac-
cination has been approved in over 
100 countries, as the vaccines are 
both safe and efficacious (Koutsky 
and Harper 2006).  In Australia 
two types of HPV vaccines have 
been approved for use, Gardasil® 
and Cervarix® (Szarewski 2012; 
Brotherton et al 2011). Since 2007 
Gardasil® has been included in the 
Australian school-based vaccina-
tion program, which includes the 
vaccination of girls aged 12 to 13 
years, at no cost to the individual 
(Australian Government Depart-
ment of Health and Ageing 2006). 
Gardasil® is administered as an 
intramuscular injection (IM), given 
in three doses with the initial dose, 
then at two and six months (CSL 
Limited 2013). Potential side effects 
may include allergic reactions, 
injection site reactions, headaches, 
fever, nausea and dizziness (CSL 
Limited 2013). Contraindications to 
Gardasil® include hypersensitiv-
ity or severe allergy to yeast, prior 
allergic reaction to Gardasil® and 
pregnancy (CSL Limited 2013). 
It is important to note HPV vac-
cines are not a therapeutic vaccine, 
rather they are designed to prevent 
initial HPV infection (Brotherton et 
al 2011; Harper et al 2006; Villa et 
al 2005), therefore the vaccine is 
most effective if all three doses are 
administered to females prior to 
the commencement of sexual ac-
tivity (Brotherton et al 2011; Harper 
et al 2006; Villa et al 2005). Whilst 
the advisement by HPV vaccination 
guidelines is to vaccinate young 
girls before their sexual debut, nat-
ural history studies indicate that all 
sexually active women may benefit 
from the vaccination (Brotherton 
2008; Ault 2007; Harper et al 
2006; Villa et al 2005). Should 
the girl or woman have already 
initiated sexual activity she may 
still be offered vaccination after 
a discussion about the risks and 
benefits to assist her in making an 
informed decision (Castellsagué 
et al 2009). Health care providers 
should educate the woman of the 
benefits of vaccination combined 
with the importance of continued 
cervical screening (Castellsagué et 
al 2009). 
Secondary prevention:  
cervical screening
Australia’s cervical screening pro-
gram operates as a joint program 
of the Australian government and 
state and territory governments, 
with a target group of women aged 
18-69 years (NCSP 2011). The pri-
mary cervical screening tool used 
in Australia, is the Pap smear, or 
‘Pap test’. Pap smears enable iden-
tification of early cellular changes 
in the cervix, which if left unde-
tected and untreated may progress 
to cervical cancer (AIHW 2013). 
Pap smears have been proven to 
prevent 70% of cases of squamous 
cell carcinoma (AIHW 2013) and 
thus, promotion of regular cervical 
screening to all eligible female 
patients is crucial. Over 50% of 
women who develop cervical can-
cer have never had a Pap smear, 
have been screened irregularly, or 
have not been screened within the 
previous five years (Coleman and 
Poznansky 2006).
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Tips for explaining cervi-
cal cancer prevention to 
women
• HPV vaccination offers protec-
tion against HR HPV types 16 
and 18, which cause 70% of 
cervical cancers.
• In Australia there are two types 
of HPV vaccines, Gardasil® and 
Cervarix®, which protect against 
HPV types 16 and 18.
• Gardasil® is free for girls aged 12 
to 13 years, as part of the school-
based vaccination program.
• HPV vaccination does not 
protect against all cancer caus-
ing types of HPV and therefore 
vaccinated women still need to 
have regular Pap smears.
• Pap smears are looking for any 
cervical cell changes, which if 
found early, can be managed 
and possibly treated if required, 
before progression to cervical 
cancer.
How do you manage preg-
nant women?
Pregnancy is a time when women 
often have the greatest interest in 
their health and thus are likely to 
participate in cervical screening, 
should it be offered. Offering cervi-
cal screening to pregnant women 
is essential as 1-3% of women 
diagnosed with cervical cancer are 
pregnant or postpartum at the time 
of cancer diagnosis (Nguyen et al 
2005; Creasman 2001). Approxi-
mately 50% of these cases are 
diagnosed prenatally and the other 
half is diagnosed within 12 months 
of the delivery (Smith et al 2001). 
As a Pap smear provider you may 
be able to promote opportunistic 
screening at the patient’s booking 
visit or, if more appropriate for the 
woman, at the follow-up visit.
The Royal Australian and New 
Zealand College of Obstetricians 
and Gynaecologists advises a Pap 
smear should be offered to every 
asymptomatic pregnant woman 
who is due for cervical screening 
(NCSP 2011). Ideally screening 
would occur prior to the third tri-
mester; however, screening is safe 
beyond this gestation (NCSP 2011). 
Symptomatic pregnant women are 
managed the same as non-preg-
nant women, with a requirement of 
referral and further investigation 
(NCSP 2011). Pregnant women with 
abnormal smear results should be 
managed in accordance with the 
NHMRC guidelines (NCSP 2011).
How do you manage pa-
tients with screen detected 
abnormalities?
Patients who may require specific 
clinical management outside the 
2005 NHMRC guidelines include 
those who present with symptoms 
such as:
• intermenstrual bleeding or  
spotting;
• postcoital bleeding or spotting; 
and
• postmenopausal bleeding or 
spotting.
Patients with any of the above 
symptoms or any other signs or 
symptoms of concern should be 
immediately referred for further 
tests so that their condition can 
be clinically assessed and an 
appropriate management plan 
formulated (NCSP 2011). 
The Pap smear provider must 
have an awareness of health care 
agencies and community resources 
available to women for follow-up 
care and treatment of cervical 
abnormalities (Queensland Cervi-
cal Screening Program 2012). A 
diverse range of health care provid-
ers and resources available within 
the immediate locality need to be 
provided to the woman so that 
she has a range of options for her 
follow-up and treatment plan. All 
steps taken to encourage the wom-
an to attend for follow-up should 
be clearly documented in the 
woman’s record. For medico-legal 
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Pap smear result Clinical interpretation Communication to woman
Unsatisfactory 
Pap smear
The laboratory report should state why the Pap smear 
was unsatisfactory, which may include reasons such as: 
• the cells may be obscured by blood or inflammation/
mucous;
• there may not be enough cells on the sample to give 
an accurate assessment;
• the cells may be atrophic and difficult to interpret; 
• the smear may not have been properly prepared 
or the slide may have broken during transit to the 
laboratory.
When providing the results to the 
woman ensure that she clearly 
understands:
• The unsatisfactory result does not 
indicate cancer;
• The laboratory was unable to get a 
clear reading and is therefore unable 
to provide a result;
• A repeat Pap smear is required within 
three months
Negative  
Pap smear
A negative Pap smear result for asymptomatic women 
who have no history suggestive of cervical pathology 
means their test result was normal. 
• Recommendation of repeat Pap smear in two years.
• Pap smear result was normal.
• All the cells seen were normal.
• Repeat Pap smear in two years.
Possible or 
definite low-
grade squamous 
intraepithelial 
lesion (LSIL)
This result indicates minor squamous cell changes 
that are often due to an acute infection with human 
papillomavirus (HPV). 
A woman with a Pap smear report of LSIL should be 
managed in the same manner, irrespective of whether 
the cervical abnormality is reported as possible or 
definite LSIL, and offered a repeat Pap smear in 12 
months. 
Note:
Women aged 30 years or more with a possible or 
definite LSIL, without a negative Pap smear history 
in the preceding two to three years are managed 
differently. These cohorts of women need to have an 
immediate colposcopy or a repeat Pap smear within six 
months.
• This result means that the cells seen 
are a little bit different. This is not a 
diagnosis of cancer.
• The cells are a little bit different 
because of an HPV infection.
• The body will normally clear the 
infection by itself in one to two years.
• A repeat Pap smear is needed in 12 
months to check the cells again and 
ensure the body has cleared the 
infection.
Possible or 
definite high-
grade squamous 
intraepithelial 
lesion (HSIL)
Women with a possible or definite HSIL should be 
referred to a gynaecologist for colposcopic assessment 
and targeted biopsy. This result represents suspected or 
definite changes commonly associated with a persistent 
HPV infection which, if left untreated, may progress to 
cervical cancer.
• This result means that the cervical 
cells are different and need to be 
looked at carefully. This does not 
mean a diagnosis of cancer.
• This result means that there is a 
lasting HPV infection that may require 
treatment.
• You will be referred to a specialist 
who can look at your cervix and work 
out if treatment is needed.
Cervical 
glandular 
abnormalities
A Pap smear result reporting:
• adenocarcinoma;
• endocervical adenocarcinoma in situ;
• possible high-grade glandular lesion;
• atypical endocervical cells;
• endocervical cells of undetermined significance.
Should be referred as soon as possible to a 
gynaecologist with expertise in colposcopic 
evaluation of suspected glandular malignancies, or a 
gynaecological oncologist.
• Glandular cells are located inside the 
cervix.
• These cells are harder to locate and 
look at. 
• For these reasons you need to be 
seen by a specialist who can have a 
better look at these cell changes and 
provide treatment. 
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4
reasons, the Pap smear provider 
must keep documented evidence 
of all correspondence relating to 
the follow-up of abnormal results.
Conclusion
Nurses and midwives that provide 
women’s health services, including 
the provision of Pap smears, are 
well placed to encourage women’s 
participation in cervical screening. 
Through collaboration, Australian 
nurses and midwives can actively 
contribute to decreasing morbid-
ity and mortality from this largely 
preventable disease. Together, 
nursing and midwifery health care 
providers can increase women’s 
access to safe and culturally appro-
priate cervical screening services 
throughout Australia.
HEIDI pAvICIC Is clInIcal nurse 
consultant
AIME MuNRO Is a PHD canDIDate, 
researcH anD evaluatIon 
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Foreword 
The WA Cervical Cancer Prevention Program (WACCPP) was established in 1992 as part of 
the National Cervical Screening Program and is one of the six programs that reside within the 
Women’s Health Clinical Care Unit (WHCCU) in the Women and Newborn Health Service. The 
WACCPP is committed to increasing the number of credentialed nurses and midwives as Pap 
smear providers to deliver cervical screening services throughout Western Australia. Pap smear 
providers play a critical role in women’s health as they: 
• enhance and complement existing cervical screening services  
• ensure that Western Australian women have access to high quality cervical screening 
services 
• increase women’s access to female health care providers (as the majority of nurses and 
midwives are female 
• assist women in overcoming barriers that prevent them from participating in regular 
cervical screening 
The cervical screening synopsis was developed with valuable input from women’s health care 
providers and professional organisations in WA and was endorsed by the WACCPP in 2013. 
The purpose of this document is to: 
• support health care providers in their delivery of cervical screening services 
• guide clinical practice in accordance with the National Health and Medical Research 
Council guidelines Screening to Prevent Cervical Cancer: Guidelines for the 
Management of Asymptomatic Women with Screen Detected Abnormalities 
• promote best practice standards 
• be used as a quality assurance reference 
The WHCCU adopts a holistic approach to promote the health and wellbeing of WA women. 
Through collaborative relationships we strive to improve women’s health, particularly for 
vulnerable women who are at most risk for cervical abnormalities. We hope that the distribution 
and use of this document will assist the WACCPP in reaching these goals.  
 
 
 
 
Paula Chatfield     Assoc Prof Jonathan Rampono 
Director       Chair 
Women’s Health Clinical Care Unit   Women’s Health Clinical Care Unit 
Women and Newborn Health Service  Women and Newborn Health Service 
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1. Executive summary 
Cervical cancer is a worldwide health issue and is one of the most preventable of all 
cancers. Since the introduction of the Papanicolaou (Pap) smear as a cervical 
screening tool, up to 90% of squamous cell carcinomas have been prevented. Human 
papillomavirus (HPV) infection is well-established as the principal cause of 99.7% of 
cervical cancer cases. There are many different subtypes of HPV that can infect the 
anogenital tract, but two HPV subtypes known as type 16 and 18 are responsible for 
70% of all cervical cancer cases worldwide. HPV vaccines that prevent HPV type 16 
and 18 infections are now available and have the potential to reduce the incidence of 
cervical and other anogenital cancers.  
In 1991, the Australian Government accepted recommendations made by the 
Screening Evaluation Steering Committee to the Australian Health Ministers’ Advisory 
Council (AHMAC) and implemented the Organised Approach to Preventing Cancer of 
the Cervix, now known as the National Cervical Screening Program (NCSP). The 
NCSP operates as a joint program of the Australian, and state and territory 
governments. The Australian cervical screening program recommends a 2-yearly 
screening interval for asymptomatic women, has adopted standardised quality 
assurance guidelines for the management of screen detected abnormalities and 
established Pap smear registries in every state and territory.  
The WA Cervical Cancer Prevention Program (WACCPP) is the State funded 
component of the NCSP, and is responsible for the management and operation of the 
statewide cervical screening program. The WACCPP aims to reduce the incidence and 
mortality attributable to cervical cancer. The Program achieves this through support of 
existing health care systems and the implementation of appropriate strategies to 
enhance women’s participation in cervical screening.  
 
 
 
 
 
Important Disclaimer 
All information and content in this material is provided in good faith by the WA Cervical Cancer Prevention 
Program, Women’s Health Clinical Care Unit, WA Health, in collaboration with the Centre for Population 
Health Research, Curtin University, and is based on sources believed to be reliable and accurate at the 
time of development. 
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2. Aetiology of cervical cancer 
The National Institute of Health Consensus Conference on cervical cancer stated, 
“cervical carcinoma is the first solid tumour to be shown to be virally induced in 
essentially every case.” Results from a large international collection of cervical tumour 
specimens have identified the human papillomavirus (HPV) DNA to be present in 
99.7% of all cases1. There are more than 100 types of HPV, with 40 types affecting the 
anogenital region. Among the anogenital HPV infections, there are both low risk (LR) 
HPV and high risk (HR) HPV types. LR HPV is non-oncogenic and often causes genital 
warts, with types 6 and 11 causing 90% of these incidences2. It is well recognised that 
infection with HR HPV oncogenic types is a necessary, although not sufficient cause of 
virtually all cervical cancer cases3-8. HR HPV types 16 and 18 alone are responsible for 
70% of cervical cancer incidences9. 
In Australia, 637 incidences of cervical cancer were diagnosed in 2008 and 131 women 
died from this in 200710. This is approximately 9 new cases and 2 deaths per 100,000 
women, respectively10. In 2010, for every 1,000 women screened, 9 women had a 
histologically confirmed high-grade cervical abnormality, providing health care providers 
an opportunity to treat women before possible progression to cancer10 .  
There are two main types of cervical cancer, namely squamous cell carcinoma (SCC) 
and adenocarcinoma10, 11. SCC arises in cells in the ectocervix, with the majority of 
cases being detected in the transformation zone (the ectocervix and endocervix 
junction) (Figure 1)10, 11. Adenocarcinoma arises from mucus producing cells adjacent to 
the transformation zone or in the endocervical canal11. Across Australia in 2007 SCC 
comprised 63.4% of all cervical cancer cases, followed by adenocarcinoma (24.9%), 
adenosquamous (3.9%) and all other cervical cancers (7.9%)12.   
Figure 1. Female reproductive organs, endocervix, ectocervix and transformation zone. 
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The development of squamous cervical carcinoma is related to both host and viral 
characteristics such as viral oncogenicity, inadequacy of the patient’s immune system 
response and any associated risk factors which may include2, 13-16: 
• multiple sexual partners 
• a partner with multiple previous or current sexual partners 
• young age at first sexual intercourse 
• persistent infection with a high risk (HR) HPV type e.g. HPV 16 or HPV 18 
• cigarette smoking 
 
There is evidence that cofactors contributing to the progression of adenocarcinoma, 
including those with HR HPV, are different from those that contribute towards 
progression to squamous cell carcinoma17. Adenocarcinomas have been associated 
with different associated risk factors such as17: 
• obesity  
• sero-positivity for Herpes simplex virus type 2 (HSV-2)  
• endogenous hormonal factors such as parity and exogenous hormone use such 
as the oral contraceptive 
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3. Pathogenesis of cervical cancer 
Human papillomavirus infection is a common sexually transmitted infection with 
approximately 11.4% of the female population estimated to be infected worldwide13, 18. 
Molecular testing has demonstrated that over 99.7% of cervical cancers are positive for 
HPV DNA1. Transmission of HPV to the anogenital region primarily occurs through 
microabrasions in the epithelium19. Most HPV infections are transient regardless of the 
age of the woman19, with approximately 50% of HPV infections spontaneously clearing 
within 8 months of initial infection and 90% being cleared within 2 years20-22.  
All sexually active women are at risk of HPV infection and it is estimated 75% will 
involve an oncogenic HPV type23. Sexual intercourse is the primary route of 
transmission of genital HPV infection18 and peak HPV prevalence has been identified 
soon after the onset of sexual activity in adolescence and early adulthood16, 24. The 
subsequent age-related decrease in prevalence reflects acquisition of immunity and 
monogamous relationships. The development of cervical cellular changes from the 
onset of genital HPV infection to the development of cervical carcinoma can take 10–20 
years, although it has been reported that in some cases may only take 1–2 years post 
sexual debut5, 16, 25.The duration of the HPV infection is related to the HPV type, on 
average HR HPV infections last longer than infections with LR HPV. Research 
indicates that there is a causal relationship between HR HPV infection longevity and 
the likelihood that it will progress towards a precancerous lesion/carcinoma16, 19, 26-28. 
Approximately, 20-30% of women with persistent HR HPV infection (>12 months) will 
be diagnosed with a high-grade abnormality within 30 months22, 26.  
The progression from HPV infection to cervical cancer may take approximately up to 5-
15 years and can be summarised into four key stages: 1) HPV transmission 2) acute 
HPV infection 3) viral persistence and the development of a precancerous lesion, and 
4) invasion through the basement membrane of the epithelium (carcinoma)16, 29, 30. 
Development of malignant lesions occurs through HR HPV DNA integrating into the 
host genome in infected cells31. Once this event occurs there is potential for the 
integrated viral genes to interfere with the normal mechanisms that control cell 
proliferation and destruction of “mutant cells” that can result in the proliferation of 
abnormal cells31. 
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4. Prevention of cervical cancer  
4.1 Human papillomavirus vaccine 
The development of prophylactic vaccines against human papillomavirus (HPV) 
infections is the most significant recent advancements in the prevention of cervical 
carcinoma32, 33. HPV vaccination offers primary prevention against HR HPV types 16 
and 18 that cause 70% of this disease34-36. HPV vaccines have been approved for use 
in over 100 countries, as the vaccine is safe, well tolerated and efficacious37. In 
Australia there are two types of prophylactic vaccines that have been approved for use, 
namely Gardasil® and Cervarix®32, 33.  
Gardasil®  
In June 2006, the Therapeutic Goods Administration (TGA) approved the use of 
Gardasil® (CSL Biotherapies/Merck & Co. Inc.) in Australia, for females aged 9 to 26 
years and males aged 9 to 15 years38. Gardasil® is a recombinant, quadrivalent HPV 
vaccine that prevents infection with genital HPV types 6, 11, 16 and 1839. The 
Australian Government covers the cost of this vaccine for girls aged 12 to 13 years, as 
part of the school based Immunisation Program38. Gardasil® has been reported to be 
98% effective at preventing cervical disease and external genital lesions when 
administered prophylactically to uninfected women (HPV DNA negative and HPV 
seronegative for relevant types)36, 40-43. Gardasil® is administered as an intramuscular 
injection (IM), given in 3 doses (0, 2 & 6 months)39. Side effects may include injection 
site reactions, headaches, fever, nausea, dizziness and allergic reactions39. 
Contraindications to this vaccine include hypersensitivity or severe allergy to yeast and  
prior allergic reaction to Gardasil39. 
Cervarix®  
The TGA approved the Cervarix® vaccine in May 2007 (GlaxoSmithKline). Cervarix® 
differs from Gardasil® as it is a recombinant protein particulate bivalent HPV vaccine 
that prevents infection by HPV types 16 and 1844. It is registered for use in females 
aged 10–45 years44; however, the Australian Government does not support the cost of 
this vaccine. Cervarix® has been administered and tested in clinical trials capturing 
approximately 40,000 females, and has consistently displayed high levels of efficacy 
(upwards of 98%) in preventing precancerous lesions due to HPV types 16 and 1835. 
Cervarix® is administered as an IM injection given in 3 doses (0, 1 & 6 months)44. The 
most common side effects include injection site reactions, headaches, gastrointestinal 
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symptoms, myalgia, arthralgia and allergic reaction44. Contraindications to the vaccine 
include pregnancy and a prior negative reaction to Cervarix®. Its use is cautioned in 
women who are either allergic to or have a sensitivity to latex44.  
It is important to note that HPV vaccines are designed to prevent initial HPV infection33, 
35, 36. They are not a therapeutic vaccine, thus, the vaccine is most effective if given to 
females prior to the commencement of sexual activity33, 35, 36. Whilst vaccinating young 
girls before their sexual debut is consistently advised by current HPV vaccination 
guidelines, natural history studies indicate that all sexually active women may benefit 
from the vaccination34-36, 41. Research suggests that only women with confirmed current 
infections by both oncogenic HPV vaccine types will not benefit from the vaccination 45. 
Health care providers should assist women of all ages to make an informed decision 
when considering HPV vaccination45. Should the woman be over 25 years of age she 
may still be offered vaccination after a discussion about the risks and benefits to assist 
her in making an informed decision45.  
Health care providers should emphasise the benefits of vaccination combined with the 
importance of continued cervical screening45.  
4.2 Cervical screening 
Australia’s cervical screening program operates as a joint program of the Australian 
Government and state and territory governments, targeting women aged 20-69 years12. 
The Australian cervical screening program, utilises the systematic application of a 
validated test to identify asymptomatic individuals in a population who may have 
cervical abnormalities46.   
In Australia, the Pap smear, or ‘Pap test’ is used as the primary cervical screening tool. 
Pap smears identify early cellular changes in the cervix, which if left undetected and 
untreated may progress to cervical cancer12. A Pap smear can be a personally 
challenging procedure for a woman; therefore, as a Pap smear provider it is important 
that women participating in cervical screening are both psychologically and physically 
comfortable throughout the examination47, 48.  
 
4.3 National Cervical Screening Program Policy 
The National Cervical Screening Program (NCSP) recommends that all women aged 18 
to 69 years, who have ever been sexually active, whether vaccinated or not, should 
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participate in 2-yearly cervical screening. This policy applies only to asymptomatic 
women. Symptomatic women require referral and further investigation. The Policy 
states12:  
• All women who have ever been sexually active (any genital-skin to genital-skin 
contact) should commence having Pap smears between the ages of 18 and 20 
years, or one to two years after sexual debut, whichever is later.  
• Pap smears may cease at the age of 70 years for women who have had two 
normal Pap smears within the last five years. Women aged 70 years and over 
who have never had a Pap smear, or who request a Pap smear, should be 
screened. 
• Women with a past history of high-grade cervical lesions, or who are being 
followed-up for previous abnormal smears should be managed in accordance 
with the National Health and Medical Research Council (NHMRC) guidelines 
Screening to prevent cervical cancer: guidelines for the management of 
asymptomatic women with screen detected abnormalities 49. 
4.4 National Cervical Screening Program Policy on pregnancy 
Pregnancy is a time when women often have the greatest interest in their health and are 
more likely to participate in cervical screening if it is offered47, 48. Opportunistic 
screening may be undertaken at the booking visit, unless there is a clinical reason, such 
as bleeding, which would prohibit performing the Pap smear12. The Pap smear could 
then be performed at the follow-up visit. 
The Royal Australian and New Zealand College of Obstetricians and Gynaecologists 
advised the NCSP that a Pap smear should be offered to every well pregnant woman 
(without symptoms of cervical cancer) who is due for cervical screening12. Ideally 
screening would occur prior to 24 weeks; however, screening is safe beyond this 
gestation12. Symptomatic pregnant women will need referral and further investigation12. 
Pregnant women with abnormal smear results should be managed in accordance with 
the NHMRC guidelines49. 
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5. Classification of cervical abnormalities 
The Australian working party, using the Bethesda System as its basis, derived a unique 
Australian terminology system for squamous and glandular lesions called the Australian 
Modified Bethesda System (AMBS 2004, Table 1 and Table 2). 
Table 1.  The Australian Modified Bethesda System (AMBS 2004) for squamous 
abnormalities49  
AMBS 2004 Incorporates 
Possible low-grade squamous intraepithelial 
lesion 
Non-specific minor squamous cell changes. 
Changes that suggest, but fall short of, HPV/ 
cervical intraepithelial neoplasia (CIN) 1 
Low-grade squamous intraepithelial lesion 
(LSIL) 
HPV effect, CIN 1 
Possible high-grade squamous intraepithelial 
lesion 
Changes that suggest, but fall short of, CIN 
2, CIN 3 or squamous cell carcinoma 
High-grade squamous intraepithelial lesion 
(HSIL) 
CIN 2, CIN 3 
Squamous cell carcinoma Squamous cell carcinoma 
 
Squamous abnormalities are classified into possible or definite low-grade squamous 
intraepithelial lesions (LSIL or HPV+/-CIN 1), possible high-grade squamous 
intraepithelial lesion (where the presence of a high-grade abnormality such as CIN 2, 
CIN 3 or squamous cell carcinoma cannot be excluded), high-grade squamous 
intraepithelial lesions (HSIL, CIN 2 or CIN 3) and squamous cell carcinoma. The 
cervical cytology classification system assists the medical scientist and pathologist to 
classify the cervical cellular changes to allow appropriate follow-up recommendations 
and clinical management49.  
The classification of squamous intraepithelial lesions is characterised by abnormal 
cellular proliferation and maturation, together with nuclear atypia. In LSIL, the changes 
predominantly occupy the lower third of the epithelium and marked HPV cytopathic 
effects (koilocytosis) are often seen. In HSIL, the changes inhabit the lower two thirds of 
the epithelium (CIN 2), or the full thickness of the epithelium (CIN 3), and the nuclei are 
hyperchromatic and irregular. HSILs are also characterised by detectable high risk (HR) 
HPV DNA and chromosomal instability6. 
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Although adenocarcinoma in situ (AIS) is defined as a preinvasive cervical lesion, 
natural history studies to confirm its potential to progress are lacking50. AIS is much less 
commonly diagnosed than the corresponding squamous preinvasive lesions10. No 
terminologies of glandular lesions with lower degrees of nuclear atypia have been 
established due to rarity in biopsies51-53.   
 
Table 2.  AMBS (2004) for glandular abnormalities49. 
 
 
 
 
 
 
 
 
 
 
 
 
 
AMBS 2004 Incorporates 
Atypical endocervical cells of undetermined 
significance 
Non-specific minor cell changes in 
endocervical cells  
Atypical glandular cells of undetermined 
significance 
Non-specific minor cell changes in 
glandular cells 
Possible high-grade glandular lesion Changes that suggest, but fall short of, 
AIS or adenocarcinoma 
Endocervical adenocarcinoma in situ Adenocarcinoma in situ 
Adenocarcinoma Adenocarcinoma 
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6. Credentialing as a Pap smear provider 
The WA Cervical Cancer Prevention Program (WACCPP) is responsible for the 
management and delivery of the Pap Smear Provider Initiative (PSPI). The PSPI 
encourages and supports nurses and midwives to credential as a Pap smear provider to 
increase the opportunity for women to access high quality cervical screening services 
throughout WA, especially in rural and remote areas. The credentialing process exists 
to support and ensure high-quality delivery of patient care. Credentialing promotes both 
the autonomy of an individual’s practice and the advancement of nursing and midwifery 
through: 
• increasing recognition of Pap smear provider practice by colleagues and other 
health disciplines 
• increasing the public’s awareness of Pap smear provider skills and 
competencies 
The process for credentialing includes submission of documentation to the WACCPP in 
support of these requirements. Further information can be found at 
http://www.health.wa.gov.au/cervical/healthprof/hp_become.cfm 
 
6.1 Health practitioner registration 
Credentialed Pap smear providers are required to be registered with the Nurses and 
Midwives Board, which is regulated by the Australian Health Practitioner Regulation 
Agency (AHPRA). AHPRA is responsible for the regulation of registration and 
accreditation of fourteen health professions across Australia. 
 
For further information on health practitioner registration and accreditation, please visit: 
www.ahpra.gov.au 
 
6.2 Essential education and training 
To be eligible to credential, nurses and midwives need to have completed an 
educational program deemed appropriate by the WA Pap Smear Provider Credentialing 
Committee. For further information relating to approved education programs please 
contact the WACCPP on 13 15 56. 
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6.3 National competency standards for nurse Pap smear providers 
The National Standards for Nurse Pap Smear Providers (1997) relate to the legal and 
ethical responsibilities for Pap smear providers, and includes accountability for clinical 
services. 
The National Standards for Nurse Pap Smear Providers comprise eight competencies. 
These include: 
• Demonstrate accurate knowledge for safe practice 
• Protects the rights of individuals 
• Recognises own ability and level of professional competence 
• Acts to enhance the dignity and integrity of women 
• Maintains a physical and psycho-social environment which promotes safety, 
security and optimal health care 
• Acts to maintain the right of women to make informed decisions 
• Integrates comprehensive health assessment and interpretive skills to achieve 
optimal care for women 
• Collaborates with the health care team to achieve desired outcomes 
 
For further information regarding the national competency standards for nurse Pap 
smear providers, please refer to Appendix A. 
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7. Performing a Pap smear  
The Pap smear is a procedure in which cells are collected from the cervix, smeared 
onto a microscope slide, and sent to a pathology laboratory for cytological examination. 
Worldwide, the Pap smear is currently the most effective test to prevent squamous 
cervical cancer worldwide. Correct sampling technique increases the accuracy and 
adequacy of the smear sample, and decreases the risk of a false negative result54. 
7.1 Positive outcomes of Pap smears 
As part of quality assurance measures it is important a for a Pap smear provider to seek 
feedback from patients. Positive outcomes of a Pap smear may include47, 48: 
• a satisfactory cervical smear is obtained 
• minor cell changes are detected early and appropriately managed 
• the woman is given appropriate referral for the management of any abnormalities 
noted 
• the woman and Pap smear provider decide the appropriate process for the 
notification of the Pap smear test results and this plan is adhered to 
• the role and benefit of the Cervical Cytology Registry of WA are explained to the 
woman 
• the woman expresses positive satisfaction with her Pap smear examination 
• the woman knows when her next Pap smear is due 
• the woman continues to participate in regular cervical screening 
7.2 What are common errors in Pap smear preparation? 
Pap smear providers are responsible for the correct preparation, fixation (preservation) 
and staining of specimens. Mistakes which may seriously interfere with the correct 
cytological interpretation of the slides may include47, 48: 
• use of slides which are not clean 
• excess use of lubricants  
• insufficient cells collected 
• excessive blood associated with collection or menstrual cycle 
• excessive inflammatory cells in cases where there is evidence of purulent 
discharge 
• cells collected from the incorrect site i.e. vaginal walls instead of cervix 
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• incorrect application of cells onto slides 
• time delay in applying fixation spray 
• insufficient or excess fixation spray used to cover cells on the slide 
7.3  The Pap smear assessment 
Depending upon the clinical environment in which the Pap smear provider practises, the 
order of these steps may need to be altered to adapt to the woman’s requirements 47, 48. 
 
Obtain a thorough gynaecological or obstetrical history, particularly any: 
 
• postmenopausal bleeding (PMB) or spotting 
• postcoital bleeding (PCB) or spotting  
• intermenstrual bleeding (IMB) or spotting 
• abnormal vaginal discharge 
Assessment of the woman prior to the Pap smear determines:  
• the need for additional investigations 
• the position to be adopted by the woman during the procedure 
• the speculum size to be used 
• ways in which to ensure the woman’s comfort (both physical and psychological) 
throughout the procedure  
• need for referral 
7.4  The Pap smear examination 
Pap smear providers need to ensure women receive personal care that is sensitive, 
appropriate, and due regard is given to safety, comfort and dignity throughout the 
procedure. The steps below are suggested as a guide: 
1. Explain the procedure, meaning of the test and results. Make a plan for Pap 
smear result notification 
2. Position the woman comfortably. The supine position is usually best, with the 
knees slightly bent and falling apart. Cover the woman’s lower half with a sheet 
to create a sense of privacy 
3. As the procedure is carried out, explain each step to the woman (if she desires) 
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4. Inspect external genitalia for any abnormalities 
5. Moisten and warm the speculum with water. If lubricant is used, use it sparingly 
and avoid contact with the cervix 
6. Gently part labia and slowly insert closed speculum at a posterior angle into the 
vagina. Observe the patient for signs of discomfort and encourage feedback 
throughout the procedure 
7. Open speculum to allow visualisation of the cervical external os 
8. If there is any difficulty in visualising the cervical external os; 
a. If the cervix is obscured by the lateral vaginal walls bulging inwards, 
consider using a larger speculum or applying a condom over the speculum 
(cut off the reservoir tip of the condom so you can sample the cervix) to 
support the lateral vaginal walls and offer better visibility 
b. Ask the woman to lift her buttocks slightly off the bed temporarily, and 
place either a rolled towel or ask her to place her clenched fists under her 
buttocks (this assists in the visualisation of a posterior cervix) 
c. Close and then reinsert speculum at an anterior angle (this assists in 
visualisation of an anterior cervix)  
d. If still unable to locate the cervix, close the speculum and withdraw it from 
the vagina. Palpate the position of the cervix with a gloved hand, moistened 
with water, preferably not lubricant. Once the position of the cervix has been 
located, reinsert the speculum into the vagina at the appropriate angle  
9. Inspect the cervix for the following: 
• colour, size, shape 
• position 
• lesions 
• surface characteristics 
• squamocolumnar junction  
• discharge 
Note: if visual inspection of the cervix is abnormal, the woman requires specialist 
referral as soon as possible (regardless of the Pap smear result) 
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10.  Take the Pap smear sample and other samples if necessary 
11.  Close the speculum and remove from the vagina 
12.  Offer the woman a tissue and panty liner if required 
7.5 Completing the Pap smear pathology form 
Accurate documentation is essential when delivering cervical screening services. The 
appropriate clinical management of the woman requires that the woman is uniquely 
identified. The following information will assist the examining laboratory to interpret the 
Pap smear and make clinical recommendations that are appropriate for each individual 
woman. These include48: 
• collector’s practice name 
• collector’s practice address 
• patient Medicare number 
• cervical or vault smear 
• unit/unique medical record number (UMRN) 
• name (previous surname if applicable) 
• date of birth 
• address 
• date of Pap smear 
• date of last normal menstrual period (LNMP) 
• previous abnormal smear results or treatment 
• pregnancy (gestation) 
• hormonal therapy: hormone replacement therapy, oral contraceptive pill, 
Implanon, Depo Provera etc 
• hysterectomy 
• abnormal symptoms such as postcoital bleeding (PCB) or spotting and 
intermenstrual bleeding (IMB) or spotting 
• abnormal or suspicious appearance of the cervix 
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7.6 Management of women with screen detected cervical abnormalities 
Women who are symptomatic need to be clinically managed in accordance with their 
presenting history and symptoms. Women who may require specific clinical 
management outside the NHMRC guidelines include those who present with symptoms 
such as: 
• intermenstrual bleeding or spotting 
• postcoital bleeding or spotting 
• postmenopausal bleeding or spotting 
 
Women with any of the above symptoms or any other signs or symptoms of concern 
should be immediately referred for further tests to a specialist gynaecologist so that their 
condition can be clinically assessed and an appropriate management plan formulated49. 
7.7 Referral of women with screen detected cervical abnormalities 
The Pap smear provider must have knowledge of health care agencies and community 
resources available to women for follow-up care and treatment of cervical 
abnormalities48. A diverse range of health care providers and resources available within 
the immediate locality need to be provided to the woman so that she has a range of 
options for her follow-up and treatment plan48. 
 
When a cervical abnormality has been detected, a letter of referral is sent to the 
patient’s nominated GP (or other medical provider) along with a copy of her Pap smear 
result48.  
 
A request for confirmation that the referral and Pap smear result has been received by 
the health care provider should be included in the letter. The patient should also be 
provided with a copy of the referral letter that was sent to her health care provider. It is 
the responsibility of the Pap smear provider to ensure that the referral is sent and 
received in a timely manner48. 
 
All steps taken to encourage the woman to attend for follow-up should be clearly 
documented in the woman’s record. For medico-legal reasons, the Pap smear provider 
must keep documented evidence of all correspondence relating to the follow-up of 
abnormal results48. 
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7.8 Interpretation of Pap smear reports 
The Pap smear provider should provide the woman with information regarding her 
cervical screening result. Should a cervical abnormality be detected, the Pap smear 
provider should assist the woman in understanding the meaning of her Pap smear 
result. The Pap smear provider should advise the woman clearly about her follow-up or 
treatment options to aid her in making an informed decision47, 48. The Pap smear 
provider then needs to make an appropriate referral based on the woman’s choice, and 
clearly document the outcomes of the consult. 
The Pap smear report 
The Pap smear provider will receive the Pap smear result within two to 14 days, 
depending upon where the specimen was collected and where it was examined. Pap 
smear report forms may differ in their format; however, they contain similar information. 
This section will also note whether it is a conventional Pap smear sample or a Thin 
Prep® sample. The information on a Pap smear report includes: 
 
Specimen: Identifies the site of the cytology sample. 
Possible explanations are: 
• Slide Pap smear - Cervical 
• Slide Pap smear - Vault 
 
Result: Identifies if the result is negative or abnormal or not suitable for analysis. 
Possible results include: 
• Unsatisfactory 
• Negative for intraepithelial lesion or malignancy 
• Possible low-grade squamous intraepithelial lesion 
• Low-grade squamous intraepithelial lesion 
• Possible high-grade squamous intraepithelial lesion 
• High-grade squamous intraepithelial lesion 
• Atypical glandular cells  
• Possible high-grade glandular lesion 
• High-grade glandular lesion 
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Specific diagnosis: 
A more detailed description of the result is given in this section of the report. Along with 
the report on the presence or absence of any cellular abnormality, the coexisting 
presence of specific microorganisms may be given. This part of the report also includes 
a comment on the presence or absence of an endocervical component. 
 
National Health and Medical Research Council Recommendations: 
Recommendations are according to the National Health and Medical Research Council 
screening to prevent cervical cancer: guidelines for the management of asymptomatic 
women with screen detected abnormalities49 . 
 
Unsatisfactory Pap smear 
If a woman has an unsatisfactory smear she will be asked to have another Pap smear in 
approximately 6 to 12 weeks. The laboratory report should state why the Pap smear 
was unsatisfactory and may include reasons such as49:  
• the cells may be obscured by blood or inflammation / mucous 
• there may not be enough cells on the sample to give an accurate assessment 
• the cells may be atrophic and difficult to interpret  
• the smear may not have been properly prepared   
• the slide may have broken during transit to the laboratory 
 
Atrophic smears can be difficult for the cytologist to interpret. Atrophic Pap smears 
commonly occur in postmenopausal and postnatal women, particularly if they are 
breastfeeding. These unsatisfactory Pap smears result from decreased oestrogen 
levels, which affect the quality of the cervical cells. It is recommended that if the Pap 
smear is unsatisfactory due to atrophic changes, the woman has a repeat Pap smear in 
3 months after being treated with local oestrogen. 
 
An unsatisfactory Pap smear due to inflammation may be caused by an infection such 
as Candida spp or Trichomonas. Pap smears may detect the cause of the inflammation; 
however, additional investigations should be undertaken to identify and treat the cause. 
Once the cause is treated, the woman should return within 3 months for a repeat Pap 
smear. 
 
 
  
 
22 
Negative Pap smear 
A negative Pap smear result for asymptomatic women who have no history suggestive 
of cervical pathology would have a recommendation of repeat Pap smear in 2 years. 
 
Possible or definite low-grade squamous intraepithelial lesion (LSIL) 
This result indicates minor squamous cell changes that are often due to an acute 
infection with human papillomavirus (HPV). A woman with a Pap smear report of LSIL 
should be managed in the same manner, irrespective of whether the cervical 
abnormality is reported as possible or definite LSIL, and offered a repeat Pap smear in 
12 months49.  
 
Women aged 30 years or more with a possible or definite LSIL, without a negative Pap 
smear history in the preceding 2 to 3 years are managed differently. These cohorts of 
women need to have an immediate colposcopy or a repeat Pap smear within 6 
months49.  The reason for this management approach is two-fold: 1) health care 
providers may be concerned that an occult HSIL will remain undetected and progress to 
cancer, and 2) health care providers may be concerned that women will not comply with 
cytological surveillance49. 
 
Possible or definite high-grade squamous intraepithelial lesion (HSIL)  
Women with a possible or definite HSIL should be referred to a gynaecologist for 
colposcopic assessment and targeted biopsy49. This result represents suspected or 
definite changes commonly associated with a persistent HPV infection which, if left 
untreated, may progress to cervical cancer49.  
 
Cervical glandular abnormalities 
A Pap smear result reporting adenocarcinoma, endocervical adenocarcinoma in situ, 
possible high-grade glandular lesion, atypical endocervical or endocervical cells of 
undetermined significance, should be referred as soon as possible to a gynaecologist 
with expertise in colposcopic evaluation of suspected glandular malignancies, or a 
gynaecological oncologist49. 
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8. Result follow-up and notification  
The National Pathology Accreditation Advisory Council (NPAAC) requires pathology 
laboratories that report cervical cytology process 90% of smears within 5 working days. The 
turnaround time for notification of Pap smear results can vary from 5 to 14 days depending on 
the location of the laboratory and Pap smear provider. The quick turnaround times support Pap 
smear providers in promptly following-up and treating screen detected cervical abnormalities. 
Laboratories are responsible for ensuring communication of Pap smear results, in writing, 
directly to the Pap smear provider. It is not the laboratories responsibility to notify a woman 
directly, or to provide them with a copy of their Pap smear result. The responsibility of 
communicating with a woman rests with the Pap smear provider. If you are not the primary 
health care provider for the woman, you should request a copy be forwarded to the woman’s 
nominated provider to promote continuity of care. 
During the Pap smear consultation, the Pap smear provider must establish a mutually 
acceptable method of notifying the woman of her Pap smear result. Pap smear providers have a 
duty of care to the woman they provide cervical screening services to; therefore, they must have 
appropriate systems in place to review and follow-up all Pap smear results. The Pap smear 
provider is required to ensure that a woman is informed of her cervical test result and that the 
information is provided to her in a way that she understands. During this explanation it is a good 
time to advise the woman when her next Pap smear is due.  
It is the woman’s responsibility to follow this advice and ensure that the Pap smear provider has 
her current demographic details (i.e. her most current address). In the event that the Pap smear 
provider is unable to contact or follow-up a woman, it is recommended that the Pap smear 
provider record all attempts made to contact her. For example the Pap smear provider should 
record the date and time the woman was phoned, if a letter was sent to her. Documentation of 
such attempts to contact the woman is an important risk management strategy.  
The Cervical Cytology Registry (CCR) of WA also plays an integral role in reminding women 
when they are overdue for the next Pap smear and in following-up women that have had an 
abnormal Pap smear. It is important to understand that the CCR is not a ‘reminder service’ for 
health care providers. The CCR is a ‘safety net’ for women throughout WA and through direct 
mail will advise women and their health care provider when cervical screening tests are 
overdue. The ‘safety net’ is enacted in accordance with the WA Protocol of Actions for 
Reminder and Follow-up Letters (see Appendix B).  
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ACIS%
What%is%the%“gold%standard”?%
What%is%a%cone%biopsy?%
Why%is%the%gold%standard%not%followed?%
%
%
What%are%the%clinical%outcomes%for%LEEP%versus%
CKC?%
Conflicts)
Member,)WA)Cervical)Cancer)Preven6on)
Program)Advisory)Group)
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“Gold&standard”&
NHMRC&Guidelines&2005&(p67)&
“Gold&standard”&
“Cone&biopsy&should&be&
tailored&according&to&the&
colposcopic&findings&and&the&
pa8ent’s&age&and&
childbearing&requirements.”&
NHMRC&Guidelines&2005&(p67)&
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“Gold&standard”&
ACIS%
85%&<15mm&from&SCJ&
& && & & & & & &&<36yo&usually&<10&mm&
&
&
&
&
&
Older&women&are&more&likely&
to&have&more&extensive&
lesions&…&requiring&deeper&
excisions&
Nicklin&JL,&et&al.&ANZJOG&1991;&31(2):179–183&
“Gold&standard”&
&
Size&
Margins&
Specimen&number&
Complica9ons&
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Cone%biopsy%
Cone%biopsy%is%indicated%for%the%further%assessment%and%treatment%of%a%
woman%with%a%cytology%report%predic7ng%AIS.%There%are%several%methods%of%
cone%biopsy.%These%include%cold>knife%cone,%laser%cone,%large%loop%excision%of%
the%cervical%TZ%(LLETZ)%and%Fisher%cone.%Cold>knife%cone%biopsy%should%be%
considered%the%‘gold%standard’.%
Data%suggest%that%women%treated%by%LLETZ%tend%to%undergo%shallower%
procedures%with%higher%rates%of%endocervical%margin%involvement,%and%LLETZ%
is%therefore%best%avoided%for%this%purpose%(Widrich%et%al%1996,%Wolf%et%al%
1996,%Azodi%et%al%1999).%There%are%very%liPle%data%regarding%the%use%of%either%
laser%or%Fisher%cone%for%the%management%of%glandular%abnormali7es.%
Cone%biopsy%should%be%tailored%according%to%the%colposcopic%findings%and%the%
pa7ent’s%age%and%childbearing%requirements.%
%
NHMRC%Guidelines%2005%(p67)%
Australian*case-series*data*confirm*that*85%*of*AIS*will*extend*
to*less*than*15*mm*from*the*SCJ*(Nicklin*et*al*1991).*However,*
the*SCJ*may*not*always*be*visible*and*the*proximal*linear*
extent*of*AIS*may*be*as*far*as*25*mm*along*the*canal*from*the*
SCJ.*The*proximal*linear*extent*of*AIS*is*related*to*age.*
Women*under*36*are*unlikely*to*have*disease*extending*more*
than*10*mm*from*the*SCJ,*allowing*for*more*limited*excision.*
Older*women*are*likely*to*have*more*extensive*lesions*and*
require*deeper*excisions*of*at*least*25–30*mm*(Nicklin*et*al*
1991).*
*
NHMRC*2005*(p90)*
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ACIS%
What%is%actually%happening?%
%
What%are%the%clinical%outcomes%for%LEEP%versus%
CKC%in%ACIS?%
Pa#ent'age'<30/≥30'
Socio'Economic'Index'for'Area''
Histopathology'–'modality,'depth,'margin'
status,'number'of'specimens'
'
'
CKC'vs'LEEP'
 110 
 
 
 
 
 
 
Follow%up(
Clinical(outcomes(
(
(
CKC(vs(LEEP(
CKC#vs#LEEP#
Retrospec0ve,#popula0on#based#
Registry#data#from#2001#–#2012#
18#years#and#older#
Western#Australia#
ACIS#diagnosed#on#Pap/biopsy#
#
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338#cases#
#
#
231#CKC# # # # # # # # # # # #107#LEEP#
(68.3%)# # # # # # # # # # # #(31.7%)#
#
CKC#vs#LEEP#
231 $ $ $ $ $ $ $ $ $ $ $ $ $ $ $107$
Significant$difference$
$
Number$of$specimens$
Specimen$depth$
CKC$vs$LEEP$
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Margin'status'
'
93'had'posi1ve'margin'
'54'had'further'treatment'(CKC,'LEEP,'Hyst)'
' 'No'significant'difference'in'ACIS'with'ini1al'modality'(p'='0.42)'
' 'No'significant'difference'in'Ca'with'ini1al'modality'(p'='0.88)'
'
39'(42%)'were'observed'
CKC'vs'LEEP'
231 $ $ $ $ $ $ $ $ $ $ $ $ $ $ $107$
Margin$status$
Not$significant$(p$=$0.432)$
$
69.7% $ $ $ $Nega>ve$margin$ $ $ $62.6%$
25.5% $ $ $ $Posi>ve$margin $ $ $ $31.8%$
4.8%$ $ $ $Indeterminate$margin$ $ $5.6%$
$
$ $ $
Margin'status'
'
When'adjusted'for'margin'status,'no'sta4s4cally'
significant'difference'between'
'age,'SEIFA,'coexistent'CIN'
'specimen'depth'
'modality'
and'ACIS'persistence/recurrence'
CKC'vs'LEEP'
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Outcomes)<12)months)
)
24)(7.1%))had)persistent)ACIS))
)10)had)nega@ve)margin))
) )4.4%)overall)risk)of)persistent)ACIS)even)if)nega@ve)margin))
)
8)(2.4%))risk)endocervical)adenocarcinoma)
CKC)vs)LEEP)
Margin'status'
'
3.4'.mes'increased'rate'(95%'CI'1.5'–'7.8)'of'
ACIS'persistence'/recurrence'if'posi.ve'margin'
CKC'vs'LEEP'
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CONCLUSIONS(
(
Ideal(to(have(single(specimen(
(
Ideal(to(have(adequate(depth…but(even(with(
nega=ve(margins,(overall(4.4%(risk(of(persistent(
ACIS(
(
CKC(vs(LEEP(
CONCLUSIONS(
(
No(significant(difference(in(margin(status(
between(CKC(and(LEEP(
(
No(difference(in(ACIS(persistence(or(recurrence(
between(CKC(and(LEEP(
CKC(vs(LEEP(
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